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SUMMARY
To select potentially therapeutic anti-mycobacterial agents, 9 compounds were screened 
on the basis of their capacity to arrest M. avium growth in liquid broth. Out of the 8 
compounds that proved suitable, 2 were singled out upon evaluation of their 
apoptotic/necrotic effects on THP-1 macrophage-like cells. One of them controlled poorly 
M. avium intra-macrophage growth and showed deleterious effects on some function 
parameters of resting and activated host cells that led to its elimination as a potential 
antibiotic. The remaining compound was the substituted hydroxy-naphthoquinone 
lapachol, a natural product from a South American tree bark.
Lapachol was bacteriostatic toward M. avium, did not induce apoptosis or necrosis of 
THP-1 macrophages at < 32 fxg/mL (132 pM) and arrested the intra-macrophage growth of 
M. avium at the lower dose of 16 pg/mL (66 pM). The study of the effects of lapachol on 
the expression of function parameters and cytokine secretion by THP-1 macrophages 
showed that it immunomodulated resting and TLR2-agonised human macrophage 
functions, some of which can lead to improved host cell responses to infection. Favourable 
effects were increases in IFNyRl and MHCII surface expression and a marked inhibition 
of IL-10 secretion. The up-regulation of IFNyRl and MHCII can potentially improve the 
capacity to respond to IFNy and present antigens, respectively. The inhibition of IL-10 
secretion would prevent macrophage de-activation, improving the capacity of macrophages 
to control the intracellular growth of M. avium. Lapachol did not affect important aspects 
of host cell function such as ER or oxidative stress and TLR2 agonism-induced capacity to 
produce oxygen and nitrogen metabolites and secrete TNF-a. The drug resulted in a 
reduction of IL-1|3 and TNF-a secretion only from resting and IFN-y-treated cells, and in a 
decrease in latex bead and M. avium internalization. A proteomic approach to study the 
influence of lapachol on the expression of proteins modulated by IFN-y or TLR2 agonism 
showed important reductions in the expression levels of three proteases, the ER protein
DnaJ homolog that forms part of complexes together with grp78 regulates grp78 activity 
and two cytoskeletal proteins, L-plastin and fascin. The down-regulation of these 
cytoskeletal proteins could hypothetically affect cell migration and phagocytosis. Lapachol 
treatment resulted in important increases in cytosolic protein disulfide isomerase A3 
(ERp57), thought to be involved in Stat3 complexing and in disulfide bond cleavages 
coupled to protein degradation, and glucose-6-P-dehydrogenase, involved in NADPH 
generation and, as a consequence, in the protection against damage by hydrogen peroxide. 
The results obtained during this work suggest the convenience of in vivo experiments to 
further test lapachol regarding its potential as a new anti-mycobacterial agent and 
immunomodulator.
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RATIONALE AND AIMS
M. avium is a non-tuberculous, facultative intracellular pathogen that shares a number 
of characteristics with M. tuberculosis concerning intra-macrophage growth and inhibition 
of host cell responses. Besides, M  avium is an agent increasingly causing disease 
worldwide. New compounds, synthesized or isolated from natural sources, are not often 
tested for their efficacy against microorganisms growing intracellularly, as is the case for 
pathogenic mycobacteria. Even fewer candidate compounds are studied in relationship 
with their effects on mammalian host cells. This is an important issue concerning 
mycobacterial infections, since pathogen growth control or elimination requires treatments 
with antibiotics for up to 2 years in the case of resistant mycobacterial strains or in non- 
tuberculous disease, like the one caused by M. avium.
The aim of this thesis was to test new compounds for their anti-mycobacterial activity, 
using M. avium as the target bacterium, and for their effect on resting, activated and M  
tfv/ww-infected host cells (THP-1 macrophages). By establishing criteria for the in vitro 
selection of putative anti-mycobacterial drugs, they can be shortlisted before moving to in 
vivo studies. The screening of candidate compounds was based on their effects on 
parameters indicative of functions such as viability, oxygen and nitrogen metabolism, 
endoplasmic reticulum stress, migration, phagocytosis, antigen presentation and cytokine 
secretion. A proteomic approach was finally used for the evaluation of the effects of the 
naphthoquinone lapachol, which was the only compound left after the screening mentioned 
above.
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INTRODUCTION
1. The genus Mycobacterium
The genus Mycobacterium is a member of a GC rich group of Gram-positive bacteria 
consisting mainly of non-pathogenic, environmental organisms. They belong to the 
Actinobacteria genera and are closed related to Streptomyces, which are characterized by 
forming spores. However, the ability of Mycobacterium to form spores is questioned. 
Ghosh et al (Ghosh, Larsson et al. 2009) demonstrated the presence of spores in old 
cultures of Mycobacterium marinum, but Traag et al (Traag, Driks et al. 2010) failed to 
detect them. Moreover, the latter reported the absence of orthologs of conserved genes 
responsible for endospore formation in high GC mycobacteria.
Despite the fact that most of the species within the Mycobacterium genus are 
environmental, some like M. tuberculosis, M  marinum, M. ulcerans, M. leprea, and M. 
avium complex developed the ability to reside and proliferate within mammalian host cells 
and this made them successful pathogens. Mutant strains of M. tuberculosis that do not 
express the pathogenicity-related genes sigE or erp fail to grow within macrophages in 
culture and show a reduced pathogenicity in vivo (Berthet, Lagranderie et al. 1998; 
Manganelli, Voskuil et al. 2001; Ando, Yoshimatsu et al. 2003). SigE is a sigma factor 
known to be involved in responses to heat shock, oxidative and low pH stress. Erp encodes 
exported repetitive proteins that may be involved in phagosome maturation control. Thus, 
it can be concluded that replication within macrophages is an important requirement for 
mycobacterial pathogenicity. It is conceptually interesting to try and understand why a 
pathogen that can survive and replicate on its own did not avoid phagocytose, the cells 
meant to kill them, but instead developed mechanisms to gain access and survive in the 
intracellular environment of those cells.
Mycobacterium tuberculosis is an efficient, successful human pathogen causing 
tuberculous disease. It infects one third of the world population, and out of more than 9
26
million new cases per year almost 15% are HIV positive patients. In spite of being a 
curable disease in most cases, tuberculosis still results in more than 2 million deaths per 
year (WHO 2009). Mycobacterium avium complex, Mycobacterium abscessus and other 
non-tuberculous organisms cause infections that had been previously associated only with 
immune deficiencies such as AIDS and cystic fibrosis but have now extended among the 
population at large. These organisms are ubiquitous in the environment and particularly in 
acid soils and hypo-oxygenated, organic matter-rich water (Griffith, Aksamit et al. 2007; 
Piersimoni and Scarparo 2008).
After being internalized by phagocytes into a cytoplasmic, membrane-bound 
phagosome, pathogenic mycobacteria inhibit cellular responses controlling infection. 
Among these responses, mycobacteria particularly target autophagy (Deretic, Singh et al. 
2006). Kumar et al (Kumar, Nath et al. 2010) have recently reported a genome analysis of 
macrophages infected by different strains of M. tuberculosis and concluded that autophagy 
inhibition is a general strategy employed by pathogenic mycobacteria to subvert the host 
immune response, in association with the induction of an enhancement in the expression of 
anti-inflammatory molecules. Moreover, mycobacteria also block phagosome acidification 
by exclusion of ATPase pumps (Pieters 2001; Huynh and Grinstein 2007) and prevent the 
fusion of the phagosomes with lysosomes (Via, Deretic et al. 1997). These alterations of 
the host cell behaviour create a niche that favours mycobacterial survival and replication. 
Pathogenic mycobacteria also inhibit apoptosis and instead induce necrosis, which favours 
bacterial spreading in the host organism.
During the establishment of infections, the replication of pathogenic mycobacteria has 
a special requirement for iron storage, which is an important co-factor of certain enzymes 
such as KatG, a catalase/peroxidase. This is a protective enzyme that needs iron to be able 
to scavenge hydrogen peroxide. In consequence, iron deficiency can generate bacterial 
oxidative stress (Dussurget and Smith 1998). Macrophages are an important source of iron
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since they can phagocyte senescent erythrocytes. However, the availability of free iron at 
phagosomal pH (~6.1-6.5) is low, due to its poor solubility. In order to obtain the required 
amount of iron, mycobacteria have developed mechanisms to compete with the host for the 
scarce amount available. Mycobacteria are capable of synthesizing siderophores that 
compete and remove iron from the human iron-stocking proteins transferrin and ferritin, 
which are siderophores themselves. Two types of mycobacterial siderophores have been 
described, the cell wall anchored mycobactin and extracellular carboxymycobactin, 
secreted by pathogenic microorganisms, and exochelin, secreted by saprophytes. These 
siderophores provide mycobacteria with the necessary amount of iron for their metabolism, 
therefore they constitute an important target for new anti-mycobacterial drugs. For 
instance, the anti-mycobacterial drug /^-aminosalicylic acid is speculated to exert its 
activity by inhibiting mycobactin rather than folic acid synthesis (Ratledge 2004; Boelaert, 
Vandecasteele et al. 2007).
2. The mycobacterial cell wall
Mycobacteria are slender, aerobic restricted and facultative intracellular rods that 
infect most usually mononuclear phagocytes (Jozefowski, Sobota et al. 2008). Their lipid- 
rich cell wall consists of complex lipids containing long chain fatty acids and mycolic 
acids, waxes, glycolipids, proteins, polysaccharides, and lipoglycans. It is responsible for 
an intrinsic resistance to antimicrobial agents as well as playing an important role in 
intracellular survival (Nigou, Gilleron et al. 2003; Primm, Lucero et al. 2004).
The mycobacterial cell wall is composed by an upper and a lower section. The lower 
section consists of an asymmetric bilayer membrane. The most common phospholipids 
found in mycobacterial membrane are phosphatidylglycerol, diphosphatidylglycerol, 
phosphatidyl-ethanolamine and phosphatidylinositol mannosides (PIMs). Beyond the 
membrane there is a cell wall core composed of peptidoglycan, arabinogalactan (AG) and 
mycolic acid, also called mycolyl-arabinogalactan-peptidoglycan (mAGP), where the
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peptidoglycan is covalently attached via a phosphodiester bond to the complex 
arabinogalactan-mycolic acid. This core is essential for cell viability and understanding its 
biosynthesis is fundamental for the development of new anti-mycobacterial drugs. The 
upper section of the cell wall is composed of free lipids such as phthiocerol 
dimycoserosate, cord factor (CF) (in M. tuberculosis) and sulfolipids. Embedded in the cell 
wall there are PIMs, lipomannan (LM) and lipoarabinomannan (LAM), which play an 
important role in mycobacterial virulence (Figure 1) (Brennan and Nikaido 1995; 
Chatterjee 1997; Brennan 2003).
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Figure 1. Mycobacterial cell wall structure. Above the cell membrane there is the core of 
mycobacterial cell wall, consisting of peptidoglycan covalently attached to arabinogalactan and 
mycolic acids (mycolyl-AG-peptidoglycan complex). In non-tuberculous mycobacteria the core is 
covered by a layer composed of different free glycolipids, which confer virulence. This figure has 
been extracted with modifications from Chatterjee, D. (Chatterjee and Khoo 2001).
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Most mycobacterial virulence factors are cell wall glycolipids. Lipoglycans are 
recognized by cells from the immune system as pathogen-associated molecular patterns 
(PAMPs), a phenomenon that constitutes the first stage of induction of immune responses. 
Phosphatidyl-inositol mannosides and their hyperglycosylated derivatives, lipomannan 
(LM) and lipoarabinomannan (LAM) are the most important glycolipids present in the 
mycobacterial cell wall. LAM and LM are expressed in slow-growing, pathogenic 
mycobacteria, are non-covalently anchored to the plasma membrane and extend to the 
external part of the cell wall (Briken, Porcelli et al. 2004; Crellin, Kovacevic et al. 2008). 
In virulent strains, LAMs are capped with mannose generating a molecule called Man- 
LAM. Fast-growing, atypical mycobacteria express phosphoinositide-capped LAM 
(PILAM). ManLAM is known to be a potent inhibitor of phagosomal maturation (Fratti, 
Chua et al. 2003). This occurs following ManLAM incorporation into macrophage 
membrane rafts (Welin, Winberg et al. 2008). Uncapped LAM (AraLAM) is the glycolipid 
present in the avirulent mycobacteria M. smegmatis and M. chelonae (Nigou, Gilleron et 
al. 2003). ManLAM is recognized by the mannose receptor (ManR) of macrophages, 
which promotes phagocytosis and induces in general an anti-inflammatory response, whilst 
LM, AraLAM and PILAM trigger the TLR2 signalling pathway and induce macrophage 
activation (Wieland, Knapp et al. 2004; Jozefowski, Sobota et al. 2008).
The M. avium subsp. avium cell wall is a complex array of hydrocarbon chains 
containing the arabinogalactan-peptidoglycan-mycolic acid core found in all mycobacteria, 
surrounded by a second electron-dense layer made up in part of serovar-specific 
glycopeptidolipids (ssGPL) exclusive to M. avium complex. ssGPLs consist of non­
specific GPLs common to many environmental mycobacteria, modified by the addition of 
serovar-specific oligosaccharide side chains (Chatterjee and Khoo 2001; Laurent, Hauge et 
al. 2003; Schorey and Sweet 2008).
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3. Dormancy
A hallmark of mycobacterial behaviour is the capacity of the bacillus to go into a 
dormant state at low oxygen tensions. In order to survive, the metabolic machinery starts to 
use nitrate as the final electron acceptor. This situation was reproduced in vitro by Wayne 
and Hayes (Wayne and Hayes 1996). In these conditions bacteria do not replicate and 
show a limited metabolic activity, with scarce synthesis of new RNA and proteins, a strong 
induction of respiratory nitrate reductase activity, and a change in energy metabolism. This 
allows mycobacteria to survive in immunocompetent hosts for many years. In addition, this 
feature makes them non-susceptible to many antibiotics used to treat active infections 
(Honer zu Bentrup and Russell 2001; Wayne and Sohaskey 2001; Zahrt 2003; Sohaskey
2008). However, dormant bacteria have been reported to be sensitive to some drug 
associations (Iona, Giannoni et al. 2007; Filippini, Iona et al. 2010).
4. Strategies to control mycobacterial infection
4.1. Chemotherapy
An effective anti-mycobacterial compound must either kill bacteria or suppress their 
replication within the host cell (Amaral, Martins et al. 2007). The usual therapeutic 
schemes to treat mycobacterium infections employ combinations of bacteriostatic and 
bactericidal compounds, chosen according to their effectiveness and cost as first or second- 
line compounds (Table 1). First-line antibiotics are more effective, cheaper, and present 
less side effects than second -line compounds. These combinations are intended to 
minimize the risk of appearance of resistance. As opposed to bactericidal compounds that 
kill bacteria directly, bacteriostatic compounds prevent bacterial growth, therefore the 
host’s immune system is needed to control the infection. However, this classification is not 
rigid and depends on factors such as the target organism (the same compound can be 
bactericidal or bacteriostatic toward different bacteria), the concentration and the tissue
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penetration of the antibiotic drug. Since bacteriostatic compounds do not really eliminate 
the pathogen, bactericidal compounds are additionally necessary in some situations, e.g. 
when the infection foci are in tissues with poor blood penetration (bone) or in nervous 
tissue protected by a blood barrier, or when the host suffers from an immunological 
disorder, e.g. HIV (Pankey and Sabath 2004).
4.1.1. Treatment of non-tuberculous disease.
Disease caused by non-tuberculous mycobacteria requires long treatments, during 
which drug interactions, side-effects and patient compliance rates may be a problem. 
Ethambutol, rifampin, clarithromycin and azithromycin are widely prescribed for non- 
tuberculous disease therapy (Piersimoni and Scarparo 2008; Ballarino, Olivier et al. 2009). 
MAC infections are more difficult to cure than tuberculosis, and treatment includes the 
association of first and second line drugs for 10-12 months after sputum conversion. 
Among second-line compounds, fluoroquinolones have shown promising results (Jacobs 
2004). Some drugs used for the treatment of other diseases have been found to be active 
against M. avium complex (MAC), such as the immunomodulators methotrexate and 
azathioprine, the anti-inflammatory 5-amino-salicylic acid and the immunosuppressants 
cyclosporine A, rapamycin and tacrolimus (Greenstein, Su et al. 2008; Juste, Elguezabal et 
al. 2008).
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First Line Drugs
Drug
Year
D iscovered
M echanism  o f Action
Bactericidal /  
Bacteriostatic
M ajor A dverse R eactions
Isoniazid 1952
Cell wall synthesis 
inhibitor
Bactericidal
Hepatitis, peripheral 
neuropathy, lupus-like 
syndrome, drug interactions
Drug interactions, orange
Rifampin 1966
RNA synthesis 
inhibitor
Bactericidal
color o f  body fluids, 
GI, hepatitis, fever, acute
renal failure, hemolytic 
anemia
Pyrazinamide 1952
Disruption o f  electron 
transport across the 
membrane
Bacteriostatic
Hyperuricemia, gouty 
arthritis, rarely nephritis
Ethambutol 1961 Cell wall inhibitor Bacteriostatic
Optic neuritis, exfoliative 
rash
Streptomycin 1944
Protein synthesis 
inhibitor
Bactericidal
Cochlear and vestibular 
toxicity, nephrotoxicity
Second Line Drugs
Drug
Year
D iscovered
M echanism  o f  Action
B actericidal / 
B acteriostatic
M ajor A dverse R eactions
Capreomycin 1956
Protein synthesis 
inhibitor
Bactericidal
Cochlear and vestibular 
toxicity, nephrotoxicity
Kanamycin 1957
Protein synthesis 
inhibitor
Bactericidal
Cochlear and vestibular 
toxicity, nephrotoxicity
Amikacin 1974
Protein synthesis 
inhibitor
Bactericidal
Cochlear and vestibular 
toxicity, nephrotoxicity
Ethionamide 1956
Inhibitor o f  mycolic 
acid synthesis
Bactericidal
GI
toxicity/hepatitis/dizziness
Am inosalicylic 
Acid (PAS)
1946 Inhibitor o f  folic acid Bacteriostatic GI toxicity, fever, rash
Cycloserine 1952
Inhibitor o f  
peptidoglycan synthesis
Bacteriostatic Dizziness, depression, CNS
Ciprofloxacin 1986
Inhibitor o f  DNA  
gyrase
Bactericidal
GI toxicity, CNS, tendon 
rupture
Ofloxacin 1995
Inhibitor o f  DNA  
gyrase
Bactericidal
GI toxicity, CNS, tendon 
rupture
Levofloxacin 1996
Inhibitor o f  DNA  
gyrase
Bactericidal
GI toxicity, CNS, tendon 
rupture
M oxifloxacin 1999
Inhibitor o f  DNA  
gyrase
Bactericidal
GI toxicity, CNS, tendon 
rupture
Gatifloxacin 1999
Inhibitor o f  DNA  
gyrase
Bactericidal
GI toxicity, CNS, tendon 
rupture
Binding o f  
mycobacterial DNA  
and mRNA
GI toxicity, cutaneous,
Clofazimine 1954 Bacteriostatic
ocular discoloration/ 
pigmentation QT 
prolongation, dizziness
Table 1. Main characteristics of the drugs currently used in anti-tubercular treatm ents.
Information about first- and second-line antibiotics currently employed in tuberculosis treatments. 
Adapted from Laurenzi, M. et al (Laurenzi, Ginsberg et al. 2007), with modifications. GI: 
gastrointestinal; CNS : Central nervous system; QT : time between initial deflection of QRS 
complex to the end o f T wave in electrocardiogram.
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4.1.2. Treatment of tuberculous disease.
The chemotherapeutic scheme against M. tuberculosis infections recommended by the 
Word Health Organization (WHO) consists in combinations of the five first-line drugs 
isoniazid, rifampin, pyrazinamide, streptomycin and ethambutol, in order to achieve good 
efficacy and tolerability. When strictly followed, this scheme results in a rate of cure 
exceeding 90% (Fattorini, Migliori et al. 2007). The association of drugs with different 
mechanisms of action is a general strategy to avoid the development of resistance and 
increase efficacy. However, the regime requires at least six months in the case of sensitive 
strains, which in itself is an important limitation. In fact, lack of patient adherence to the 
therapeutic schemes causes the appearance of resistant strains that can result in MultiDrug- 
Resistant (MDR) and extensively Drug-Resistant TB (XDR-TB). The long treatment 
needed for mycobacterial infections compared with those caused by other Gram-positive or 
negative bacteria is attributed to “physiological” heterogeneity of M. tuberculosis. Even 
when a bacterial population is genetically sensitive, a small proportion of the 
microorganisms can be phenotypically resistant and be present in a dormant or non- 
replicative state with a metabolic activity different from that of sensitive, actively 
replicating organisms. Co-infection with HIV represents another limitation for the 
treatment of mycobacterial infections due to drug interactions, apart from facilitating the 
progression from latent infection to active disease.
Bacteria develop resistance to antimicrobial compounds by mutation and selection of 
resistant individuals, in a mechanism termed vertical evolution, or by acquiring the genetic 
information that encodes resistance from other bacteria, called horizontal evolution 
(Tenover 2006). In the case of mycobacterium, development of resistance to first and 
second-line antibiotics seems associated with vertical evolution (Telenti, Imboden et al. 
1993; Morris, Bai et al. 1995; Blanchard 1996). Mutations can confer resistance by altering 
the antibiotic target protein (Jugheli, Bzekalava et al. 2009), up-regulating antibiotic- 
inactivating enzymes as in the case of (3-lactam (Kong, Schneper et al. 2010), changing a
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pro-drug-activating enzyme (Slayden and Barry 2000), down-regulating or altering 
membrane proteins necessary for drug entry, or up-regulating the expression of efflux 
pumps (Ramon-Garcia, Martin et al. 2009).
MDR strains are resistant to isoniazid and rifampin, the two most effective first line 
drugs, and are responsible for 1-3 % of global TB cases. Treatment of MDR-TB is based 
on the bacterial susceptibility to the remaining first-line drugs, used in combination with 
second-line drugs (kanamycin, ofloxacin, capreomycin, ethionamide, p-aminosalicylic 
acid, and cycloserine). Treatments are longer and the cure rate is lower compared with TB 
due to sensitive strains. This increases the risk of appearance of further resistant strains (Di 
Perri and Bonora 2004; Chambers, Turner et al. 2005; Fattorini, Migliori et al. 2007).
The term extensively Drug-Resistant TB (XDR-TB) is used from 2006 for M. 
tuberculosis strains resistant to isoniazid and rifampin, to any fluoroquinolone and to at 
least one of the three second-line drug amikacin, capreomycin or kanamycin. These strains 
are associated with high mortality and their emergence is related to inadequate TB 
treatment and the HIV epidemic (Fattorini, Migliori et al. 2007; Elston and Thaker 2008; 
Jain and Mondal 2008; Madariaga, Lalloo et al. 2008). The appearance of XDR strains has 
led to the development of alternative treatments with the introduction of compounds 
usually employed in the treatment of other illnesses that proved to possess anti- 
mycobacterial activity (Amaral, Martins et al. 2008; Mor, Bingham et al. 2008; Kinnings, 
Liu et al. 2009).
4.1.3. Approaches to develop new anti-mycobacterial compounds
The reduced existing options of antimicrobial agents and the increase in resistant strains 
make necessary the development of new active compounds without cross-resistance. The 
aim of new compounds should be to reduce the length of treatment, which decreases the 
chances of new resistances, and to eliminate latent disease (Sensi 1989). A good
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knowledge of mycobacterial biochemistry could result in discovering new specific targets 
for the fight against this microorganism. The sequencing of the Mycobacterium 
tuberculosis genome has provided valuable information about putative targets. Mdluli & 
Spigelman (Mdluli and Spigelman 2006) and Murphy, D.J. & Brown, J.R. (Murphy and 
Brown 2008) have reported several mycobacterial genes involved in key biochemical 
pathways such as cell wall and fatty acid biosynthesis. If these pathways are restricted to 
the microorganism, they would result in fewer or no side-effects for the host. Some of the 
gene products could also constitute possible molecular targets for dormant cells.
New active compounds are urgently needed for the treatment of mycobacterial 
infections, yet developing new drugs is time consuming. Label extension is an approach 
involving the extension of existing treatments for other diseases. This approach could 
shorten the times necessary to reach clinical use and reduce costs (Kinnings, Liu et al. 
2009). For instance, immunomodulatory agents used to treat inflammatory bowel disease 
such as methotrexate, 5-amino-salycilic acid and azathioprine, and immunosuppressants 
such as cyclosporine A, rapamycin and tacrolimus have been recently reported to inhibit 
M. avium subsp. paratuberculosis growth (Greenstein, Su et al. 2008; Juste, Elguezabal et 
al. 2008). Similarly, the drugs entacapone and tolcapone, prescribed for Parkinson’s 
disease, have been predicted to bind to the M. tuberculosis target enzyme InhA and could 
prove useful for the treatment of tuberculosis (Kinnings, Liu et al. 2009). Along the same 
lines, the neuroleptic compound thioridazine has been recently proposed for the treatment 
of MDR- and XDR-TB because it acts as an inhibitor of bacterial efflux pumps (Amaral, 
Martins et al. 2008).
High-throughput cell-free methods are another alternative to shorten screening times
to test anti-mycobacterial compounds. The Alamar Blue assay (MABA) measures
mycobacterial viability by enzymatic reduction of resazurin. Radiometric assays such as
the BACTEC system have shortened the time to determine viability but employing
radioactive isotopes is costly (Collins and Franzblau 1997). Arain has described a method
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to quantify anti-mycobacterial activity based on luminescence, using strains carrying the 
luciferase gene (Arain, Resconi et al. 1996). However, all these methods deal with drug 
activity against mycobacteria grown in liquid broth. An anti-mycobacterial compound of 
therapeutic potential must be active against mycobacteria growing within host cells, 
usually macrophages. A high-throughput screening has been recently set up based on 
confocal microscopy images that can be used to study cell toxicity and for drug discovery 
(Zock 2009). The efficacy of this technique was demonstrated by screening the anti- 
plasmodial activities within red cells, employing fluorescent DNA staining of Plasmodium 
falciparum (Baniecki, Wirth et al. 2007). Using the same principle, Christophe et al 
infected mouse macrophages with GFP-expressing mycobacteria and screened the activity 
of candidate anti-mycobacterial compounds by measuring the fluorescence emitted by the 
intra-cellular mycobacteria (Christophe, Jackson et al. 2009). In this way they were able to 
demonstrate that nitrobenzamide had a good activity, which turned out to be a new 
mechanism of action due to the inhibition of arabinan biosynthesis.
4.2. Vaccination
4.2.1. Bacille Calmatte-Guerin (BCG)
The vaccine against tuberculosis used at present was developed by Albert Calmette 
and Camille Guerin in 1921, using an attenuated virulent strain of Mycobacterium bovis. 
After 230 subcultures in potato-glycerine-ox bile for 11 years they produced an attenuated 
strain of M. bovis that was called bacille Calmatte-Guerin (BCG) (Sakula 1983). This 
strain failed to cause tuberculosis in different animal models due to the loss or 
rearrangement of several genes that confer virulence (Behr, Wilson et al. 1999). BCG is 
the most widely used vaccine in the world. It has a good adjuvant activity and can elicit 
both humoral and cell-mediated immune responses. BCG is inexpensive compared with 
other live vaccines, and a single inoculum can give life-long protection. However, the 
efficacy of BCG ranges from excellent protection to no protection against TB. This wide
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variation can be partly explained by the diversity of strains generated by the many passages 
performed in different laboratories, which have resulted in strains of different 
immunogenicity (Martin 2005). BCG can provide a good protection against TB in children. 
However, its low efficacy against pulmonary TB in adults fails to control the increase of 
new TB cases worldwide. BCG vaccination may be useful in preventing first infections but 
has no relevant effect on people already infected and in cases of disease reactivation 
(Agger and Andersen 2002).
4.2.2. New vaccines against TB
The increasing difficulty in controlling new TB cases is driving the development of 
vaccines either alternative or complementary to BCG. Several candidates based on living 
or non-living organisms are being tested, including some at the stage of pre-clinical trials 
(Girard, Fruth et al. 2005). M. tuberculosis attenuated strains are among the candidates to 
produce live TB vaccines. Their main advantage resides in the fact that many of the genes 
deleted from BCG during laboratory passages are still present in M. tuberculosis, such as 
ESAT-6 and CFP10, which have been reported to be important to promote protection 
against further M. tuberculosis challenge (Pym, Brodin et al. 2003). However, safety and 
stability problems must be solved concerning the use of live strains.
Because of the convenient attributes, safety, low cost, and easy mass production of 
BCG, a major effort is being made to obtain recombinant BCG strains expressing M  
tuberculosis genes, thus creating a vaccine vehicle with increased protection efficiency 
against M. tuberculosis compared with wild type BCG (Ohara and Yamada 2001; Bastos, 
Borsuk et al. 2009). A study by Castanon-Arreola reported that vaccination with a 
recombinant BCG expressing a M  tuberculosis 38 kDa protein (rBCG38) increased the 
survival of mice after M. tuberculosis challenge, inducing a strong Thl response 
(Castanon-Arreola, Lopez-Vidal et al. 2005). Grode et al (Grode, Seiler et al. 2005) 
described the use of a urease C-deficient rBCG expressing the membrane-perforating
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protein listeriolysin of Listeria monocytogenes. The ingested organisms showed an acidic 
intraphagosomal pH that was optimum for listeriolysin activity, and this resulted in the 
formation of phagosomal membrane pores allowing antigen translocation into the 
cytoplasm followed by MHCI presentation to CD8+ T cells. The superior vaccine efficacy 
observed, as compared with parental BCG, is then based on improved cross-priming, 
which causes a stronger and more specific CD8+ T cell response.
Non-living vaccine candidates are subunit protein- or DNA-based. Subunit protein 
technology employs protein, lipid and/or carbohydrate components of M. tuberculosis 
known to be immunogenic as immunogenic particles. However, this strategy showed the 
same level of protection as BCG, is expensive and requires multiple boosters (Nor and 
Musa 2004). A more promising non-living vaccine employs plasmid DNA encoding 
antigens that can elicit protective response against tuberculosis. Gao et al (Gao, Yue et al.
2009) inserted sequences corresponding to four different mycobacterial antigens known to 
confer protection in the HSP65 gene, building a multi-epitope DNA vaccine. After 
intramuscularly immunization of BALB/c mice, this vaccine generated a specific Thl 
response against tuberculosis, with high INF-y and IL-12 levels, as well as an increase in 
cytolytic activity due to the known ability of HSP65 to facilitate antigen presentation by 
MHCI molecules via cross-presentation by dendritic cells.
5. The immune response against mycobacterial infections
5.1. Phagocytes / Antigen presenting cells
Phagocytes and antigen presenting cells (APCs) are responsible for the surveillance of 
tissues against invading pathogens. These cells are able to recognize PAMPs through 
specific surface receptors. Pathogens are then internalized, proteolytically processed and 
their antigens are loaded on MHC molecules and presented to T cells, linking the innate 
with adaptive immune response. The role of APCs is played by dendritic cells (DCs), 
macrophages and neutrophils, and in some circumstances also by eosinophils. These cells
39
are tissue sentinels; they act in association with each other and control and/or potentiate the 
immune response (Gordon and Taylor 2005). Phagocytes originate from a unique ancestor 
in the bone marrow. Bone marrow stem cells divide under the effect of cytokines such as 
IL-1, IL-3 and IL-6, generating a common progenitor of macrophages and granulocytes 
known as granulocyte-macrophage colony-forming unit (GM-CFU). Another cytokine, the 
macrophage colony-stimulating factor (M-CSF) induces then the maturation of GM-, 
which gives rise to monoblasts, pro-monocytes and finally monocytes (Valledor, Borras et 
al. 1998).
5.1.1. Neutrophils
Neutrophils are the most abundant leukocytes in the circulation and the first 
immunological cells to migrate to the infection site thanks to interactions between 
neutrophil and epithelial cell adhesion molecules. Neutrophil migration is followed by a 
second wave of cells composed mainly of macrophages. Neutrophils engulf bacteria 
efficiently and can kill them using antimicrobial machinery consisting of antimicrobial 
peptides and proteins, proteases, and oxygen and nitrogen reactive species. The short life 
span of neutrophils somehow limits their role in the control of acute infection. However, 
their importance is demonstrated by the fact that neutropenia increases substantially the 
risk of chronic infections. Neutrophils are also able to uptake pathogens in peripheral 
tissues and transport them to lymphoid tissues, eliciting the activation of T cells through 
MHCII (Nathan 2006; Appelberg 2007).
After encountering pathogens, neutrophils play a role in initiating adaptive immunity 
by secreting pro-inflammatory cytokines such as IL-12. Apoptotic neutrophils that had 
previously ingested and killed bacteria can deliver pathogenic antigens to macrophages and 
DCs by being engulfed and processed by them, facilitating antigen cross-presentation to T 
cells. Neutrophil degranulation can enhance the phagocytic ability of macrophages and, 
moreover, the engulfment of apoptotic neutrophils results in the transfer of antimicrobial
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molecules (e.g. antimicrobial peptides) to macrophages, enhancing their killing ability 
(Silva 2010).
5.1.2. Dendritic cells (DCs)
Human monocytes do not replicate, they leave the bone marrow and enter the 
circulation. Circulating monocytes are divided in two main populations according to their 
levels of CD 14 and CD 16 expression. These surface receptors are involved in the 
recognition of LPS and of IgG- opsonised pathogens, respectively. CD14hlghCD16' cells 
are called classical monocytes since they constitute the major monocyte population in 
healthy people, whereas CD14+CD16+ monocytes express higher levels of MHC II and 
CD32 and are referred to as pro-inflammatory monocytes because they secrete substantial 
amounts of TNF-a upon TLR agonism. They are believed to be the precursors of DCs 
because of their ability to migrate across endothelial cell layers, helped by the expression 
of chemokine receptors and adhesion molecules (Strauss-Ayali, Conrad et al. 2007; 
Serbina, Jia et al. 2008).
Monocyte subsets can give origin to macrophages or dendritic cells through a 
differentiation process that is dependent on the milieu. In vitro culture of monocytes in the 
presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) together with 
IL-4 triggers differentiation into DCs. DCs have a high phagocytic capacity that enable 
them to acquire, process and present antigens to T and B cells in lymphoid tissues, helped 
by their high migratory ability. They have a short life-span and are continuously replaced 
by their blood precursor (Geissmann, Manz et al. 2010). DCs are believed to be the main 
cell type capable of transporting and presenting antigens to T cells in lymphoid tissues. 
However, macrophages and neutrophils (Abadie, Badell et al. 2005; Pozzi, Maciaszek et 
al. 2005) are also able to acquire antigens and migrate to lymphoid tissues. DCs are 
involved in the cross presentation of foreign antigens, in vivo. Cross presentation involves 
the uptake of exogenous antigens, their association with MHC class I molecules and their
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presentation, on the cell surface, to CD8+ T cells. The mechanism of cross presentation by 
DCs, still not completely understood, can generate cytotoxic immunity to viral infections, 
tumours and in response to DNA vaccination (Heath, Belz et al. 2004; Amigorena and 
Savina 2010). DCs in peripheral tissues have a high phagocytic capacity, and after being 
challenged they migrate via lymphatic vessels to the draining lymph node. During their 
migration they undergo maturation, which involves an enhancement in the expression of 
MHC II and co-stimulatory molecules that facilitates their interaction with T cells (Hope, 
Thom et al. 2004). In particular, infection of DCs with mycobacteria elicits initially the 
secretion of pro-inflammatory cytokines and later the secretion of IL-10, an anti­
inflammatory cytokine. IL-10 is a de-activating cytokine that favours intracellular 
mycobacterial survival and replication, and disease establishment (Beamer, Flaherty et al. 
2008). ManLAM present in the mycobacterial cell wall is the main ligand of DC-SIGN, a 
C-type lectin receptor on the DC surface (Maeda, Nigou et al. 2003), and this seems to be a 
key DC deactivating event. Geijtenbeek et al. reported that different strains of 
mycobacterium such as M. tuberculosis H37Ra and H37Rv, M. bovis BCG, and M  
paratuberculosis, interact with DC-SIGN via their ManLAM, and that this interaction 
stimulates the secretion of IL-10 which in turn prevents DC maturation (Geijtenbeek, Van 
Vliet et al. 2003). IFN-y activated DCs control M. tuberculosis replication but, differently 
to macrophages, do not kill intra-cellular mycobacteria, therefore these cells can become a 
reservoir of mycobacteria (Bodnar, Serbina et al. 2001).
5.1.3. Macrophages
Exposure of monocytes to macrophage colony-stimulating factor (M-CSF) induces
their differentiation into macrophages, which can then migrate to tissues (Geissmann,
Manz et al. 2010). Macrophages participate in the protection against infections, tissue
remodelling, coordination of the adaptive immune response and inflammation. They are
professional phagocytes that can efficiently internalise particles and antigens, and their
endosomal/lysosomal system is able to process from molecules to macromolecular
42
structures (Harding, Ramachandra et al. 2003). Macrophages show a high degree of 
heterogeneity, which is reflected in different functions according to the host tissue. Some 
tissue macrophages such as Langerhans cells in the epidermis, alveolar macrophages in 
alveoli and microglia cells in the central nervous system can proliferate in situ and 
maintain the cell population, while in other tissues like bone and liver the replacement of 
macrophages is from peripheral blood (Gordon and Taylor 2005). Monocyte differentiation 
is plastic and its fate is under the influence of environmental factors, as reported by 
Chomarat et al. (Chomarat, Banchereau et al. 2000). These authors observed that 
differentiation of peripheral blood monocytes into DCs, induced by GM-CSF and IL-4, 
was reversed by co-incubation with fibroblasts. The monocyte-fibroblast interaction 
induces the secretion of IL-6 by the fibroblasts, and this cytokine promotes the expression 
of M-CSF receptor on monocytes. In this way, monocytes can be influenced by the M-CSF 
they produce themselves. In turn, M-CSF directs monocyte differentiation to macrophages 
rather than DCs.
Lung alveolar macrophages (AM) constitute the first line of protection again air-borne 
organisms, including mycobacteria, and play an important role in their elimination (Hope, 
Thom et al. 2004; Kirby, Raynes et al. 2006; Kirby, Coles et al. 2009). They derive from 
peripheral blood monocytes that migrate to the lung and differentiate into alveolar 
macrophages, where they can proliferate sufficiently as to maintain the size of the lung cell 
population unchanged. Alveolar macrophages express intermediate levels of MHCII and 
high levels CD llb and CDllc, (MHCIl'"' C D llbhish CD llcl,i8h) (Strauss-Ayali, Conrad et 
al. 2007). Unlike their precursor cells, which undergo rapid apoptosis, alveolar 
macrophages are long-lived and tend to be resistant to apoptotic stimuli. Differentiation 
into alveolar macrophages results in an increased activity of the pro-survival phosphatidyl- 
inositol 3-kinase (PI 3-K)/Akt system and a decrease in the levels of a negative PI 3-K 
regulator, as well as an increased baseline ROS generation (Flaherty, Monick et al. 2006).
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Alveolar macrophages phagocytose apoptotic cells and external pathogens, and have 
recently been found to transport pathogens to lung draining lymph nodes (Kirby, Coles et 
al. 2009). They are also involved in tissue remodelling (Smith, Standiford et al. 2007). 
Alveolar macrophages express high levels of pathogen and opsonization recognition 
receptors, e.g. CR3, Fc receptors (Reynolds, Atkinson et al. 1975), SR-A (Arredouani, 
Palecanda et al. 2005), ManR (Zhang, Zhu et al. 2004), and Dectin-1 (Steele, Marrero et al. 
2003). In the lung environment, a port of entry for pathogens and particles, the expression 
of a wide range of receptors by macrophages facilitates an immediate recognition of 
pathogens that results in a more efficient innate immune response (Smith, Standiford et al. 
2007).
Li et al. have compared blood monocytes, AMs and macrophage-CSF-differentiated 
monocytes (MDMs) from different donors for changes in gene expression (Li, Pritchard et 
al. 2007). They found that, out of a total of 13,583 probes tested, 161 genes were strongly 
up-regulated and 210 were strongly down-regulated in AMs compared with MDMs. 
MHCII(DRa, DQ(31, DRp3, DPpi, DPal and DR(3), inhibin bA, the receptor MARCO, 
the chemokine CCL18, the member of the Ras oncogen family rab4A and a serine 
proteinase inhibitor can be mentioned among those more expressed in AMs. Among those 
expressed less in AMs were chitinase 3-like 1, a nuclear factor, GATA-binding protein, 
pleiotrophin, cyclin Dl, cytochrome P450 CYP1B1, the antigen CD36, adenosine 
monophosphate deaminase and the chemokine CCL3.
5.2. Phagocytosis and the phagosome
Phagocytosis is the first of a sequence of events after pathogen recognition by 
phagocytic cells. Engulfment involves the isolation of the pathogen in a phagosome, aimed 
at killing the organism and proteolytically degrade it in order to present antigens at the cell 
surface and initiate an immunological response. After uptake, the pathogen is confined in a 
cytoplasmic vesicle called phagosome that immediately starts to acquire new molecules
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from the cytoplasm through its fusion with endosomes, in a process called phagosomal 
maturation. Phagosomes recruit different Rab GTPases according to the maturation stage. 
In fact, these proteins are involved in the transport control and interaction between 
membrane-bound cytoplasmic vesicles. Fusion of phagosomes with early endosomes 
results in the acquisition of early endosomal markers such as Rab5 and early endosome 
antigen-1 (EEA-1) on the phagosomal surface. In a process termed Rab conversion, Rab5 
is exchanged for Rab7, a component of late endosomes. Rab7 recruitment is concomitant 
with the acquisition of lysosome-associated membrane proteins 1 and 2 (LAMP-1/2), 
localized in acidic lysosomes (Fig. 2).
The maturation process is accompanied by a gradual acidification of the phagosomal 
lumen, carried out by recruitment of a vacuolar ATPase proton pump from cytoplasmic 
vesicles. Concomitantly, activation of the NADPH oxidase superoxide forming system 
takes place (Rosenberger and Finlay 2003; Blander and Medzhitov 2006; Kinchen and 
Ravichandran 2008). During the initial phases of a phagosome, its pH is still close to that 
of the external milieu of the cell and this is favourable to the activity of some bactericidal 
proteins (Segal, Geisow et al. 1981). A progressive phagosomal acidification is essential 
for the activity of hydrolases and proteases such as cathepsins, which are delivered to the 
phagosome at different stages of phagosomal maturation. Garin et al. have isolated latex 
beads phagosomes and shown that their cathepsins A, D, S, and Z levels change with time 
(Garin, Diez et al. 2001). The gradual acidification of phagosomes results in a proper 
processing and presentation of antigens. Lysosomal fusion gives rise to mature 
phagolysosomes and provides a high degradative capability. In conclusion, processing of 
the phagosomal cargo ends up in the loading of MHC molecules for antigen presentation 
and, lastly, to the complete breakdown of the microorganism contained within.
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FIGURE 2. Process of phagosome formation and m aturation.
The following stages are shown: 1, pathogen recognition by a surface receptor; 2, formation of the 
phagocytic cup through pseudopode emission; 3, nascent phagosome; 4, early phagosome with its 
surface markers Rab5 and EEA-l; 5, late phagosome, which after the loss of Rab5 acquires Rab7 
and LAMP1 and 2 from late endosomes; 6, phagolysosome, a mature phagosome that fuses with 
lysosomes, acquiring proteolytic and hydrolytic enzymes. The formation of phagolysosomes is 
impaired when the pathogen ingested is a virulent mycobacteria.
Reproduced from Steinberg & Grinstein (Steinberg and Grinstein 2008), with modifications.
Rab5 and 7: small GTPase family proteins; V-ATPase: vacuolar-ATPase ; EEA-l: early endosomal 
antigen-1; LAMP1/2: lysosome-associated membrane proteins 
EE: Early endosome; LE: Late endosome; Ly: Lysosome.
Proteomic studies of mycobacterial phagosomes have reported that phagosomal 
maturation is altered by virulent strains of mycobacteria. Maturation is blocked at some 
stage, preventing the acquisition of late endosomal markers (Rao, Singh et al. 2009). 
Moreover, these studies open the discussion about ER influence in phagosome formation, 
based on the finding of several ER proteins in phagosomes. The dynamics of protein 
expression during phagosomal maturation suggests that the classical model of maturation 
is over simplistic (Rogers and Foster 2008). Trost et al. have reported the influence of IFN- 
y on mouse macrophage activation and phagosomal protein expression, showing the up- 
regulation of several classical phagosomal markers (Trost, English et al. 2009). They also 
found that, concomitantly with the effects on phagosomal maturation, IFN-y delayed the
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maturation of early endosomes and could be the reason for the increase in antigen 
presentation, supported by the presence of MHC molecules in early endosomes.
5.3. Macrophage activation
Circulating monocytes that migrate to tissues and differentiate to macrophages can 
acquire different activation states after encountering microbial products, cytokines and 
diverse tissue conditions, which translate into differences in cell phenotypes. The 
differences concern the expression of surface receptors, antimicrobial activities, antigen 
presentation and co-stimulation ability (Gordon and Taylor 2005). IFN-y or LPS induce the 
so called classical activation of macrophages that results in enhanced microbicidal activity 
associated with the production of pro-inflammatory cytokines and cell mediated immunity. 
IL-4 and IL-13, instead, induce an activation associated with tissue repair and humoral 
immunity, called alternative activation. A third kind of activated macrophages is induced 
by treating TLR4-primed cells with immune complexes (Gerber and Mosser 2001). These 
cells become anti-inflammatory and their weak response minimizes tissue damages. They 
are known as regulatory macrophages.
5.3.1. Classical activation of macrophages
Classically activated macrophages (Ca-MOs) are induced by the cytokines IFN-y and 
TNF-a. Ca-MOs are also named Ml polarized macrophages. These macrophages present 
enhanced anti-microbial and anti-tumor activities due to their increased capacity to 
generate reactive oxygen and nitrogen species, and are specifically involved in the 
protection against intracellular pathogens. Mice deficient in IFN-y and IL-12 have been 
reported to be more susceptible to infection by several mycobacterium strains (Jouanguy, 
Doffinger et al. 1999). They secrete higher amounts of pro-inflammatory cytokines (TNF- 
a , IL-ip, IL-6, IL-12 and IL-23) and chemokines (CCL15, CCL20, CXCL8-11 and 
CXCL13). The expression of the surface molecules MHCI and II, the co-stimulatory 
molecules CD80 and CD86 and ICAM-1 (Pestka, Langer et al. 1987; Boehm, Klamp et al.
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1997; Zhang, Guo et al. 2003) is up-regulated, which increases the capacity of Ca-MOs for 
antigen presentation and migration. Phagocytosis is also enhanced due to the up-regulation 
of the expression of complement receptor 3 and FcRyl (CD64), which favours the uptake 
of IgG-opsonised bacteria (Fridman, Gresser et al. 1980; Schroder, Hertzog et al. 2004).
IFN-y is initially secreted by activated natural killer (NK) cells. That secretion is 
transient, and IFN-y generation is later sustained by CD4+ Thl cells, CD8+ T cytotoxic 
lymphocytes, gamma/delta T cells and dendritic cells. IFN-y has antiviral, 
immunoregulatory and anti-tumour properties. It up-regulates the transcription of genes 
involved in pathogen recognition and killing, antigen processing and presentation, 
apoptosis, trafficking and inhibition of cellular proliferation. It suppresses Th2 cell activity, 
promotes the adhesion and binding requirements for leukocyte migration, enhances NK 
cell activity, activates APCs and promotes Thl differentiation.
Macrophage de-activation occurs due to increased amounts of IL-10 and TGF-P, by a 
complex process (Schroder, Hertzog et al. 2004; Gordon 2007).
53.1.1. IFN-y signalling pathway
Macrophage activation is induced through a signalling network triggered after binding
of IFN-y to IFN-yRl on the cell surface (Figure 3). IFN-yR is a transmembrane molecule
composed of two IFN-yRl chains associated with two IFN-yR2 chains (Schroder, Hertzog
et al. 2004). Binding of IFN-y to IFN-yRl induces conformational changes in the receptor,
allowing the interaction of the Janus kinases Jakl and Jak2 that are already associated with
IFN-yRl and IFN-yR2, respectively. These kinases can then phosphorylate each other, as
well as a residue within the cytosolic domain IFN-yRl. This phosphorylated residue works
as an anchor for the transcription factor STATla, which gets phosphorylated in its C-
terminus and forms dimers. These dimers dissociate from the IFN-yR and translocate to the
nucleus, where they initiate the transcription of genes through GAS (gamma-activated
sequence) promoter elements (Hu, Chen et al. 2007; Gough, Levy et al. 2008), resulting in
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the cellular effects of IFN-y (see sections 5.3 and 5.3.1 above). The importance of this 
cytokine is illustrated by the failure of IFN-y-deficient mice infected with M. tuberculosis 
to mount a Thl response and control the infection (Murray, Young et al. 1998). The IFN-y 
signal is physiologically regulated by suppressors of cytokine signalling (SOCS) 1 and 3, 
which are induced by IFN-y in a negative feedback, and inhibit the tyrosine kinase activity 
of Jakl and 2 (Diamond, Doran et al. 2000). IFN-y signalling is also affected by 
mycobacterial infection. M. avium is able to down-regulate IFN-yR through the expression 
of a transcriptionally inactive STAT1(3, therefore compromising the transcriptional 
response of macrophages to IFN-y (Hussain, Zwilling et al. 1999; Alvarez, Zwilling et al. 
2003).
v w
FIGURE 3. IFN-y signalling pathway. IFN-y binds to the IFN-yRl subunit on the cell surface. 
The binding induces a change in the morphological confonnation of this receptor resulting in 
inactive Jak2 kinase to be activated by phosphorylation. Jak2 in turn phosphorylates Jakl. 
Activated Jakl phosphorylates functionally critical tyrosine residues of each of the IFN-yRl chains, 
creating two adjacent docking sites for Statl. Statl dimers then translocate toward the nucleus 
where they bind to the IFN-y-activation promoter site, initiating gene transcription. Negative 
regulation of gene transcription is done by IRF-2 that antagonizes transcriptional activation of 
many (IRF-1-inducible) genes by competing for binding sites without promoting gene expression. 
Extracted from (Takaoka and Yanai 2006), with modifications.
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5.3.I.2. Toll-Like Receptors
TNF-a production and secretion by macrophages is elicited after stimulation of TLRs. 
TLR triggering induces macrophage activation, characterized by the secretion of pro- 
inflammatory cytokines, enhanced capacity to produce reactive oxygen and nitrogen 
species and an efficient association with Thl lymphocyte responses (Yadav and Schorey 
2006; Gordon 2007). Apart from TLRs, receptors such as CD 14 and dectin-1 can also 
recognise pathogens and activate macrophages (Gordon 2003).
TLRs are mammalian homologues of the protein coded by the Toll gene of Drosophila. 
They are evolutionary conserved proteins present in vertebrates, as well as in invertebrates. 
TLR molecular building blocks are represented in bacteria and in plants, and in the latter 
are known to be required for host defence against infection. The TLRs thus appear to be 
one of the most ancient, conserved components of the immune system. Nine molecules are 
operative in humans: TLRs 1-9 (Albiger, Dahlberg et al. 2007; Carpenter and O'Neill 
2007). They are transmembrane glycoproteins with an extracellular, leucin-rich domain 
responsible for PAMP recognition and a cytoplasmic portion homologous to interleukin-1 
receptor (IL-1R) (Kaisho and Akira 2002; Jin, Kim et al. 2007). TLR 1, 2, 4, 5, and 6 are 
expressed on the cell surface and recognise molecules present on the pathogen surface. 
TLR 3, 7, 8, and 9 are located intracellularly in endosomes and recognize pathogen nucleic 
acids, for which previous microbe degradation is necessary (McGettrick and O'Neill 2010). 
Binding of microbial PAMPs to the extracellular domain of TLRs triggers the recruitment 
of signalling molecules such as the adapter molecule myeloid differentiation primary- 
response protein (MyD88), with the exception of TLR3 that has TRIF as signalling 
adaptor; IL-lR-associated kinases (IRAKs); transforming growth factor-P (TGF-P)- 
activated kinase (TAK1); TAKl-binding proteins (TAB1, TAB2) and tumour necrosis 
factor-receptor associated factor 6 (TRAF6) (Akira and Takeda 2004) (Fig. 4). The 
importance of MyD88 in TLR activation is demonstrated by the fact that MyD88-/- mice 
have a reduced ability to kill M. avium (Feng, Scanga et al. 2003). Signalling ends in the
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activation of the transcription factor NF-kB present in the cell cytosol. This involves the 
phosphorylation of the NF-kB inhibitor IkB followed by its ubiquitination and subsequent 
proteolytic degradation. Free NF-kB then translocates to the nucleus and promotes the 
transcription of inflammatory cytokines (see Fig. 4 below). NF-kB also participates in 
protecting the host cell against apoptotic stimuli, making possible intracellular 
mycobacterial growth (Kaisho and Akira 2002; Akira and Takeda 2004; Cristofaro and 
Opal 2006; Dhiman, Raje et al. 2007).
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FIGURE 4. TLR2 signalling pathway. TLR2 signalling is triggered by PAMP binding. It starts 
with the association of MyD88 to the cytoplasmic region of TLR2. MyD88 recruits IRAK4, that 
associates and phosphorylates IRAKI. Phosphorylated IRAKI recruits TRAF6 (tumour-necrosis- 
factor receptor-associated factor 6), and the complex IRAKI-TRAF6 leaves the receptor and 
associates with TAK1 (transforming-growth factor-P-activated kinase), TAB1 (TAK 1-binding 
protein 1) and TAB2 (TAKl-binding protein 2). This association induces the phosphorylation of 
TAB2 and TAK1 and the detachment of IRAKI. The complex TRAF6-TAK1-TAB1-TAB2 
migrates to the cytosol and associates the two ubiquitin ligases UEV1A and UBC13, which 
ubiquitinylate TRAF6. In turn, this promotes TAK1 activation. Activated TAK1 phosphorylates 
MAP kinases and the IKK complex. The IKK complex phosphorylates IkB, which frees NF-kB 
that can then translocate to the nucleus and promote the expression of selected genes, e.g. those of 
pro-inflammatory cytokines. Extracted from Kumar, H. et al (Kumar, Kawai et al. 2009), with 
modification.
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5.3.2. Alternative activation of macrophages
Alternatively activated macrophages (AaM<E>), also named M2 polarized macrophages 
or wound-healing macrophages, are involved in the immune response to helminths 
(Kreider, Anthony et al. 2007) and protozoa (Noel, Raes et al. 2004; Raes, Beschin et al. 
2007) and in tissue repair. They are induced by the cytokines IL-4 and IL-13, produced by 
CD4+ Th2 and CD8+ T cells, NKT cells, basophils, mast cells and eosinophils in the early 
stages of tissue damage. AaMOs show an enhanced expression of SR-A, ManR and 
MHCII, and secrete more IL-4R, IL-10, IL-lra, TGF-|3 and prostaglandin E2. These 
secretion products induce a down-regulation of the inflammatory events initiated by Thl 
cytokines (Gordon 2003; Ma, Chen et al. 2003; Benoit, Desnues et al. 2008). Puig-Kroger 
et al have reported that alternative activation increases the expression of DC-SIGN in 
monocyte-derived macrophages and THP-1 macrophage-like cells, indicating that this 
receptor is a marker not only of DCs but also of alternative activation (Puig-Kroger, 
Serrano-Gomez et al. 2004).
AaMOs express increased arginase-1 but not NOS2 activity. In this way L-arginine is 
converted to ornithine, a precursor of polyamines and collagen, thus contributing to tissue 
repair (Gratchev, Guillot et al. 2001; Hesse, Modolell et al. 2001; Gordon 2003). The fact 
that IL-4 down-regulates nitric oxide generation and up-regulates the expression of 
transferrin receptor, needed for the iron uptake that is crucial for mycobacterial viability, 
creates proper conditions for mycobacterial survival (Kahnert, Seiler et al. 2006; Varin and 
Gordon 2009). In addition, treatment with IL-4 and IL-13 prevents macrophage autophagy 
induced by IFN-y, i.e. providing one more element against the control of M. tuberculosis 
infection (Harris, De Haro et al. 2007).
In general terms, intracellular pathogens and allergic diseases result in a shift of 
immune responses from Thl to Th2 and in consequence promote AaMO phenotypes 
(Noel, Raes et al. 2004; Raes, Beschin et al. 2007; Fairweather and Cihakova 2009).
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5.3.3. Regulatory (Reg) macrophages
Reg macrophages (RegMOs) are induced by a first priming signal which can be 
prostaglandins, immune complexes, glucocorticoids, adenine nucleotides, etc, followed by 
stimulation via TLRs. A change in cytokine secretion pattern, with an overproduction of 
IL-10 and a shutting off of IL-12 generation, is observed. Therefore, RegMOs are anti­
inflammatory and play an important role in diminishing tissue damage (Mosser and 
Edwards 2008). Although anti-inflammatory, RegMOs present functional and biochemical 
differences compared with AaMOs. Edwards et al. reported that RegMOs express low 
levels of arginase-1 and high levels of NOS2, as well as of MHCII and co-stimulatory 
molecules (Edwards, Zhang et al. 2006). These data suggest a similarity between RegMOs 
and CaMOs rather than AaMOs.
5.4. The use of THP-1 cells to study mycobacterium-macrophage interactions
Human macrophage-mycobacteria interactions can be studied using primary cells 
(blood monocyte-derived macrophages, alveolar macrophages from lung lavages) or in 
vitro differentiated cells. Although the use of primary cells is undoubtedly closer to a 
physiological situation, they are difficult to obtain in high amounts and suffer from the 
disadvantage of a considerable variability in cell behaviour between donors.
The THP-1 cell line originates in a monocytic leukemia. These cells become adherent 
upon treatment with low concentrations of PMA (phorbol 12-myristate 13-acetate) and 
exhibit many similarities to macrophages (Tsuchiya, Kobayashi et al. 1982).
PMA exerts its effect by activating protein kinase/s that regulate cell proliferation and 
differentiation (Schwende, Fitzke et al. 1996). Differentiated, macrophage-like cells 
acquire a macrophage morphology and phagocytic capacity similar to those of monocyte- 
derived macrophages (Daigneault, Preston et al. 2010).
Kohro et al. reported a number of differences in gene expression between MDMs and 
PMA-differentiated THP-1 cells, and between non-differentiated and differentiated THP-1
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cells. Differentiated THP-1 cells expressed higher levels of CD14, IL-lp, ManR and 
scavenger receptor A (SR-A) than undifferentiated ones (Kohro, Tanaka et al. 2004). 
CD 14 expression by PMA-differentiated THP-1 cells was also examined by Daigneault et 
al, who detected a slight, non-significant increase in the expression of CD 14 after 
differentiation, with these CD 14 levels being similar to those of MDMs (Daigneault, 
Preston et al. 2010).
The expression of some genes was similar in differentiated THP-1 cells and MDMs, e.g. 
apolipoprotein E, matrix metalloproteinase 9, integrin p 5, CD59, CSF-1, Na, K-ATPase P- 
1 subunit and transferrin receptor. Some genes involved in innate immunity such as 
ficolinl, MHC II DRal and interferon y-inducible protein were expressed by MDMs but 
not by PMA differentiated THP-1. It is worth noting that Kohro et al. used PMA at a high 
concentration (200 nM) for differentiation (Kohro, Tanaka et al. 2004).
Differentiated THP-1 cells and MDMs have been found to bind to a similar extent 
opsonised and non-opsonised M. tuberculosis, a reflection of the fact that they express 
equivalent amounts of M. tuberculosis binding receptors, but they differ in the expression 
of glucan receptor, responsible for yeast recognition (Stokes and Doxsee 1999). These 
authors also observed that both cells allowed the intracellular replication of M 
tuberculosis. Additionally, Isoniazid was active against intra-cellular mycobacteria in both 
cells, indicating that both constitute viable models for intra-cellular activity studies (Stokes 
and Doxsee 1999).
Transcriptional studies showed that THP-1 macrophage-like cells and AMs regulated 
different apoptotic genes in response to Bacillus anthracis spore challenge. Nevertheless, 
both cells were able to mount a pro-inflammatory response and secrete high amounts of 
TNF-a (Bradbume, Chung et al. 2008; Dozmorov, Wu et al. 2009). Moreover, THP-1 
macrophages were found to resist entering apoptosis after infection by virulent M. 
tuberculosis and M. bovis strains, like alveolar macrophages (Riendeau and Komfeld
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2003). Dhiman et al. showed later that the resistance of THP-1 macrophages to apoptosis is 
mediated by a long term NF-kB activation (Dhiman, Raje et al. 2007).
5.5. Killing mechanisms of macrophages
After being recognised and internalised by macrophages, invading pathogens are 
confined inside phagosomes formed by a plasma membrane invagination, with which 
cytoplasmic endosomes and lysosomes gradually fuse. Microbial killing is induced by 
lysosomal antimicrobial proteins (Martin, Ganz et al. 1995; Houghton, Hartzell et al. 2009) 
and by reactive oxygen species, nitric oxide and derived molecules (Miller and Britigan 
1997; Storz and Imlay 1999). Oxygen and nitrogen metabolites are generated by enzymes 
or protein complexes present in the plasma membrane of phagocytes and also in the plasma 
membrane-derived phagosomal membranes. These enzymes are barely active in resting 
cells (basal activity) and are activated during the process of pathogen recognition and 
uptake. Activation is favoured by inflammatory cytokines such as IFN-y and TNF-a.
Oxygen metabolites (reactive oxygen species, ROS) are generated by oxygen reduction, 
catalysed by the NADPH oxidase complex, and nitric oxide is formed from arginine 
through the activity of nitric oxide synthase (NOS2) (Babior 2000) (see reactions in Figs. 5 
and 7, sections 5.5.1.1 and 5.5.2). Since the active molecules generated can be damaging to 
the phagocyte itself and their surroundings, their levels are regulated by scavenging 
enzymes: superoxide dismutases (SOD), hydrogen peroxide-degrading catalases and 
arginine-degrading arginases. Oxygen and nitrogen metabolites exert their microbicidal 
action by reacting with key bacterial molecules. They oxidize membranes and enzymes, 
induce DNA damage and mutagenesis, and produce inhibition of membrane transport 
processes (Miller and Britigan 1997; Imlay 2003).
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5.5.1. Superoxide/ROS formation and degradation
5.5.1.1. NADPH oxidase
This enzyme complex is in a dormant stage in resting professional phagocytes and after 
becoming active catalyses the synthesis of superoxide (O2') from O2 and NADPH (Babior
2000), which leads to the generation of ROS (Fig. 5). The NADPH oxidase is composed of 
different proteins distributed between the cell membrane and cytosol. Ligation of receptors 
on the phagocyte or phagosome membrane triggers the assembly of the NADPH oxidase 
components at or close to the receptors site and oxygen reduction is switched on. 
Superoxide anion, a long-lived oxygen radical, begins to be generated on the external side 
of the cellular membrane and/or on the lumenal side of the phagosomal membrane, i.e. 
where the engulfed pathogen is present. The membrane components of the NADPH 
oxidase are gp9 \phox and p22phox, closely interacting with each other. Gp9 \phox is the 
catalytic protein in charge of the electron transfer from NADPH toward O2 . The cytosolic 
components of the NADPH oxidase are ^41phox, p67phox and p40pAo*, which associate with 
the small G protein Racl (Babior 2004). As a consequence of cell activation (receptor 
ligation), the cytosolic NADPH components translocate toward the membrane and 
assemble with the membrane-bound components to form the active oxidase complex. 
Translocation is driven by p41phox, which becomes strongly phosphorylated on serine 
residues by the action of different protein kinases, after cell activation. This induces 
conformational and affinity changes that result in the translocation of the complex and the 
activation of its catalytic activity (Figure 5) (El-Benna, Dang et al. 2008; El-Benna, Dang 
et al. 2009).
The relevance of oxygen metabolites in the protection against pathogens is illustrated by 
the situation in patients with chronic granulomatous disease. These subjects fail to activate 
the NADPH oxidase for different reasons according to the disease variant and, as a 
consequence, do not produce ROS. The result is a strong impairment in the clearance of
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many bacterial and fungal pathogens which often ends in premature death (Segal, Romani 
et al. 2009).
Extra-cellular space 
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FIGURE 5. NADPH oxidase complex assembly and superoxide generation. In resting cells, 
the components of the NADPH oxidase are distributed between the cytosol (p67phox, p47plwx, 
p40phox, Rac) and the membrane (gp91p/?av and p22phox). After receptor ligation, the cytosolic 
components are phosphorylated and translocate to the membranes where they associate with 
gp9 \phox and p22phox, constituting the active NADPH oxidase. The activated NADPH oxidase uses 
cytosolic NADPH to reduce oxygen to superoxide anion, either on the external side of the plasma 
membrane or within the phagosome, according to the site of receptor ligation. Extracted from El- 
Benna, J. et al (El-Benna, Dang et al. 2008), with modifications.
5.5.I.2. Superoxide dismutases
In order to control the negative effects of an excessive production of ROS, eukaryotic 
cells scavenge the O2' generated by the NADPH oxidase by means of superoxide 
dismutases (SODs) that catalyse the conversion of O2" to H2O2 and O2 (see Fig. 6 below).
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Dismutation of O2' can take place spontaneously but slowly, and SODs accelerate the 
reaction by 104-fold (Forman and Torres 2002).Two dismutases have been identified, the 
cytosolic, constitutive CuZnSOD and the mitochondrial, inducible MnSOD (Babior 2000). 
The H2O2 generated is bactericidal only at very high concentrations, and is quite toxic to 
cells. Catalase converts H2O2 to H2O and O2 (Fig. 6), completing the cellular protection 
system (Forman and Torres 2002).
(A) 202- + 2H+ 02 + H202
Cat
(B) 2 H20 2 -*• 2 H20  + 02
FIGURE 6. Superoxide dismutase and peroxidase reactions (protection against oxidative 
stress).
A. Superoxide dismutases catalyse the dismutation of superoxide anion in hydrogen peroxide and 
oxygen.
B. Catalase converts hydrogen peroxide in water and oxygen.
SOD : Superoxide dismutase; C a t: catalase.
5.5.2. Nitric oxide generation
The generation of nitric oxide (NO) is catalysed by NOS2 or iNOS, a soluble, 
inducible enzyme that converts L-arginine in L-citrulline and NO (see Fig. 7 below). The 
production of NO by macrophages is regulated by cytokines. Pro-inflammatory cytokines 
(IFN-y, IL-ip and TNF-a) up-regulate the expression of NOS2, increasing NO synthesis. 
The potent anti-inflammatory cytokines IL-10 and TGF-P inhibit NO generation, favouring 
the survival of intracellular pathogens. The expression of NOS2 is down-regulated when 
macrophages are alternatively activated by IL-4 and IL-13.
NOS2 activity is antagonized by arginase-1, which catalyses the hydrolysis of L- 
arginine into urea and ornithine (Fig. 7). The activity of both arginase-1 and NOS2 is 
dependent on L-arginine availability (Wanasen and Soong 2008; Pesce, Ramalingam et al.
2009), but the interplay between NOS2 and arginase-1 is not restricted to a competition for 
the same substrate. Intermediates of NO synthesis like 7V°-Hydroxy-L-arginine (NOHA)
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are able to inhibit arginase-1 activity while, on the other hand, arginase-1 can inhibit the 
expression of NOS2 at translational levels (Wu and Morris 1998).
NADPH
Arginase-1
NADP+
L-omithine 
   -
FIGURE 7. L-arginine metabolism. L-arginine is the substrate for two different enzymatic 
pathways. Classical activation of macrophages by IFN-y and TNF-a induces the expression of 
nitric oxide synthase 2 (NOS2) that uses L-arginine to generate nitric oxide (NO) and promote 
bacterial killing. Instead alternative activation of macrophages by IL-4 and IL-13, and the anti­
inflammatory cytokine IL-10, induces the expression of arginase-1 that competes with NOS2 for L- 
arginine, inducing the generation of L-omithine and collagen formation for tissue repair. Adapted 
from Gordon, S. (Gordon 2003).
NO is bactericidal at high concentrations. The effects of NO at low concentrations are 
more likely to be mediated by peroxynitrite (ONOO'), a reactive molecule generated by 
reaction of NO with O2' (Figure 8). ONOO' is a strong oxidant, its target molecules being 
deoxyribose, lipids and proteins (Bartosz 1996).
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NADPH NADP+
NO
ONOO-
NADP* NADPH
FIGURE 8. Peroxynitrite anion generation. Superoxide and nitric oxide are both generated in 
the phagosome lumen, thus having the opportunity of reacting to generate an active product, 
peroxynitrite (OONOi"). Reproduced from Fang, F.C. (Fang 2004).
6. Binding receptors involved in macrophage recruitment, signalling and 
internalisation.
An effective immune response depends on the fast recognition and elimination of
pathogens. The presence on the cell surface of more or less specific receptors that
recognise different PAMPs enables phagocytes to detect and deal with a wide range of
different pathogens. Mycobacteria express PAMPs that can be recognised simultaneously
by macrophages, involving opsonization or not. It is therefore difficult to establish which
receptor/s play more important a role. In fact, an efficient immune response may involve
the engagement of more than a single receptor. For instance, trehalose-6,6’-dimycolate (M
tuberculosis cord factor) recognition and triggering of cell signalling is mediated by
MARCO, TLR2 and CD 14 (Bowdish, Sakamoto et al. 2009). Some ligand molecules can
be recognised by more than a receptor on the phagocyte surface. In addition, the expression
of receptors changes according to the activation state of macrophages, i.e. the milieu and
tissue where they are. There is also the phenomenon of receptor cross-regulation,
commented in section 6.5 below regarding FcyRs and CRs. In any case, the route of entry
of a microorganism, in combination with the regulatory factors present in the external
milieu, will determine what signal transduction mechanism/s is/are activated and what type
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of host cell response will take place, with direct implications for bacterial survival (Ernst
1998).
6.1. Complement Receptor 3
The complement receptor 3 (CR3, <XmP2, CDllb/CD18 or Mac-1) is a heterodimeric 
surface receptor that together with lymphocyte function-associated antigen-1 (LFA-1) 
(«Lp2 or CD 11 a/CD 18), CR4 (aXp2 or CD 11 c/CD 18) and oidP2 is part of the integrin 
superfamily, with a common P2 subunit. Integrins are transmembrane proteins involved in 
cell-cell adhesion, phagocytosis, chemotaxis and cell activation (Hogg and Leitinger 2001; 
Velasco-Velazquez, Barrera et al. 2003). Activation by inflammatory mediators increases 
not only the surface expression of CR3 but also its adherence capacity, through the 
induction of conformational changes (Jones, Knaus et al. 1998).
CR3 is a promiscuous receptor that can recognize a wide variety of molecules, 
therefore it is important for the internalisation and elimination of several pathogens 
(Agramonte-Hevia, Gonzalez-Arenas et al. 2002; Mobberley-Schuman and Weiss 2005). 
Mycobacteria bind to CR3 after iC3b coating (opsonisation) or via the recognition of 
polysaccharides on its surface by the CR3 lectin domain (non-opsonic phagocytosis) 
(Mueller-Ortiz, Wanger et al. 2001). The importance of CR3 regarding the binding and 
internalization of mycobacteria was demonstrated by Stokes et al., who observed a 
significant reduction in M. tuberculosis binding after specific blocking of CR3 receptor 
with an antibody (Stokes and Doxsee 1999). However, CD 18-deficient mice were found to 
be able to phagocytose M. avium, suggesting that this pathogen can be internalized by 
receptors other than CR3 (Bermudez, Goodman et al. 1999).
Phagocytosis through CR3 is initiated after pathogen binding, which induces the 
phosphorylation of its P-chain. This leads to the association of CR3 intracellular domains 
with the cytoskeleton, resulting in phagocytic cup formation. Gaining entry through CRs is 
important for the fate of intracellular pathogens since it does not induce a respiratory burst
and results in a decreased synthesis of TNF-a and IL-12 by macrophages (Ehlers 2000;
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Irani and Maslow 2005), therefore being favourable to mycobacterial proliferation (Wright 
and Silverstein 1983).
6.2. Mannose Receptor
Mannose receptor (ManR) is a transmembrane protein belonging to the C-type lectin 
family that binds to mannose and fucose through its lectin-like carbohydrate recognition 
domain (Stahl and Ezekowitz 1998). ManR interacts with mannose-capped 
lipoarabinomannan (ManLAM) molecules of the mycobacterial cell wall, and this is a 
favourable route of entry for mycobacteria since a respiratory burst is not induced (Kang 
and Schlesinger 1998; Astarie-Dequeker, N'Diaye et al. 1999; Torrelles, Azad et al. 2006). 
Moreover, the ManR-dependent internalisation of heat-killed S. aureus or of beads coated 
with M. avium cell wall glycopeptidolipids containing mannose delays phagosome 
maturation (Shimada, Takimoto et al. 2006; Sweet, Singh et al. 2010). The importance of 
ManR was established by inhibition assays using mAb against ManR, which reduced the 
binding of virulent M. tuberculosis strains to monocyte derived macrophages by 
approximately 50% (Schlesinger 1993).
6.3. CD14
CD 14 is a glycoprotein anchored to the plasma membrane of mononuclear phagocytes. 
It is a receptor for lipopolysaccharide (LPS) from Gram-negative bacteria and 
lipoarabinomannan and phosphatidylinositol-anchored lipoglycan on mycobacteria cell 
walls (Wright 1995). CD14, associated to TLR4 and to a non-membrane-bound myeloid 
differentiation protein 2 (MD-2), forms a surface complex that recognises LPSs captured 
by soluble LPS binding protein (LBP). In this complex, the recognition of LPS is done by 
CD 14, whereas TLR4 activates signal transduction, which in turn elicits the activation of 
NF-kB followed by the secretion of pro-inflammatory cytokines such as TNF-a and IL-ip 
(Chow, Young et al. 1999; Takeuchi, Hoshino et al. 1999; Thorgersen, Pharo et al. 2009). 
CD 14 also plays a role in the uptake of non-opsonized mycobacteria by human THP-1
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macrophage-like cells and by microglia, which is a LBP-dependent event (Peterson, 
Gekker et al. 1995; Schiff, Kline et al. 1997). Although CD14 alone can induce 
mycobacterial uptake, optimal internalisation is achieved when CD 14, in combination with 
TLR2, triggers signalling leading to a more active CR3 (Sendide, Reiner et al. 2005).
6.4. Scavenger receptors
Scavenger receptors (SRs) are a group of transmembrane glycoproteins that bind and 
uptake chemically modified low density lipoproteins (LDL), apoptotic cells, and 
pathogens. These receptors have been divided in different classes according to their 
structure and ligand affinities (Gough and Gordon 2000; Palecanda and Kobzik 2001), 
with the molecules in the SR-A group being those with binding affinity for pattern 
recognition molecules (Gordon 2002). The SR-A family is composed by SR-AI, SR-AII 
and MARCO (Macrophage Receptor with Collagenous structure). The first two are 
expressed by the same gene, with the differences being due to mRNA splicing, while 
MARCO is expressed by a different gene. These SRs recognize trehalose dimycolate or 
Cord Factor (CF) from Mycobacterium tuberculosis, lipoteichoic acid (LTA) from Gram- 
positive and LPS from Gram-negative bacteria as their PAMPs, in an opsonin-independent 
way (Haworth, Platt et al. 1997; Kraal, van der Laan et al. 2000). While the binding of LPS 
to CD 14 is a mediator of macrophage activation and elicits the secretion of pro- 
inflammatory cytokines (TNF-a, IL-6, IL-12 and IL-ip), its binding to SR-A does not 
result in TNF-a or IL-12 secretion. This suggests that SR-A may be playing a protective 
role regarding excessive responses, by removing any surplus of circulating LPS (Haworth, 
Platt et al. 1997; Jozefowski, Arredouani et al. 2005; Ozeki, Tsutsui et al. 2006). Instead, 
the synergic combination of MARCO, TLR2 and CD 14 does result in macrophage 
cytokine response to trehalose-dimycolate (Bowdish, Sakamoto et al. 2009).
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6.5. Fey receptors (FcyRs)
FcyRs are a group of transmembrane proteins that bind the Fc domain of IgG. Three 
classes of receptors have been identified, FcyRI (CD64), FcyRII (CD32) and FcyRIII 
(CD 16), encoded by different genes. These receptors are involved in phagocytosis, 
endocytosis, antibody-dependent cell-mediated cytotoxicity (ADCC) and antigen 
presentation. FcyRI (CD64) is expressed in monocytes and macrophages, binds the Fc 
portion of monomeric IgG with high affinity and its expression is up-regulated by pro- 
inflammatory cytokines such as IFN-y and IL-12. FcyRII (CD32) and FcyRIII (CD 16) are 
widely expressed by innate immune cells and recognize only multimeric IgG since they 
have low affinity for IgG (Raghavan and Bjorkman 1996; Dijstelbloem, van de Winkel et 
al. 2001; Gerber and Mosser 2001; Davis, Olsen et al. 2006). FcyRs promote the 
endocytosis of small antigen-IgG complexes, enhancing in this way antigen processing and 
presentation by MHC II molecules (Raghavan and Bjorkman 1996; Ravetch and Bolland 
2001; Ortiz-Stern and Rosales 2003). FcyR structure comprises an extracellular domain 
that recognises the Fc domain of IgGs, a transmembrane domain and a cytosolic tail that is 
crucial for signalling. The latter is based on tyrosine phosphorylations, in the case of 
FcyRII variant A, or on interactions with small transmembrane proteins that contain 
phosphorylation sites. FcyRII variant B works as an inhibitory receptor through tyrosine- 
containing inhibitory motifs recruiting phosphatases that down-modulate signals by other 
FcyRs (Gerber and Mosser 2001; Park 2003). Phagocytosis elicited by FcyRs is 
characterized by the formation of a phagocytic cup after activation of Src family kinases 
and casein kinase II, which are important for actin polymerization (May and Machesky
2001). FcyRs are also able to interact with the |32-integrin subunit of complement receptors 
and modulate their activity (Ortiz-Stern and Rosales 2003).
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7. Antigen presentation
The innate immune response is extended by secretion of pro-inflammatory cytokines 
and by presentation of antigens to T cells, which initiates the adaptive immune response. 
This relies on signals induced by the major histocompatibility complex (MHC) and co­
stimulatory molecules, in the immunological synapse.
Naive T cell activation requires two distinct signals in the immunological synapse, the 
main one being antigen recognition by interaction of the TCR complex (T cell receptor 
plus its co-receptor CD4+ or CD84) with MHCI or II molecules. This interaction is critical 
to maintain the specificity of the immune response. The second signal is associated with 
co-stimulation, it is antigen-independent and is required for sustained T cell proliferation. 
The absence of co-stimulation leads to a state of T cell unresponsiveness (Bromley, Burack 
et al. 2001). Co-stimulation involves the binding of molecules of the B7 family (CD80 and 
CD86) and CD83, expressed by APCs, to CD28 on the T cell surface. This interaction is 
crucial for T cell differentiation in either CD4+ or CD8+. Differentiation is followed by 
expansion and secretion of cytokines such IL-1, IL-2, IL-4, IL-5, IFN-y, TNF-a. At a later 
activation stage, counter-receptor cytotoxic T lymphocyte antigen 4 (CTLA-4 or CD 152) is 
recruited to the immunological synapse. CTLA-4 shares the same ligands with CD28, but 
it antagonises CD28 by eliciting an inhibitory signal that works as a negative feedback in 
the regulation the T cell activation levels (Lenschow, Walunas et al. 1996; Greenwald, 
Latchman et al. 2002). Other receptors have also been described as co-stimulatory, e.g. 
ICAM-1 (Zuckerman, Pullen et al. 1998). ICAM-1 is important for the stabilization of the 
immunological synapse by binding LFA-1 on the T cell surface (Boisvert, Edmondson et 
al. 2004).
The cellular junction of the synapse is initially composed of LFA-1 on the T cell 
surface and ICAM-1 on the APC surface, which provides a base for the subsequent 
interaction between TCR on the T cell and MHC-antigen complexes on the APC surface. 
The complex TCR-MHC-antigen moves to the central part of the synapse through an actin-
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dependent mechanism, constituting the so called central supramolecular activation cluster 
(SMAC). This central SMAC is surrounded by a peripheral SMAC composed of LFA -l- 
ICAM-1 complexes that confers stability to the synapse (Grakoui, Bromley et al. 1999). 
The additional interaction of co-stimulatory molecules located on both sides, i.e. CD80, 
CD86 and CD83 on T cells and CD28 on APCs, provides signals for actin rearrangement, 
immunological synapse maturation, and T cell activation (Samstag, Eibert et al. 2003; 
Wabnitz, Kocher et al. 2007).
7.1. Molecules responsible for the immunological synapse on the APC
7.1.1. Major Histocompatibility class I molecules (MHCI)
MHCI molecules are expressed by different cell types. They are responsible for the 
priming of naive CD8+ T cells, initiating the cytotoxic immune response and the immune 
response against viral infections and tumors (Raghavan, Del Cid et al. 2008).
The MHCI heavy chain is a transmembrane glycoprotein that associates to the 
chaperone calnexin on the ER membrane and undergoes folding and disulfide bond-related 
conformational changes. The re-arranged heavy chain, together with fc microglobulin 
(fcm), is then incorporated into the peptide-loading complex involving TAP (transporter 
associated with antigen processing, composed of 2 subunits), tapasin, calreticulin, and the 
thiol oxidoreductase ERp57. Peptides generated in the cytosol are transported to the ER by 
TAPs and bind to the heavy chain of MHCI, i.e. they are loaded on the MHCI- fcm 
complex. The MHCI-peptide complex then leaves the ER and reaches the plasma 
membrane through Golgi apparatus, where it can be recognized by CD8+ T cells 
(Cresswell, Ackerman et al. 2005).
The presentation of foreign antigens is generally accepted to take place via MHCII 
molecules (section 7.1.2). However, APCs, especially dendritic cells, can acquire foreign 
antigens by phagocytosis or receptor-mediated internalization and present them associated
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with MHCI in a process called cross-presentation. Cross-presentation involves the transfer 
of internalized proteins from the phagosome to the cytosol, followed by proteolysis and 
loading on MHCI in the ER (Shen and Rock 2006).
Mycobacteria replicate within host cell phagosomes and prevent their maturation into 
phagolysosomes (Flynn and Chan 2001). Virulent strains of mycobacteria have been 
reported to be able to translocate to the cytosol contemporarily with the beginning of intra- 
phagosomal replication (van der Wei, Hava et al. 2007). Once in the cytosol, these bacteria 
can release some of their proteins, which are then proteolytically degraded. The 
corresponding peptides are transported to the ER by TAPs and loaded on MHCI molecules 
to be presented. In this way, mycobacteria can elicit cross-priming of CD8+ T cells 
(Weerdenburg, Peters et al. 2010).
7.1.2. Major Histocompatibility class II molecules (MHCH)
MHCII molecules are receptors expressed constitutively by antigen presenting cells 
(APCs), while MHCI is more widely expressed. They are responsible for the antigen- 
specific activation of CD4+ T cells that recognise MHC-antigen complexes through their 
T-cell receptor (TCR). MHC II expression is modulated by IFN-y, and this modulation can 
be modified by several other stimuli such as IL-4, TNF-a, TGF-p, IFN-a and p. Cell-cell 
interactions can also regulate MHCII expression, as well as infection with M. tuberculosis, 
which is inhibitory (Noss, Pai et al. 2001).
MHCII is a group of heterodimeric glycoproteins consisting of two non-covalently- 
linked subunits, a  (33-35 kDa) and p (25-30 kDa). The ap  dimer is assembled in the ER to 
include a third molecule, an invariant chain called Ii. After proteolysis of Ii in the ap-Ii 
complex, the ap  dimer becomes associated with the CLIP peptide. This association 
protects the complex until it reaches the endosome or lysosome, where CLIP is exchanged 
for antigenic peptides. Finally, the complex MHC-antigen is transported to the cell 
membrane, where it can be recognised by the TCR of CD4+ cells (Cresswell 1994; Mach,
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Steimle et al. 1996; Pieters 1997; Villadangos 2001; Torres, Ramachandra et al. 2006; 
Rocha-Ramirez, Estrada-Garcia et al. 2008).
7.1.3. Co-stimulatory molecules (B-7 family, CD83, ICAM-1)
These molecules are receptors responsible for the second signal that promotes T cell 
activation together with that induced by MHCI and II. They are critical for T cell 
activation, and their absence results in anergy of these cells. The interactions between APC 
and T cells are antigen independent and involve the co-stimulatory molecules B7.1 
(CD80), B7.2 (CD86) and CD83 as well as adhesion molecules like ICAM-1 and CD58 on 
the APC surface, and their corresponding ligands CD28, CTLA-4, LFA-1 (CD 11 a/CD 18) 
and CD2 on the T cell surface counterpart (Mohagheghpour, Gammon et al. 1997; 
Rajavelu and Das 2008).
7.1.3.1, B7 family
The B7 family is composed of B7.1 (CD80) and B7.2 (CD86). CD86 is constitutively 
expressed and is up-regulated immediately after MHC binding to TCR, while CD80 is 
weakly expressed in resting cells and its expression increases gradually with T cell 
activation. This reflects the different roles played by these receptors in the immune 
response: CD86 is crucial to initiate it, while CD80 is important for sustaining T cell 
activation (Vincenti 2008). CD80 and CD86 bind to the same ligand on T CD4+ cells. 
Initially they interact with the constitutively expressed CD28, leading to the activation of 
the T lymphocytes. Successively, CD28 levels are down-regulated and those of its 
homologous CTLA4 increase. CTLA4 has a high affinity for CD80 and CD86 but, 
differently to CD28, dampens the activation of T cells, keeping a balance in the immune 
response (McAdam, Schweitzer et al. 1998). Studies using blocking mAb against CD80 
and CD86, in mice, have demonstrated the importance of these receptors for CD4+ T cell 
expansion and activation (Lang, Nguyen et al. 2002). The expression of CD80 and CD86 is
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negatively affected by M. tuberculosis infection, which could compromise T cell activation 
(Kan-Sutton, Jagannath et al. 2009).
7.1.3.2. CD83
CD83 is directly involved in the modulation of antigen presentation, with its 
expression being correlated with CD86 and MHCII. During antigen presentation and 
immunological synapse formation, CD83 binds to its ligand on the T cell surface. Studies 
using CD83-deficient mice concluded that CD83 is critical for the generation CD4+ T cells 
(Fujimoto, Tu et al. 2002; Garcia-Martinez, Appleby et al. 2004). CD83 expression is well 
established in dendritic cells. It is also present in intracellular compartments of monocytes 
and macrophages, and translocates to the cell membrane upon activation by LPS (Cao, Lee 
et al. 2005; Klein, Koch et al. 2005; Breloer and Fleischer 2008).
7.1.3.3. ICAM-1 (CD54)
Intercellular Adhesion Molecule-1 (ICAM-1) is a transmembrane glycoprotein and a 
member of the immunoglobulin family with five Ig-like domains. It is expressed 
constitutively at low levels in leukocytes, and is up-regulated by pro-inflammatory 
cytokines such as IL-ip, TNF-a and IFN-y or by lipopolysaccharide (LPS). ICAM-1 
mediates cell-cell and cell-matrix interactions. CR3 (CDllb/CD18) is recognized by the 
third Ig-like domain of ICAM-1, and LFA-1 (CD 11 a/CD 18) by the first Ig-like domain. 
These interactions play an important role in leukocyte migration and in the activation of T 
cells, where it acts as a co-stimulatory molecule (Miller, Knorr et al. 1995; Fisher, Lu et al. 
1997; Roebuck and Finnegan 1999; Hubbard and Rothlein 2000).
Infection with M. avium down-regulates ICAM-1 expression in macrophages (van de 
Stolpe and van der Saag 1996; Mohagheghpour, Gammon et al. 1997; Thornton and 
McDaniel 2005). This could affect antigen presentation and the initiation of the adaptive 
immune response.
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8. Cytokine secretion
Cytokines are fine regulators of macrophage activation. They control macrophage 
responses in order to achieve a satisfactory clearance of pathogens and, on the other hand, 
to avoid excessive inflammation (Hu, Chakravarty et al. 2008).
After being challenged by pathogen molecules through TLRs, innate immunity cells 
(neutrophils, NK cells and macrophages) become activated and inflammation is promoted 
(Danelishvilli and Bermudez 2003). This active phase is characterized by the secretion of 
type 1 cytokines such as IL-lp, TNF-cx and IL-12 (Wang, Wakeham et al. 1999).
IL-12 plays an important role in the protection against intracellular pathogens by 
promoting and maintaining a Thl response. IL-12 is able to induce the production of IFN-y 
by T and NK cells. Both TNF-a and IFN-y will activate macrophages and increase their 
bactericidal activity (Brombacher, Kastelein et al. 2003; Trinchieri 2003; Langrish, 
McKenzie et al. 2004). Studies with mice deficient in the p40 subunit of IL-12 (IL-12 p40' 
have confirmed that this cytokine is critical for the control of mycobacterial infection 
through the induction of IFN-y secretion (Cooper, Magram et al. 1997; Cooper, Kipnis et 
al. 2002).
IL-lp is produced as an inactive pro-form after TLR stimulation of macrophages, and 
becomes active after a proteolytic cleavage involving the inflammasome (Martinon, Bums 
et al. 2002). M. tuberculosis infection has been reported to prevent inflammasome 
activation and therefore IL-lp activation could be compromised in infected macrophages 
(Master, Rampini et al. 2008). The cytoplasmic domain of the IL-lp receptor, IL-1R, is 
homologous to that of TLRs, and provides the link to a signal transduction leading to the 
activation of NF-kB. This results in the secretion of pro-inflammatory cytokines, i.e. in 
macrophage auto-activation (Kontny, Ziolkowska et al. 1999; Sutterwala, Ogura et al. 
2007; O'Neill 2008; Netea, Nold-Petry et al. 2009).
TNF-a is an important macrophage autocrine activating cytokine. It plays a central
role in controlling infection by inducing apoptosis of infected cells and promoting the
70
generation of oxygen radicals and nitric oxide. Contemporarily, and in order to protect the 
cells against the deleterious effects of oxygen metabolites, TNF-a increases the expression 
of mitochondrial Mn-superoxide dismutase (MnSOD) without affecting that of cytosolic 
CuZnSOD (Wong 1995). In mycobacterial diseases, TNF-a contributes to granuloma 
formation and therefore to the control of infection (Kwon 1997; Okamoto, Fujita et al. 
2006). Its role in tuberculosis control is illustrated by the effects of TNF-a blocking 
therapies employed in the treatment of Crohn’s disease and rheumatoid arthritis. In fact, 
these therapies have been found associated with an increase in pulmonary tuberculosis 
(Keane, Gershon et al. 2001; Mayordomo, Marenco et al. 2002).
The macrophage-activating effects of the IFN-y secreted by T and NK cells are 
discussed in section 5.3.1 (Classical activation of macrophages).
In order to balance the immune response and avoid tissue damages, type 2 cytokines 
(IL-4, IL-6, IL-10, TGF-P) are secreted, that counteract the pro-inflammatory activities 
elicited by infection (Opal and DePalo 2000).
IL-6 is a pleiotropic cytokine expressed during the acute-phase of infection, showing 
anti-inflammatory effects (Opal and DePalo 2000). It down-regulates the expression of the 
pro-inflammatory cytokines IL-ip and IFN-y and decreases the expression of TNF-a 
receptors, therefore decreasing the cellular response to TNF-a. It stimulates the secretion 
of anti-inflammatory molecules such as IL-1R antagonist (IL-IRa) and soluble TNF-aR, 
while it does not affect the secretion of IL-10 and TGF-|3. In addition, IL-6 also impairs 
antigen presentation by infected macrophages, which limits T cell activation (Xing, 
Gauldie et al. 1998; Danelishvilli and Bermudez 2003).
IL-10 is an important anti-inflammatory cytokine that tunes the immune response,
limiting its duration and intensity, hence diminishing tissue damage (Herrero, Hu et al.
2003). It is produced by Thl and Th2 cells, B cells, monocytes, macrophages and dendritic
cells, after stimulation. TLR2/4 agonism is a potent inducer of IL-10 synthesis. IL-10
inhibits antigen presentation by APCs through the down-regulation of the expression of
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MHCII molecules as well as the co-stimulatory receptors ICAM-1, CD80 and CD86. It 
decreases the secretion of IFN-y by Thl cells, and arrests the secretion of the pro- 
inflammatory cytokines IL-1, IL-6, IL-12 and TNF-a. Additionally, IL-10 induces the 
secretion of IL-1 Ra by macrophages, so blocking IL-1 effects (Maynard and Weaver 2008; 
Mosser and Zhang 2008). IL-10-deficient mice have been observed to be more susceptible 
to mycobacterial infection, confirming the importance of IL-10 for the regulation of 
immune responses against intracellular pathogens (Murray and Young 1999).
TGF-P is secreted in a latent form that requires proteolysis to become active. Plasmin 
is considered the most important enzyme involved in TGF-P activation, but 
thrombospondin-1, reactive oxygen species, and integrins show the same action (Khalil 
1999; Taylor 2009). In general, TGF-P dampens the function of inflammatory cells and 
promotes that of Treg cells, which induce tolerance (Wan and Flavell 2007). It acts in a 
similarly to IL-10 but in a milder way (Chen and Wahl 1999; Opal and DePalo 2000). 
TGF-P shows contrasting effects on macrophages, depending on their activation status. 
TGF-P induces an initial pro-inflammatory response when acting on resting monocytes, 
but anti-inflammatory effects on activated macrophages (Ashcroft 1999), where it inhibits 
the secretion of TNF-a and IL-1. The immunosuppressive effect of TGF-P has been shown 
by the restoration of the capacity of peripheral blood monocytes from TB patients to 
secrete IFN-y following TGF-P blocking (Hirsch, Hussain et al. 1996).
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9. Mycobacterial infection of macrophages
9.1. Mycobacteria and TLRs
Mycobacteria have developed mechanisms to escape the immune response, yet they 
express PAMPs able to activate macrophage and dendritic cells via TLR2 and TLR4 
agonism. TLR2 forms heterodimers with TLR1 and TLR6, which allows interactions with 
a broad spectrum of ligands. TLR2/TLR1 recognizes triacylated lipoproteins whereas 
TLR2/TLR6 recognizes diacylated lipoproteins and lipoteichoic acid (LTA)(Kumagai, 
Takeuchi et al. 2008). The mycobacterial lipoglycans phosphoinositol-capped 
lipoarabinomannan (LAM) and phosphatidyl-myoinositol mannosides and two 
lipoproteins, LpqH (19 kDa mycobacterial lipoprotein) and LprG, constitute the major 
mycobacterial ligands of TLR2. The role of TLR4 is not well characterized except for the 
fact that blocking TLR4 with antagonists eliminates M. tuberculosis-induced human 
alveolar macrophage apoptosis (Means, Jones et al. 2001; Gehring, Dobos et al. 2004; 
Krutzik and Modlin 2004). It is also known that, in contrast to M  tuberculosis, live M  
avium and M. bovis BCG do not activate cells in a TLR4-dependent manner (Means, Wang 
et al. 1999; Wang, Lafuse et al. 2000; Heldwein, Liang et al. 2003). TLRs do not work as 
phagocytic receptors for the uptake of mycobacteria, like CR3, ManR and FcRs do. 
However, TLR activation promotes phagocytosis by inducing the expression of 
macrophage scavenger receptor-1 (MSR1), C-type lectins, CD36, complement and Fc 
receptors (Doyle, O'Connell et al. 2004; Mae, Iyori et al. 2007).
The recognition of mycobacterial LAM by macrophage TLR2 in a CD 14-dependent 
way leads to the activation of a pro-inflammatory response (Savedra, Delude et al. 1996; 
Means, Lien et al. 1999). The ensuing signalling induces NF-kB activation and secretion of 
IL-12, which in turn drives the secretion of IFN-y (mainly by NK cells), TNF-a, IL-1 p and 
IL-6 (Zhang, Doerfler et al. 1993; Flynn and Chan 2001). In particular, ManLAM has been 
found to inhibit the secretion of the pro-inflammatory cytokine IL-12 and promote instead
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the secretion of anti-inflammatory cytokines such as IL-10 and TGF-p that deactivate host 
cells, and IL-4, that directs the immune response to Th2 (Flynn and Chan 2001; van 
Crevel, Ottenhoff et al. 2002; Appelmelk, den Dunnen et al. 2008). This creates conditions 
for the intra-cellular persistence of mycobacteria.
TLR stimulation favours the formation of reactive oxygen and nitrogen species that 
play a key role in microorganism killing. In the case of mycobacteria, intracellular killing 
is nitric oxide- but not oxygen metabolite-dependent, and TLR activation results in an 
increase in NOS2 which provides a better capacity to generate NO and kill these 
microorganisms (Raupach and Kaufmann 2001). TLR2 activation is also responsible for an 
enhanced expression of the antimicrobial peptide cathelicidin that is active against 
mycobacteria (Sundaramurthy and Pieters 2007). Additionally, TLR2 agonism down- 
regulates the expression of MHCII by macrophages (Noss, Pai et al. 2001), weakening 
antigen presentation and T cell activation (Alvarez, Zwilling et al. 2003; Banaiee, Kincaid 
et al. 2006).
Concerning other TLRs, an attenuated TLR9 activation of human macrophages by M  
tuberculosis DNA has been recently suggested to contribute to the insufficient response of 
these cells to virulent mycobacteria (Kiemer, Senaratne et al. 2009).
9.2. Subversion of the Immune response by mycobacteria
9.2.1. Defences against oxidative mechanisms
The survival of intracellular bacteria depends on how they manage to avoid the 
microbicidal mechanisms of macrophages. Oxygen and nitrogen reactive species constitute 
a powerful machinery to kill intra-cellular pathogens. Mycobacteria are not sensitive to 
oxygen but to nitrogen reactive species, but oxygen metabolism could also be of some 
relevance concerning mycobacterial growth control due to the interaction of the superoxide 
anion radical with NO that generates the powerful oxidant molecule peroxynitrite (Fig. 8). 
IFN-y treated macrophages effectively kill mycobacteria by means of reactive nitrogen
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intermediates, while ROS play a secondary role (Chan, Chan et al. 2001). Mycobacteria 
have developed mechanisms of resistance that are based on a detoxification machinery 
consisting of molecular scavengers, antioxidant enzymes and repair systems (Shiloh and 
Nathan 2000). Indeed, both M. tuberculosis and M. avium express superoxide dismutase 
and catalase activities that convert superoxide in O2 and H2O (Kusunose, Ichihara et al. 
1976; Mayer and Falkinham 1986; Mayer 1986; Wayne and Diaz 1988; Manca, Paul et al.
1999). The contribution of these enzymes to the resistance to oxidative killing was 
demonstrated by Manca et al., who observed that M. tuberculosis strains expressing low 
levels of the catalase KatG are more sensitive to oxidative killing by macrophages (Manca, 
Paul et al. 1999).
9.2.2. Effect of mycobacteria on phagosome maturation
After being recognised by TLRs and/or internalised after ligation to phagocytic 
receptors on the macrophage surface, mycobacteria employ strategies to overcome the 
killing mechanisms of the host cell and create an environment favourable to their intra­
cellular survival and replication. One of the main strategies is based on the arrest of 
phagosomal maturation. M. tuberculosis and M. avium can impair phagosomal 
acidification by inhibiting the trafficking of an ATP-dependent vacuolar proton pump 
(Schaible, Sturgill-Koszycki et al. 1998). Lack of acidification results in an inefficient or 
absent action of proteolytic/hydrolytic enzymes delivered to the phagosome by lysosomal 
fusion. Mycobacterial phagosomes do not mature properly. They retain the early 
endosomal marker Rab5 and transferrin receptor, and there is no acquisition of the late 
endosome markers Rab7 and LAMP1, nor of the tryptophan/aspartate-containing coat 
protein (TACO) which is a F-actin binding protein implicated in cytoskeletal organization 
and vesicle fusion (Figure 5) (Bhatt and Salgame 2007; Sundaramurthy and Pieters 2007). 
One of the mycobacterial molecules responsible for blocking phagosomal maturation is 
ManLAM, which inhibits increases in cytosolic calcium that are necessary for the 
recruitment of phosphatidyl-inositol-3-kinase (VPS34) to the phagosome by Rab5,
diminishes the formation of phosphatidyl-inositol-3-phosphate (PI3P) and its association 
with early endosomal antigen 1 (EEA1), finally blocking the recruitment of Rab7 that 
regulates the fusion between phagosomes and lysosomes (Kang, Azad et al. 2005; 
Shimada, Takimoto et al. 2006; Torrelles, Azad et al. 2006). The iron concentration in M 
avium and M. tuberculosis phagosomes has been reported to be higher than that in 
phagosomes containing non-pathogenic M. smegmatis (Wagner, Maser et al. 2005), and 
this may be due to a mechanism not requiring energy employed by pathogenic strains for 
iron uptake (Ratledge 2004). The altered characteristics of mycobacterial phagosomes 
prevent the fusion of lysosomes and create better conditions for mycobacterial survival 
(Pieters 2001; Amer and Swanson 2002). The block in phagosome maturation does not 
occur if macrophages are activated by IFN-y before infection, in which case mycobacteria 
can be more efficiently eliminated (Schaible, Sturgill-Koszycki et al. 1998; Hostetter, 
Steadham et al. 2002). The activity of IFN-y is antagonized mostly by IL-10, a potent anti­
inflammatory, de-activating cytokine secreted by mycobacterium-infected cells (Bermudez 
and Champsi 1993). Mycobacterial phagosomes from IL-10 knockout mice have been 
reported to be more acid than those from normal mice (Via, Fratti et al. 1998).
9.2.3. Other effects of mycobacteria on macrophage function
After becoming established within macrophages, mycobacteria start to replicate and 
secrete proteins that, in addition to the mechanisms outlined in the preceding paragraph, 
help to down-regulate host cell responses. For instance, CFP-10 (10-kDa culture filtrate 
protein) is able to reduce NO production by macrophages even after IFN-y activation, as 
well as to down-regulate the expression of the co-stimulatory molecule CD80 (Trajkovic, 
Natarajan et al. 2004). Studies on macrophage or monocyte infection with M. tuberculosis 
or M. avium, respectively, reported a reduction in co-stimulatory receptors and MHCII 
expression, and that they were less effective in presenting antigens and inducing T cell
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activation and proliferation (Mohagheghpour, Gammon et al. 1997; Kan-Sutton, Jagannath 
et al. 2009). These effects compromise the development of an adaptive immune response.
10. Potential application of natural compounds in human disease
Nature is a constant source of new compounds with potential to be employed in human 
diseases. Numerous natural substances of different chemical structure, showing 
antimicrobial activity, have been identified as potentially useful (Saleem, Nazir et al. 
2010). Plants are the origin of 25% of the drugs currently used (Demain 2009).
Since the discovery of penicillin by Alexander Fleming, many compounds have been 
isolated from microorganisms and plants and are still found in the market, e.g. 
cephalosporin, erythromycin, vancomycin, fusic acid (Pelaez 2006). Streptomycin, a 
protein synthesis inhibitor, is a classical example of successful anti-mycobacterial 
compound. Originally isolated from the actinobacterium Streptomyces griseus in 1943, it is 
still in use as first-line compound to treat M tuberculosis infection.
Some natural compounds with antibiotic activity are already close to clinical trials as 
potential candidates for tuberculosis treatment, e.g. pleuromutilin, thiolactomycin and 
cerulenin. The last two are inhibitors of a fatty acid synthase, an important target in 
mycobacteria (de Souza 2009). Mascia Lopes et al observed that extracts from Davilla 
elliptica were anti-mycobacterial toward broth-grown organisms (Mascia Lopes, Polesi 
Placeres et al. 2007). These extracts modulated macrophage responses, increasing 
oxidative and nitrosative stress, as well as an augmenting TNF-a secretion. The long list of 
plant compounds reported to be active against different mycobacterial strains confirms the 
potential of this source (Newton, Lau et al. 2000). It is hoped that some of them could 
prove effective against resistant strains. Immunostimulation has been observed after 
treating macrophages with chlorophyllin. This chlorophyll derivative enhanced the 
phagocytosis of gram-negative bacteria and was effective in preventing cell apoptosis 
through an increase in the expression of anti-apoptotic genes (Sharma, Kumar et al. 2007).
Another plant derivative, the compound albacol, induced an anti-inflammatory effect 
suppressing the LPS-induced secretion (i.e. TLR4-dependent) of pro-inflammatory 
cytokines by macrophages and dendritic cells (Liu, Shu et al. 2008; Liu, Shu et al. 2008). 
Mushrooms are an important source of immunomodulatory molecules (Borchers, 
Krishnamurthy et al. 2008) such as davallialactone, that supressed nitric oxide generation 
as well as the expression of co-stimulatory molecules, therefore compromising both innate 
and adaptive immunity (Lee, Lee et al. 2008).
p-glucans from fungi and some herbs stimulate hematopoiesis and have been used as 
adjuvants in cancer treatments since they potentiate the anti-tumour immune response, p- 
glucans are recognized by macrophages via several receptors, such as TLR2, dectin-1 and 
CR3. After being ingested, they are processed and released as small fragments. These 
small fragments are taken by phagocytes and presented to CD4+ T cells via MHCII. In this 
way (3-glucans trigger an innate immune response, enhancing phagocytosis and secretion 
of pro-inflammatory cytokines and adaptive immune response through an increase in CD4+ 
cell proliferation (Novak and Vetvicka 2008; Chan, Chan et al. 2009).
Extracts from Hippophae rhamnoides have shown an antioxidant capacity similar to 
vitamin C (Geetha, Singh et al. 2005). Similar properties have also been observed for 
statins isolated from fungi (Benati, Ferro et al. 2010); quercetin, present in apples, berries 
and onion (Kumar, Sehgal et al. 2008; Woo, Kim et al. 2008); and resveratrol, present in 
grapes, berries and peanuts (Mikstacka, Rimando et al. 2010). Besides an anti-oxidant 
activity, these compounds have been reported to inhibit iNOS and NF-kB activation (de la 
Lastra and Villegas 2007; Iyori, Kataoka et al. 2008; Youn, Lee et al. 2009), a potentially 
immunosuppressive effect due to a reduction in the secretion of pro-inflammatory 
cytokines.
Genetic polymorphisms can also be a cause of immunomodulation. Even a single 
point mutation in genes that express PRRs can change the protein and influence the 
immune response (Schroder and Schumann 2005). Polymorphisms can also limit directly
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immune responses or regulate the availability of immunomodulating molecules. Like any 
other drug, immunomodulatory drugs are subjected to cellular clearance such as by the 
cytochrome P450 system expressed from CYP genes (Zhou 2008). Inter-individual 
variability in the expression of CYP genes results in different drug metabolic rates and 
elimination among individuals (van der Weide and Steijns 1999). Thus, the efficacy of 
immunomodulatory compounds is also dependent on the genetic background.
10.1. Quinones
Tabebuia avellanedae, also known as “Ipe-roxo” or lapacho, is an evergreen tree of 
the Bignoniaceae family that grows in many tropical/subtropical countries. Natives of 
South America have traditionally used this plant for medicinal purposes. The use of teas 
made with the bark of Tabebuia is currently registered as a dietary supplement by the Food 
and Drug Administration (Gomez Castellanos, Prieto et al. 2009).
Several compounds have been identified in the bark of Tabebuia plants, and among 
them some naphthoquinones raise a particular interest. Lapachol (NSC-11905) is a 2- 
hydroxy-3-(3-methyl-2-butenyl-)-1,4-naphthoquinone and the most abundant quinone 
present in the Bignoniaceae family. It is structurally related to vitamin K (Petrova et al.,
2000) of which it is an antagonist (Preusch and Suttie, 1984).
Other 1,4-naphthoquinones such as P-lapachone, juglone, plumbagin, menadione, 
atovaquone and lawsone (Fig. 9) have had an application in clinics. Atovaquone is used for 
the treatment of Pneumocystis carinii pneumonia, and is used in association with proguanil 
as a well tolerated anti-malarial compound (Taylor and White 2004; Nakato, Vivancos et 
al. 2007). Plumbagin and (5-lapachone have been reported to have anti-tumour activity 
(Boothman, Trask et al. 1989). The anti-tumour activity of plumbagin has been ascribed to 
NF-kB inhibition (Sandur, Ichikawa et al. 2006). The same mechanism of action was 
responsible for the immunosuppressive effect of plumbagin on T cells (Checker, Sharma et
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al. 2009). Plumbagin has also been reported to be anti-mycobacterial (Mossa, El-Feraly et 
al. 2004).
Menadione, another naphthoquinone, is a vitamin K analog that generates oxidative 
stress, which is a common characteristic of this group of substances (Castro, Mariani et al. 
2008). However, menadione did not cause an increase in levels of superoxide dismutase of 
mycobacteria (Garbe, Hibler et al. 1996). Juglone has been reported to be anti-proliferative 
and cytotoxic to tumor cells (Bonifazi, Rios-Luci et al. 2010; Montenegro, Araujo et al.
2010). Lawsone is present in henna dyes used for tattooing. It stimulates oxidative stress in 
keratinocytes, but weakly compared with other compounds of this group (Klaus, Hartmann 
et al. 2010).
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FIGURE 9. Chemical structure of 1,4-naphthoquinones. 1, Lapachol; 2, |3-lapachone; 3, 
plumbagin; 4, atovaquone; 5, juglone; 6, menadione.
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Quinones in general and hydroxy-naphthoquinones in particular have been reported to 
be substrates for membrane-bound bacterial anaerobic reductases (Rothery, Chatteijee et 
al. 1998). They can also act as substrates for the cytochrome be system of prokaryotes and 
eukaryotes (Kessl, Moskalev et al. 2007), and promote the generation of reactive oxygen 
species at mitochondrial level (Docampo, De Souza et al. 1978; Bolton, Trush et al. 2000; 
Goulart, Falkowski et al. 2003). This occurs by NADPH-cytochrome P450 reductase- 
catalysed reduction, which generates semiquinone radicals. Semiquinones can be re­
converted into the original quinones by reducing oxygen to superoxide (O2"), which gives 
rise to ROS (Fig. 10) (Bachur, Gordon et al. 1979; Kumagai 1997; Goulart, Falkowski et 
al. 2003).
o-
NADPH oxidized
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o
FIGURE 10. Naphthoquinone reduction by NADPH-cytochrome P450 reductase. Redox 
cycling activity can render naphthoquinones toxic. They are reduced by cytochrome P450 
reductase at the expense o f NADPH, generating semi-naphthoquinone and superoxide anion 
radicals. Superoxide anions are reactive, oxidizing molecules that can modify proteins, DNA and 
lipids. Extracted from Bachur et al (Bachur, Gordon et al. 1979), with modifications.
Lapachol was the 1,4-naphthoquinone extensively studied during the present work. It 
is a multi-active compound reported to have larvicidal (Oliveira, Lemos et al. 2002; 
Lemos, Monte et al. 2007), antiviral (Sacau, Estevez-Braun et al. 2003), bactericidal 
(Guiraud, Steiman et al. 1994; Oliveira, Miranda et al. 2001; Machado, Pinto et al. 2003; 
Park, Lee et al. 2006; Pereira, Machado Tde et al. 2006), fungicidal (Guiraud, Steiman et 
al. 1994; Breger, Fuchs et al. 2007), anti-protozoal (Duarte, Dolabela et al. 2000; De
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Moura, Emerya et al. 2001; Teixeira, de Almeida et al. 2001; de Andrade-Neto, Goulart et 
al. 2004; Lima, Correia et al. 2004; Perez-Sacau, Estevez-Braun et al. 2005; Salas, Tapia et 
al. 2008), anti-inflammatory (de Almeida, da Silva Filho et al. 1990; Bezerra, De Oliveira 
et al. 2005; Lira, Sester et al. 2008) and limited anti-tumor (Rao, McBride et al. 1968; 
Oliveira, Lemos et al. 2002; Ravelo, Estevez-Braun et al. 2004; Bezerra, De Oliveira et al. 
2005) activities, with different efficacies. Apart from its antifungal activity (Guiraud, 
Steiman et al. 1994), the antimicrobial concentrations of lapachol were found to be > 
30pg/mL. Lapachol has been reported to be anti-proliferative at high concentrations 
(Duarte, Dolabela et al. 2000; Oliveira, Lemos et al. 2002; Bezerra, De Oliveira et al. 
2005; Esteves-Souza, Figueiredo et al. 2007), whereas some reports describe an anti­
metastatic effect in vivo, at non-toxic doses (Balassiano, De Paulo et al. 2005; Maeda, 
Murakami et al. 2008). Based on in vitro assays, lapachol has been suggested to be anti­
proliferative because it inhibits DNA-topoisomerase II-a, although only a partial inhibition 
was achieved at 0.20 mM (Esteves-Souza, Figueiredo et al. 2007). Knowledge on the 
clinical use of lapachol as an anti-infectious agent is lacking. Within the wide spectrum of 
activities of lapachol, no anti-mycobacterial action has been reported to date. No in vitro or 
in vivo studies are available either about its influence on innate immunity responses, i.e. on 
whether it shows immunomodulatory characteristics.
In vivo experiments have shown that the oral administration of lapachol (100 mg/kg) 
to rats for 5 days did not produce any alteration in total body nor in organ weights (de 
Cassia da Silveira and de Oliveira Guerra 2007). Only a reduction in male seminal vesicle 
weight was observed, while gamete production was not affected. When lapachol was 
administered at the same dose to pregnant rats, there were no indications of maternal 
toxicity or of toxicity toward pre-implantation embryo development. The only negative 
effect was a higher proportion of reabsorptions and a lower weight of fetuses and placentae 
(de Almeida ER 1988; Maganha J 2006). During studies on the anti-tumor activity of 
lapachol in rats, a maximum tolerated and a minimum effective oral dose of 750 and 90
mg/kg, respectively, were observed (Rao, McBride et al. 1968). Again, there was relatively 
little effect on body weight. The most extensive toxicology studies were carried out by 
Morrison et al. (Morrison, Brown et al. 1970). They reported high values for single dose 
LD50s in mice and rats: 0.6 g/kg and 2.4 g/kg, respectively. No lethality was found by 
administration of up to 2 g/kg daily for a month to dogs. Gross and anatomical findings 
were not remarkable: all tissues, including bone marrow and kidneys, were normal. There 
was only some hemosiderin deposition in liver Kupffer cells and splenic red pulp, and 
reversible anemia was observed. In monkeys, lethal doses were of 0.5-1.0 g/kg over 5-6 
days. Anemia was again the major feature, which returned to normal during the period of 
drug administration. Bilirubinuria and proteinuria were also detected.
Human studies of lapachol were performed by Block et al. (Block, Serpick et al. 1974) 
in relationship with its presumed anti-tumour activity, based on the animal studies 
mentioned in the paragraph above. Lapachol, although without anti-tumour activity, was 
well tolerated at <1.5 g/day for up to at least 21 days (21 mg/kg for a 70 kg body weight). 
At >2 g/day (29 mg/kg for a 70 kg body weight) nausea, vomiting and an anti-coagulant 
effect were observed (Block, Serpick et al. 1974; Sieber, Mead et al. 1976). The latter 
probably derives from its being a vitamin K antagonist, since vitamin K can correct the 
effect. These toxic effects, observed with high doses, were not severe and were reversible. 
No hematologic, renal or liver function impairments were detected after the lapachol 
treatments. The serum concentrations of lapachol achieved ranged from 6 to 26 mg/L and 
peaked at 15-26 mg/L, 8 hours after a single oral administration of 35 mg/kg. A convenient 
feature was that serum levels were rather persistent, and after 24 hours the concentration of 
lapachol was still 30-50% of the peak value. Persistence was improved by administering 3 
smaller doses in consecutive days (Block, Serpick et al. 1974).
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10.2. Other compounds causing microbial growth arrest used during the present 
work
Other synthetic compounds employed in this study were (Figure 11): l,2-0-diacyl-3- 
O-glucosylglycerol (9A), a chemically modified glycolipid of plant origin previously 
reported be active against Gram-positive and Gram-negative bacteria and Mycobacterium 
tuberculosis (Cateni, Bonivento et al. 2007); N1-(3-aryl-l-(pyridin-2-,3-,4-il)-3-oxo)- 
propyl)-2-pyridine carboxamidrazone, a synthetic compound active against against M. 
tuberculosis and M. avium (Mamolo, Falagiani et al. 1999; Banfi, Mamolo et al. 2001) ; 
and the compounds AC 178, AC201, AC202, AC203, and AC204 of unknown chemical 
structure due to the manufacturers’ protection policy.
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FIGURE 11. Chemical structure of the compounds 9A and F2 used in this study. 1,2-0- 
diacyl-3-O-glucosylglycerol (9A) (Cateni, Bonivento et al. 2007) and N1-(3-(4-CH3)aryl-l- 
(pyridin-2-il)-3-oxo)-propyl)-2-pyridine-carboxamidrazone (F2) (Banfi, Mamolo et al. 2001).
11. Rationale and strategy of the present work
In order to explore the potential of novel compounds as possible therapeutic drugs it is 
appropriate to study their effect on mammalian cell functions, at molecular level. In this 
direction, the use of cell culture systems can provide valuable information before engaging 
in in vivo experimentation. Cell cultures allow the study of both resting and activated cells, 
providing the possibility to mimic physiological activations or situations. The information 
obtained can give hints about how the situation could be when the drug is administered to a 
complex organism, and work as a first filter to exclude a number of candidate drugs at an
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early stage, avoiding unnecessary animal experimentation. Drugs that pass the cell culture 
stage of the evaluation will obviously need to be subjected to in vivo studies, and clinical 
trials will eventually follow.
During the present work, the anti-mycobacterial effect of candidate compounds was 
evaluated, first on bacteria growing in liquid broth and subsequently on intracellular 
bacteria, using macrophage-like cells as host cells. The next stage was to examine the 
influence of candidate compounds on activation-inducible macrophage functions and 
protein expression, to gain knowledge on their immunomodulating and functional effects. 
The methodology for the evaluation of anti-mycobacterial compounds included:
1. Determination of their capacity to arrest the growth of M. avium in liquid broth.
2. Assessment of their effect on macrophage-like cells viability.
3. Determination of their capacity to arrest the intra-macrophage growth of M. avium.
4. Study of their effects on macrophage responses to activation by TLR2 agonism or IFN- 
Y, or to M. avium infection, such as: oxidative and nitrosative stress, phagocytosis, antigen 
presentation and cytokine secretion.
5. Analysis of the changes in the protein expression pattern of activated or infected 
macrophages elicited by the compound studied.
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MATERIALS AND METHODS
1. Compounds of potential antibiotic activity
Lapachol (98.8% pure, according to HPLC), was kindly provided by the Antibiotic 
Department of the Federal University of Pernambuco (Brazil). The providers ensure the 
drug is LPS-ffee. It is of plant origin and is currently employed in human cancer treatment, 
for which it must be LPS-free. Concentrated stock solutions were made in DMSO. 
Clarithromycin (VECLAM®, Abbott), ethambutol (ETAPIAM®, PI AM), and rifampicin 
(RIFADIN®, Aventis) were kindly provided by Dr. Roberto Luzzati (Department of 
Infectious Diseases, University Hospital, Trieste, Italy). Concentrated stock solutions were 
made in phosphate-buffered saline (PBS). The compounds N l-(3 -(4 -CH3)aryl-l-(pyridin- 
2-il)-3-oxo)-propyl)-2-pyridine-carboxamidrazone (F2) and l,2-0-diacyl-3-0- 
glucosylglycerol (9A) were provided by Dr. Elena Banfi (Department of Biomedical 
Sciences, Microbiology Section, University of Trieste, Italy). Concentrated stock solutions 
were prepared in DMSO. The AC series compounds (AC 178, 201, 202, 203 & 204) were 
kindly provided by Avidin Ltd (Hungary). Concentrated stock solutions were made in 
DMSO. The final concentration of DMSO in mammalian cell cultures was always <1%, a 
concentration known to show no effects. Controls were always run containing the same 
concentration of DMSO as that introduced with the addition of the different compounds to 
cultures.
2. Main solutions
Protease inhibitor stock solutions (Complete®, Roche Diagnostics, Mannheim, 
Germany) were prepared by dissolving one tablet in 2 mL of water, yielding a 25x 
solution.
FACS buffer contained 5mM glucose, 0.1% (w/v) NaN3 and 1% (v/v) fetal calf serum 
(FCS), in PBS.
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5X SDS-PAGE running buffer was composed of 30g of TRIS base, 144g of glycine 
and 5g of sodium dodecyl sulphate (SDS) per litre. Western blotting solutions were made 
of 0,5X running buffer plus 5% (v/v) methanol.
The isoelectrofocusing strip equilibration buffer used for the proteomic studies 
contained 50mM Tris HC1 (pH 8 .8 ), 6  M urea, 30% (v/v) glycerol, 2% (w/v) SDS and trace 
amounts of bromophenol blue (BPB).
5X TBE buffer consisted of 54 g of TRIS base, 27.5g boric acid and 20 mL EDTA 
(0.5M, pH 8.0) per litre.
3. Cell cultures
3.1. Mammalian cell cultures
THP-1 human monocytic cells (Auwerx 1991) (ATCC TIB-202, American Type 
Culture Collection, Rockville, MA) were cultured in a humidified, 5% CO2 incubator, at 
37°C, in RPMI 1640-GlutaMAX™ medium (Gibco®, Invitrogen, Milano, Italy) containing 
25 mM glucose, 10 mM Hepes, 1 mM sodium pyruvate, and 10% (v/v) fetal bovine serum 
(EuroClone®, Celbio, Milano, Italy). The culture medium used for cell sub-culturing and 
amplification contained additionally 100 U/mL penicillin, 0.1 mg/mL (170 pM) 
streptomycin and 0.25 pg/mL (270 nM) amphotericin B (Sigma-Aldrich). Cells were 
continuously treated with 20 nM phorbol myristate acetate (PMA; Sigma). After four days, 
differentiation was complete and stimulations or infection were started, always in the 
presence of 20nM PMA.
3.2. Mycobacterium avium cultures
M. avium strain 485 (serovar 21, transparent colonies) was kindly provided by the 
Istituto Superiore della Sanita’ (Rome, Italy) (Fattorini, Xiao et al. 1994). It was originally 
isolated from the blood of an AIDS patient. The use of M. avium was based on: 1) the 
increase of infections caused by this non-tuberculous mycobacterium, and 2 ) the
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similarities between M. tuberculosis and M. avium (Sturgill-Koszycki, Schlesinger et al. 
1994; Schaible, Sturgill-Koszycki et al. 1998) in their intracellular behaviour, which make 
M. avium a good model of M. tuberculosis for in vitro studies.
3.2.1. Growth on agar
Bacterial dilutions were plated on Middlebrook 7H11 agar supplemented with 10% 
oleic acid-albumin-dextrose complex (OADC, Difco Laboratories, Detroit, MI) and grown 
at 37°C in microaerophilic jars until discrete colonies (colony forming units: CFU) were 
observed, usually after 10 to 15 days of incubation.
3.2.2. Growth in liquid medium
M. avium was grown at 37°C in Middlebrook 7H9 broth supplemented with 10% 
albumin-dextrose complex (ADC, Difco Laboratories, Detroit, MI) and 0.5% (v/v) glycerol 
until approximately 109 cells/mL. The exact number of viable colony counts was 
determined by growth on Middlebrook 7H11 agar plates. Bacterial suspensions were stored 
at -80°C.
3.2.3. Susceptibility of M. avium to potentially antibiotic compounds (growth in 
liquid culture)
This was performed by the microplate Alamar Blue assay (Franzblau, Witzig et al. 
1998), using 96-well plates (Falcon 3595; Becton Dickinson, Lincoln Park, NJ). The 
method is based on the change of colour from blue to pink on bacterial growth, indicative 
of the reduction of resazurin, to resorufin, Serial dilutions of the compound under study 
were done so that 10 out of the 12 wells in each column contained 100 pi of 7H9 broth and 
the test compound at concentrations halving sequentially from one well to the next in each 
column, from a maximum of 128 down to 0.5 pg/mL. Eight control wells, in a row, 
contained only 7H9 broth and no lapachol. Subsequently, 0.1 mL of a M. avium inoculum 
containing 106 bacteria was added to each of the wells, the plate was sealed with Parafilm 
and initially incubated at 37°C for 5 days. To follow bacterial growth, 50 pL of Alamar 
Blue mix, consisting of CellTiter-Blue™ reagent (Promega, Madison, WI) and 10% (v/v)
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Tween 80 (1:1), was added in the first place to one of the control wells. If the colour did 
not turn pink after 24 hours at 37°C, Alamar Blue mix was added to another of the control 
wells and the colour checked after further 24 hours. This was repeated until the pink colour 
of a control well indicated good M. avium growth. At that point, Alamar Blue was added to 
all the wells in the plate, i.e. those corresponding to all the different concentrations of the 
test compound as well as the remaining control wells. After 24 hours at 37°C, an image 
showing the colour of the well liquids was recorded (see figure below). The minimal 
inhibitory concentrations (MIC) of the test compound correspond to its concentration in the 
first blue well in the column (indicating no growth) immediately after a series of pink- 
coloured wells (indicating bacterial proliferation).
3.2.4. Bacteriostasis against bacterial killing
To determine whether lapachol and AC201 were bacteriostatic or bactericidal, M 
avium (starting concentration 107/mL) was cultured in the absence or presence of 16 
pg/mL (6 6 pM) or 32 pg/mL (132pM) lapachol, or 32 pg/mL (800pM) AC201, in Falcon® 
tubes. Aliquots were taken from the cultures at day=0, 1, 3 and 7, diluted appropriately and 
plated on agar as described above in section 3.2.1. CFUs were counted after 10 to 15 days 
of incubation in microaerophilic jars, at 37°C.
3.2.5. Intracellular proliferation o fM  avium
THP-1 macrophage-like cells were infected with M. avium for 4 hours in wells 
containing 106 cells each, at a bacterium-to-cell ratio of 30:1 (Pittis, Muzzolin et al. 2003), 
then washed 3 times with PBS and kept in culture at 37°C in a 5% CO2 incubator. The 
number of cell-associated bacteria was determined at time zero (end of internalisation 
period), day 3 and day 7. Cells were scraped and lysed with 0.025% SDS, after which the 
SDS in the lysates was neutralized with 0.5% albumin (Bermudez, Petrofsky et al. 2004). 
Lysates were then diluted and plated on Middlebrook 7H11 agar and incubated for 10 to 15 
days as described above in 3.2.1, in order to determine M. avium CFUs. Some of the 
colonies could have originated in extra-cellular bacteria that survived attached to the
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plastic surface of wells, not having been washed off at the end of the phagocytosis period. 
These hypothetical, non- or slowly proliferating extra-cellular bacteria would in fact 
contribute more to the total number of CFUs at early times (t=0 and day 3) than at day 7, 
when intra-cellular growth is under way. Therefore, the intra-cellular growth data 
corresponding to day 7 are likely to be underestimated relatively to the CFUs determined at 
t=0 .
3.2.5.1. Intracellular M. avium growth arrest by test compounds
The procedure was as indicated above (3.2.5) for intracellular proliferation, but adding 
16 pg/mL (6 6 pM) or 32 pg/mL (132pM) lapachol; 32 pg/mL (800pM) AC201; 0.56 
pg/mL (750nM) clarithromycin; 1.6 pg/mL (1.9pM) rifampicine or 0.35 pg/mL (1.71pM) 
ethambutol at time zero (end of internalisation period). The number of cell-associated 
viable bacteria was also determined at day 3 and day 7, as described above (3.2.5).
3.3. Staphylococcus aureus and Salmonella typhimurium cultures
S. aureus (502A strain) and S. typhimurium (SL3261AT, GFP-expressing) were used 
as examples of Gram-positive and Gram-negative organisms, respectively. They were 
grown in Luria broth (LB) overnight at 37°C and the number of viable bacteria was 
determined by plating on Luria agar and incubation overnight at 37°C. Bacteria were 
stored at -80°C.
3.3.1. Susceptibility of S. aureus and S. typhimurium to test compounds (growth 
in liquid culture)
This was performed according to the methodology described by Andrews, J. M. 
(Andrews 2001). The MIC of lapachol and AC201 toward S. aureus and S. typhimurium 
was determined in tubes containing 5 mL of LB broth and serial dilutions of the 
compounds being tested, from 256 to 0.5 pg/mL. Bacteria were then inoculated at the 
initial concentration of 105 CFU/mL. Positive controls did not contain any test compound, 
and negative controls consisted of LB without both test compounds and bacteria. The tubes 
were incubated overnight at 37°C and growth was checked the next morning by turbidity
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development. The MIC was the lowest concentration of the compound that prevented
bacterial growth.
4. Cell morphology
THP-1 morphology was examined after treating the cells with the test compounds at 
their MICs for four days. Light microscopy photographs were taken using an inverted 
microscope (Nikon, TMS-F), at 100X magnification. Quantification of cell size was 
performed recording the pixels of 100 cell areas in each case. Forward and side light 
scatter were used to quantify cell size and granularity, respectively. Results are expressed 
as averages ± SD and were analysed by ANOVA.
5. Apoptosis and necrosis
Macrophage apoptosis was quantified by detection of phosphatidylserine 
extemalisation to the outer leaflet of plasma membranes, by Annexin V-FITC staining, 
according to the manufacturer’s instructions (APOPTEST™-FITC, Nexins Research, 
Kattendijke, The Netherlands). Briefly, cells (105 to 106/mL) were washed, resuspended 
with 0.49 mL of ice-cold binding buffer and added 5 pi of 25 pg/mL Annexin V-FITC. 
After 10 min incubation in the dark, at 4°C, cells were washed with 0.25 mL of binding 
buffer and analysed immediately by flow cytometry. Blanks were cells incubated with 
binding buffer alone, negative controls were cells in the absence of antibiotics and positive 
controls were cells incubated for 48 hours with 2pg/mL (3.4 pM) etoposide in binding 
buffer, at 37°C.
Necrosis was evaluated by analyzing DNA fragmentation. DNA was prepared by 
standard phenol-chloroform extraction, after proteinase K digestion, from freshly harvested 
cells that had been treated or not with 32 pg/mL (132pM) lapachol for 4 or 7 days or with 
32 pg/mL (800pM) AC201 for 4 days. DNA (200 ng/lane) was run on 0.8% agarose gels 
containing ethidium bromide.
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6. Binding and internalisation of particles and bacteria
6.1. Latex beads
Plate-adherent macrophage-like cells were treated or not with P3CSK4 (300 nM) for 4 
days and subsequently incubated with or without lapachol (132pM) for 4 additional days. 
Latex beads were then added (amine-modified, fluorescent yellow-green, Sigma-Aldrich, 
St. Louis, MO) at a 5:1 multiplicity (chosen on the basis of preliminary experiments), 
centrifuged for 15 min at 800Xg and left for 30 min at 37°C. After washing 3 times with 
PBS, cells were scraped off, resuspended in FACS buffer and analysed by flow cytometry 
(104 cells per event). Phagocytosis (%) is expressed as [number of cells taking up any 
number of particles]/[total gated cell number] X 100. Phagocytic activity indicates the 
number of latex beads internalized into cells, and is expressed as the median fluorescence 
intensity (MFI) of the FACS histograms.
6.2. S. aureus
Plate-adherent cells were treated or not with P3CSK4 (300 nM) for 4 days and 
subsequently with lapachol (132pM) for 4 additional days. S. aureus were then added at a 
50:1 bacteria/cell multiplicity. This ratio was chosen according to preliminary 
experiments. The plates were centrifuged for 15 min at 800Xg and incubated at 4 or 37°C 
for 30 min. Cells were then washed 3 times with PBS, scraped off and pelleted. Pellets 
were lysed with 0.2 mL of 1 mM NaOH (pH 11) and the lysates were diluted and plated in 
LB agar. After overnight incubation at 37°C, CFUs were counted. Results correspond to 
cell-associated CFUs.
6.3. S. typhimurium
Plate-adherent macrophages were treated or not with P3CSK4 (300 nM) for 4 days and 
subsequently with lapachol (132juM) for 4 additional days. Fluorescent (GFP) S. 
typhimurium were then added at a ratio of 50 bacteria/cell. This ratio was chosen 
according to preliminary experiments. The plates were centrifuged for 15 min at 800Xg
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and incubated at 4 or 37°C for 30 min. Cells were then washed 3 times with PBS, scraped 
off and pelleted. Pellets were resuspended in FACS buffer (PBS containing 5 mM glucose, 
0.1% NaN3 and 1% FCS) and analysed by flow cytometry (104 cells per event). 
Phagocytosis (%) is expressed as [number of cells taking up any number of particles]/[total 
gated cell number] X 100. Phagocytic activity indicates the number of bacteria internalized 
into cells, and is expressed as the median fluorescence intensity (MFI) of the FACS 
histograms.
6.4. M. avium
6.4.1. Preparation of M. avium-FTTC
M. avium (3X108 CFUs) were incubated with fluorescein isothiocyanate isomer 1 
(FITC, Sigma-Aldrich, St. Louis, MO) for 30 min, at 20°C, in 1 mL of 50 mM Na2CC>3- 
100 mM NaCl (pH 9.2) (de Boer, Bevers et al. 1996) and washed with PBS till the 
supernatants were no longer fluorescent. These labeled bacteria were resuspended in THP- 
1 cell culture medium and used to infect adherent THP-1 cells as described below.
6.4.1.1. Binding and internalisation by flow cytometry
Adherent cells were treated or not with P3CSK4 (300 nM) for 4 days and subsequently 
treated with lapachol (132juM) for 4 additional days. M. avium-FTTC was then added at 
30:1 multiplicity. This ratio was chosen according to previous work (Pittis, Muzzolin et al. 
2003). After centrifugation for 15 min at 800Xg, they were left for 4 hours at 4 or 37°C and 
then washed 3 times with PBS. Cells were scraped off, resuspended in FACS buffer and 
analysed by flow cytometry (104 cells per event). Phagocytosis (%) is expressed as 
[number of cells taking up any number of particles]/[total gated cell number] X 1 0 0 . 
Phagocytic activity indicates the number of bacteria internalized into cells, and is 
expressed as the median fluorescence intensity (MFI) of the FACS histograms.
6.4.1.2. By fluorescent microscopy
Adherent cells were grown on round coverslips, treated with P3CSK4 (300 nM) for 4 
days and then with lapachol (132pM) for 4 additional days. They were infected at 37°C
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with M. avium-FTTC at 30:1 multiplicity. This ratio was chosen according to previous 
work (Pittis, Muzzolin et al. 2003). After centrifugation for 15 min at 800Xg cells were left 
for 4 hours and washed with PBS. They were then fixed with 4% (w/v) paraformaldehyde 
(PFA) for 20 min, washed with PBS and permeabilized with 0.1% Triton X-100 (in PBS), 
for 5 min. They were washed, incubated with 0.1M glycine in PBS to block the PFA, 
washed again and counter-stained for actin by incubation with 0.4 U/mL Rhodamine 
Phalloidin (Invitrogen, OR), for 30 min, at RT, in the dark. The coverslips were washed, 
dried, mounted on slides using Vectashield (Vector Labs., Burlingame, CA) and sealed for 
further examination under the fluorescence microscope. Digital images were acquired and 
processed using Adobe Photoshop, version 6.0 (Mountain View, CA). Phagocytosis was 
quantitated by counting the number of fluorescent M. avium in 200 cells for each situation 
or condition. It is expressed as the ratio between the total number of bacteria ingested and 
the total number of cells.
7. Cell surface markers by flow cytometry
Adherent THP-1 macrophage-like cells were treated with P3CSK4 (300 nM) or IFN-y 
(100 U/mL) for 4 days, then with lapachol (132pM) for 4 additional days. Cells were 
scraped off, pelleted, resuspended with 200 jliL  of FACS buffer (PBS containing 5 mM 
glucose, 0.1% NaN3 and 1% FCS) and incubated for 30 min at 4°C with 5 pg/mL mouse 
IgG in order to block Fc receptors. The cells were washed twice with FACS buffer and 
then incubated with the corresponding antibody at 10 pg/mL for 40 min, at 4°C. The 
following mouse monoclonal antibodies were used: for IFN-y receptor, mAb sc-12755 
(Santa Cruz Biotechnology, Santa Cruz, CA); for ICAM-1 (CD54), a mAb labeled with 
phycoerythrin (PE) (sc-107, Santa Cruz Biotechnology); for MHCII, a PE-labeled mAb 
(120P, Chemicon International, Temecula, CA); for CD 16, mAb sc-20052 (Santa Cruz 
Biotechnology, Santa Cruz, CA); for CD32, mAb sc-13527 (Santa Cruz Biotechnology, 
Santa Cruz, CA); for CD64, mAb sc-1184 (Santa Cruz Biotechnology, Santa Cruz, CA);
for CD 14, mAb sc-1182 (Santa Cruz Biotechnology, Santa Cruz, CA); for CD83, mAb sc- 
19678 (Santa Cruz Biotechnology, Santa Cruz, CA); for CD8 6 , mAb sc-19617 (Santa Cruz 
Biotechnology, Santa Cruz, CA); for CD80, mAb sc-20077 (Santa Cruz Biotechnology, 
Santa Cruz, CA); for CD 18, mAb sc-8420 (Santa Cruz Biotechnology, Santa Cruz, CA); 
for Mannose Receptor, mAb ab8918 (Abeam, Cambridge, UK); for TLR2, mAb TL2.1 
(Alexis, San Diego, CA); for CD87, mAb sc-13522 (Santa Cruz Biotechnology, Santa 
Cruz, CA); and for SR-A, rabbit polyclonal Ab sc-20441 (Santa Cruz Biotechnology, 
Santa Cruz, CA). Cells were then washed three times with FACS buffer and, in the case of 
conjugated first antibodies, analysed directly by FACS. In the other cases, cells were 
resuspended with 0.1 mL of FACS buffer containing RPE-conjugated F(ab’)2 rabbit anti­
mouse or FITC-conjugated polyclonal rabbit anti-goat or FITC-conjugated polyclonal 
swine anti-rabbit, incubated at 4°C for 40 min, washed and resuspended with 0.3 mL of 
FACS buffer for analysis. Flow cytometry (104 to 3X104 cells per event) was performed in 
a FACScalibur (Becton Dickinson, San Jose, CA). Results were analysed by means of the 
Cell Quest Pro software (Becton Dickinson). Data corresponding to 104 or 3xl04 cells were 
recorded and subsequently gated within the appropriate forward- and side-light scattering 
area, to exclude non-viable cells from the analysis. Statistical analysis was peeformed on 
the medians from histograms of single parameters (FSC, SSC, FL-1, FL-2).
8. Cytokine secretion
The concentration of human cytokines in cell-free culture supernatants was determined 
using ELISA kits for TNF-a (Endogen, Pierce Biotechnology Inc., IL, USA), IL-10, IL-12 
and IL-lp (eBioscience, San Diego, CA, USA), according to the manufacturer’s 
instructions.
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9. Subcellular fractionation
Cells were gently scraped off cell culture flask surfaces and the pellets washed 
successively with PBS and 9% sucrose-10 mM PIPES (pH 7.2), at 0-4°C. Cells were 
resuspended with 1 mL of 9% sucrose-10 mM PIPES (pH 7.2) containing protease 
inhibitors (Complete™, Roche Diagnostics GmbH, Mannheim, Germany) and passed 
repeatedly through a 23G needle until 95-100% disruption was achieved, according to 
observation by light microscopy. Nuclei and unbroken cells were pelleted at 600Xg (rmax) 
and the nuclei-free supernatants (cytoplasms) were centrifuged at 230,000Xg for 1 hr, at 
4°C. High speed supernatants (cytosolic fractions) were kept at -80°C, and high speed 
pellets (membrane fractions = plasma membrane + cytoplasmic organelles) were washed 
with 9% sucrose-10 mM PIPES (pH 7.2) containing protease inhibitors, resuspended with 
0.2 to 0.4 mL of the same solution and kept at -80°C. Protein concentrations were 
determined by the method of Bradford (BioRad GmbH, Munchen, Germany).
10. Protein Electrophoresis and Immunoblotting
Proteins of interest were detected by Western blotting of cytosolic or membrane cell 
fractions or total cell extracts. Electrophoreses were performed in 10, 12 or 14% SDS- 
polyacrylamide gels, loading 100 pg of protein per lane. Western blot membranes were 
probed with antibodies against gp91phox sc-20782 (rabbit polyclonal, Santa Cruz, CA, 
USA), p47phox sc-17844 (mouse mAb, Santa Cruz), CuZn-superoxide dismutase sc-11407 
(rabbit polyclonal, Santa Cruz), Mn-superoxide dismutase (rabbit polyclonal, Upstate 
Biotech., NY, USA), grp78 (mouse anti-KDEL Ig, Stressgen, BC, Canada), p-Actin sc- 
47778 (mouse mAb, Santa Cruz, CA, USA), arginase ab 13972 (mouse mAb, Abeam, 
Cambridge, UK), iNOS ab 15323 (rabbit polyclonal Ab, Abeam, Cambridge, UK) or 
glyceraldehyde-3-phosphate dehydrogenase sc-25778 (GADPH, rabbit polyclonal, Santa 
Cruz), and subsequently with the appropriate alkaline phosphatase-conjugated secondary
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antibodies. Bands were detected by developing with solubilized NBT-BCIP tablets (Roche 
Diagnostics GmbH, Mannheim, Germany).
11. Proteomics
11.1. Protein isolation and solubilisation
After having determined protein concentrations by the method of Bradford, cellular 
fractions containing 300 fig of protein were precipitated with 10% (final concentration, 
w/v) trichloroacetic acid (TCA), overnight, at 4 °C, and centrifuged at lOXOOOg for 15 
min. Protein pellets were washed 4 times with 400pL of cold diethylether-ethanol (1:1, 
v/v), centrifuging each time at lOXOOOg for 10 min. Pellets were dried in the air for 10 min 
and solubilised in 240pL of isoelectrofocusing (IEF) rehydration solution containing 0.6% 
IPG buffer pH 3-11 NL (GE Healthcare Bio-sciences AB, Uppsala, Sweden). These 
samples were stored at -20°C until used.
11.2. Bidimensional separations (IEF/SDS-PAGE)
Proteins were initially separated according to their isoelectric point, on non-linear 
immobilized pH gradient strips (Immobiline™ Dry Strip, pH 3-11 NL) of 13 cm (GE 
Healthcare Bio-sciences AB, Uppsala, Sweden). Sample loading was performed by in-gel 
re-swelling for 14 h, at RT. Isoelectric focusing was performed on an EttanlPGphorR IEF 
unit (Amersham Biosciences), at 20°C, using the following program: 50 V for 4 h, 500 V 
for 1 h, 1000 V for 2 h, and 8000 V up to 48 000 VXhr.
After electrofocusing, the strips were equilibrated with 2.5 mL of equilibration buffer 
( 6  M urea, 30% glycerol, 50 mM Tris-HCl pH 8 .8 , 2% [w/v] SDS, 25 mg DTT and 
bromophenol blue) for 10 min, at RT. This solution was then removed and a second 
equilibration was performed again for 1 0  min, with the same equilibration buffer but 
containing 62.5 mg of iodoacetamide instead of DTT. The second dimension of protein 
separation according to molecular mass was subsequently performed by placing each strip
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at the top of 14% SDS-polyacrylamide gels (180 x 200 x 1.5 mm) that were then run at 12 
mA per gel overnight, at RT.
11.3. Gel staining. Calculation of p/s and molecular masses
After electrophoresis, gels were fixed for 1 hour in 10% (v/v) ethanol-7% (v/v) acetic 
acid, with shaking, and then stained for 48 hours with 0.12% Colloidal G-25 Coomassie 
Blue (Candiano, Bruschi et al. 2004). Gels were washed with water in order to remove the 
excess dye, and then scanned at 300 dpi in an Epson Expression 1680 Pro instrument 
(Adobe Photoshop program). The pI  values of protein spots of interest were calculated 
according to the pH curve provided by the supplier of the immobilized pH gradient strips 
(http ://www. gelifesciences. com!. Molecular masses were calculated using the 
semilogarithmic curves of marker molecular mass (log) vs. migration distance 
corresponding to each of the gels analysed.
11.4. Protein digestion
Protein spots of interest were cut out from polyacrylamide gels, as well as control 
pieces from a protein-free region of the gel, placed in a 1.5 mL tube and washed 4 times 
with water. The gel pieces were washed with 0.5 mL of 100 mM EDTA for 15 minutes, 
with frequent vortexing. Supernatants were discarded and the gel pieces were dehydrated 
with 100% methanol for 5 min. The dehydrated gel pieces were rehydrated by incubation 
with 30% methanol, at RT. They were then washed twice with 1 mL ultra-pure water for 
10 min, mixing frequently. The gel pieces were washed 6  times, for 20 min each time, with 
50% methanol containing 20 mM diammonium phosphate (di-AP), until all traces of the 
Coomassie stain disappeared. After washing the pieces with water for 10 min, at RT, they 
were dried in a SpeedVac centrifuge for 30 min. Lastly, the dry gel pieces were rehydrated 
with a solution of 0.5 mg/mL trypsin in ammonium bicarbonate (pH 8.0) containing 10% 
acetonitrile and incubated overnight at 37°C. After trypsinization, supernatants were 
transferred to a clean tube and the remaining gel pieces were covered with 5% formic acid 
and incubated in a sonicating water bath for 2 0  minutes, in order to extract the peptides.
The supernatants therefrom were combined with the previous ones and dried in SpeedVac 
centrifuge, to be subjected to mass spectrometry analysis.
11.5. MALDI-TOF/TOF analysis and database searching
This work was a service by the Protein Network group of the ICGEB, and is briefly 
described below. Trysin digests were resuspended with 50% acetonitrile-0.1% 
trifluoroacetic acid and spotted on stainless steel sample target plates. Peptide mass spectra 
were obtained on an Applied Biosystem Sciex 4800 MALDITOF/TOF mass spectrometer. 
Data were acquired in positive MS reflector using a CalMix5 standard to calibrate the 
instrument (ABI4700 Calibration Mixture). Mass spectra were obtained from each sample 
spot by accumulation of 800 laser shots in an 800-4000 mass range. For MS/MS spectra, 
the 15 most abundant precursor ions per sample were selected for subsequent 
fragmentation by high-energy collision-induced dissociation. The collision energy was 1 
keV and the collision gas was air. The criterion for precursor selection was a minimum S/N 
of 20. The interpretation of both the MS and MS/MS data was carried out using the GPS 
Explorer software (Applied Biosystems) that acts as an interface between the Oracle 
database containing raw spectra and a local copy of the MASCOT search engine. Peptide 
mass fingerprints obtained from MS analysis were used for protein identification in the 
Swiss-Prot or TrEMBL non-redundant databases. The data obtained were screened against 
human databases. All peptide mass values are considered monoisotopic and mass tolerance 
was set at 25-50 ppm. Trypsin was the digestion enzyme, one missed cleavage site was 
allowed, cysteine carboamidomethylated was assumed as a fixed modification, and 
methionine was assumed to be partially oxidized. MASCOT (Matrix Science) scores 
greater than 70 were considered significant (p < 0.05). For MS/MS analysis, all peaks with 
an S/N greater than 20 were searched against the SwissProt database considering the same 
modifications as in the MS database search, with a fragment ion mass tolerance of less than
0.5 Da.
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12. Statistical analysis
Statistical analysis was performed using Microsoft Excel 2010. Differences between 
individual comparisons made in growth curves and protein expression data from Western 
blotting quantifications were analysed by one way ANOVA followed by Bonferroni’s 
multiple comparison test. / 7-values < 0.05 were considered significant.
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RESULTS
Chapter 1. Anti-mycobacterial activity and drug cytotoxicity
Anti-mycobacterial treatments are based on the combination of several drugs, which 
compared with mono-drug therapy have a lower probability of disease recrudescence and 
development of drug-resistant strains. Poor control of basic tuberculosis and inadequate 
treatments, associated with the absence of new drugs and strategies, led to the appearance 
of multi-drug resistant (MDR-TB) strains. These strains are resistant to Isoniazid and 
Rifampicin, both of which are established antibiotics for the treatment of tubercular 
disease. MDR-TB treatments are longer, costly, and induce more side effects than those 
against drug-susceptible strains (Di Perri and Bonora 2004).
The wrong management of non-susceptible strains led to the appearance of extensively 
drug resistance (XDR-TB). In addition to Isoniazid and Rifampicin, these strains are 
resistant to compounds of the quinolone family and to the second-line injectable drugs 
kanamycin, capreomycin and amikacin. This increases the time, cost and side effects of 
treatments. Up to date there are no guidelines available for the management of XDR 
patients requires the application of guidelines for MDR-TB (Jain and Mondal 2008; 
Madariaga, Lalloo et al. 2008). XDR-TB cases are commonly associated to HIV infection, 
which makes treatment difficult since synergism between both pathogens and drug 
interactions become additional issues to be carefully considered (Elston and Thaker 2008). 
Pharmaceutical companies have not shown sufficient interest in finding and/or developing 
new anti-tubercular compounds probably due to the low economic status of most of the 
affected countries. Rifampin, in use since 1966, is the last compound incorporated to anti- 
tubercular therapies. In conclusion, the appearance of resistant strains which are associated 
with extended treatments and the incompatibilities between anti-tubercular and anti­
retroviral therapies call for the development of new anti-mycobacterial compounds.
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Drug candidates for the fight against TB can arise from high throughput screenings or 
from chemical modification of compounds already in use, with the aim of maximizing their 
activity (Laurenzi, Ginsberg et al. 2007). Some interesting approaches are based on the 
design of compounds that can interfere with specific biochemical targets in the 
microorganisms. This has to take into consideration the mycobacterial metabolic status, 
since these microorganisms can enter a dormancy stage in which they evade the action of 
many antibiotics usually employed against infections (Sensi 1989; Murphy and Brown
2008). Another strategy, referred to as blind screening, is based on the isolation and 
identification of compounds with anti-mycobacterial activity from fermentation broths. In 
this way, several compounds such as streptomycin, kanamycin, capreomycin, and D- 
cycloserine have been isolated from different strains of Streptomyces sps. and successfully 
employed in anti-tubercular treatments (de Souza 2009). Natural product activities against 
tuberculosis have been extensively reported (Newton, Lau et al. 2000), confirming that 
they represent an excellent reservoir of novel compounds.
This thesis reports the study of the action of the synthetic compounds AC178, AC202, 
AC203, AC204, F2 and 9A, and the naphthoquinones of plant origin lapachol and P- 
lapachone against Mycobacterium avium (strain 485). Naphthoquinones in general and in 
particular lapachol, a substituted hydroxyl-naphthoquinone, show a wide spectrum of 
different biological activities (Guiraud, Steiman et al. 1994; Oliveira, Lemos et al. 2002; 
Sacau, Estevez-Braun et al. 2003; de Andrade-Neto, Goulart et al. 2004; Bezerra, De 
Oliveira et al. 2005; Breger, Fuchs et al. 2007; Lemos, Monte et al. 2007). The 
naphthoquinone plumbagin is the only one reported up to date to show activity against 
some mycobacteria in liquid culture (Mossa, El-Feraly et al. 2004). The other compounds 
the anti-mycobacterial activity of which was tested during the present work have all been 
produced by chemical synthesis.
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1. Anti-mycobacterial activity (mycobacteria in liquid culture)
The anti-mycobacterial activities of the compounds tested on M. avium growing in 
liquid culture were determined by the microplate Alamar Blue assay (Franzblau, Witzig et 
al. 1998), which is based on the reducing ability of proliferating bacteria that results in an 
indicator colour change from blue to pink. The results obtained are summarized in Table
2. F2 was the most active compound with a MIC of 8  pg/mL, different from the value 
found by Banfi et al., who reported MICs ranging from 16 to 320 pg/mL against 17 
different strains of M. avium (Banfi, Mamolo et al. 2001). The different sensibility to F2 
here observed may be due to the use of a different strain of M. avium. The AC series 
compounds, lapachol and p-lapachone showed MICs ranging from 16 to 64 pg/mL. The 
extremely high MIC of the compound 9A (>512 pg/mL) reflected its lack of efficiency 
and excluded it from further studies.
MICs of the naphthoquinone lapachol against S. aureus and S. typhimurium were also 
determined, once it was established that this was a promising anti-mycobacterial agent, as 
described further below in this chapter 2 (sections 3 to 5). The value found for S. aureus 
(128 pg/mL / 528 pM) was the same or lower than that reported in the literature for the 
most susceptible strains (Oliveira, Miranda et al. 2001), and lower than that toward 
methicillin resistant S. aureus (Pereira, Machado Tde et al. 2006). Lapachol activity 
against S. typhimurium was studied here for the first time. The compound was not 
effective against S. typhimurium, with a MIC of 256 pg/mL (1 mM). The activities against 
these bacteria served as a control of the activity of the lapachol used during this work.
The MIC values obtained for the compounds tested, with the exception of 9A, were 
compatible with their potential use as anti-mycobacterial agents. Therefore, macrophage 
cytotoxicity studies were conducted.
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Compound Source or reference M. avium S. aureus S. typhimurium
A9a Cateni, F, et al, (Cateni, Bonivento et al. 2007)
>512
(>lmM) ND ND
F2a Banfi, E. et al (Banfi, Mamolo et al. 2001) 8(22 pM) ND ND
AC 178* Avidin Ltd. 64 ND ND
AC201* Avidin Ltd. 32 128 ND
AC202* Avidin Ltd. 16 ND ND
AC203* Avidin Ltd. 32 ND ND
AC204* Avidin Ltd. 30 ND ND
Lapachof Lapacho tree
32
(132pM)
128
(530pM)
>256
(>lmM)
P-lapachonec Lapacho tree
16
(66nM)
ND ND
Table 2. Susceptibility of M. avium, S. aureus, and S. typhimurium  to putative antibiotics.
The lowest concentrations (pg/mL = mg/L) that arrested the growth of M. avium, S. aureus and S. 
typhimurium in liquid broth (Minimal Inhibitory Concentrations = MIC) were determined using the 
Microplate Alamar Blue Assay (MABA). MIC values ranged from 8 to 64. The compound A9 did 
not show any antimicrobial activity up to 512 pg/mL.
ND: Not determined
Bacteria used: M. avium strain 485, serovar 21, S. aureus strain 502A, S. typhimurium strain 
APGFP
a. A9 (l,2-0-diacyl-3-0-glucosylglycerol) and F2 (Nl-(3-(4-CH3)aryl-l-(pyridin-2-il)-3-oxo)- 
propyl)-2-pyridine-carboxamidrazone) were obtained from the Dept, of Biomedical Sciences, 
Microbiology Section, University of Trieste, Italy.
b. AC compounds series were obtained from Avidin Ltd. is a company based in Szeged, Hungary 
lwww.avidinbiotech.com).
c. Lapachol and P-lapachone were obtained from the Dept, of Antibiotics, Federal University of 
Pernambuco (Brazil).
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2. Cytotoxicity toward THP-1 macrophages: Cell morphology, apoptosis and
necrosis
The usual length of therapies for sensitive Mycobacterium tuberculosis is at least 6  
months, and this increases in the case of resistant strains (WHO 2009) or for treatments of 
non-tuberculous mycobacterial infections (Piersimoni and Scarparo 2008; Ballarino, 
Olivier et al. 2009; WHO 2009). Such long periods of treatment could result in relevant 
side effects. Some quinones, including lapachol and (3-lapachone, are known to be 
cytotoxic to tumor cells (Boothman, Trask et al. 1989). If the effects produced by 
compounds under investigation involve the innate immune system, this could result in 
rather immediate consequences. In a first stage, it was investigated whether the 
compounds described in Table 2 are toxic to THP-1 macrophages at their MICs, 
macrophages being the cells used as hosts for M. avium during this work.
A preliminary evaluation of cytotoxicity was through the observation of changes in cell 
morphology. Changes in shape, adherence, cytoplasmic swelling or 
vacuolization/granulation constitute a reliable indicator of toxicity, especially in the case of 
macrophages, which are highly sensitive to environmental conditions. Morphology 
changes are shown in Figure 12, A, where it can be seen that the compounds p-lapachone, 
F2, AC178, AC202, AC203 and AC204, at their respective MIC significantly affected the 
cell size, shape and spreading. Absence of elongation, cell rounding, and shrinking were 
observed. Cells treated with F2 and AC202 were detaching. The compounds F2, AC 178, 
AC202, AC203, AC204 and p-lapachone were therefore excluded from further 
experiments. Instead, untreated (control) and lapachol-treated cells showed similar 
characteristics. Size and granularity were not affected by lapachol (Fig. 12, B & C). Cells 
treated with AC201 were well elongated and adherent, but noticeably smaller (Fig. 12, B). 
In fact, the protein content per cell was found to be 0.39 and 0.19 mg/mL in control and 
AC201-treated cells respectively, in agreement with the microscopic observation results.
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FIGURE 12. Effect of putative anti-mycobacterial compounds on THP-1 macrophage 
morphology.
A. Morphology of THP-1 macrophages either untreated (control) or treated for 4 days with 
lapachol, P-lapachone, F2, AC 178, AC201, AC202, AC203 or AC204 at their MICs (listed in 
Table 2). Pictures correspond to inverted light microscopy images at 100 X magnification. With 
the exception of lapachol and AC201, the following changes were observed after treatment: 
absence of elongation, cell rounding, shrinking and detachment. Untreated and lapachol-treated 
cells presented an apparently similar morphology. AC201 induced cell size reduction.
B. Quantification of cell size by imaging. The size of 100 cells was determined, considering size as 
the area in pixels. Only cells treated with lapachol showed a normal size. All other compounds 
produced a significant reduction of cell size.
C. Quantification of cell size and granularity by FACS. Forward light scatter (FSC-H) and side 
light scatter (SSC-H) density plots of THP-1 macrophages and bar graphs of relative geometrical 
means of SSC and FSC. Results are expressed as means ±SD (n=10). C: control; L: lapachol 
Statistical analysis was by ANOVA (** p < 0.01, * p < 0.05)
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Apoptosis studies were subsequently performed by flow cytometry analysis of annexin 
V binding. This analysis could only be performed regarding lapachol since the compound 
AC201 has an intrinsic fluorescence which interferes with the flow cytometry analysis. 
The result of three independent experiments showed that a similar number of annexin V- 
positive cells was present after treatment of THP-1 cells with lapachol (32 pg/mL) for four 
days, compared with untreated cells (Fig. 13, A). DNA fragmentation is a common event 
of apoptosis and necrosis, with temporal differences. It takes place in the early stages of 
apoptosis, before the loss of cell membrane integrity. Instead, in necrosis it is a late event 
that follows plasma membrane permeability changes (Fairbaim and O'Neill 1995). No 
DNA degradation and/or fragmentation was observed by agarose gel electrophoresis of the 
DNA isolated from untreated and lapachol- or AC201-treated cells (Fig. 13, B & C).
3. Intracellular anti-mycobacterial activity
Once the MICs of lapachol and AC201 toward M. avium growing in liquid culture and 
the absence of apoptotic or necrotic effects on the THP-1 macrophages that were to be 
used as host cells were established, it was essential to evaluate the activity of the two 
compounds against intracellular mycobacteria. This is a crucial point when the activity of a 
drug intended for intracellular microorganisms is tested, because permeability barriers, 
efflux pumps and/or metabolic events can diminish or even prevent the drug from reaching 
its target, reducing its capability to kill or arrest the growth of the intracellular organism, as 
shown by Tomioka et al (Tomioka, Sano et al. 2002).
THP-1 macrophage-like cells were infected with M. avium at a 30:1 ratio, allowing 4 
hours to ensure maximum uptake of the microorganisms. Extra-cellular bacteria were 
washed off and the M. avium-containing host cells were cultured in the presence or 
absence of lapachol (16 or 32 ^ig/mL) or AC201 (32 jxg/mL) for 4 or 7 days. At time 0, day 
4 and day 7, host cells were lysed and plated on agar and the number of viable intra­
cellular bacteria was determined by colony counting.
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FIGURE 13. Lapachol and AC201 do not induce necrosis or apoptosis of THP-1 
macrophages.
A. Annexin V binding. The binding of annexin V-FITC on the surface of cells cultured for 4 days 
in the absence or presence of lapachol (32 pg/mL) was determined by flow cytometry. The positive 
control was cells treated with etoposide (2pg/mL) for 48 hours. The blank was cells not incubated 
with annexin V-FITC. Results are expressed as histograms and as bar graphs indicating the mean 
percentages of annexin VT cells ± S.E. (n=3, independent experiments). Statistical analysis was by 
ANOVA (* p < 0,05).
B. Influence of lapachol on DNA fragmentation. DNA was extracted from cells cultured for 4 or 7 
days in the presence of lapachol (32 pg/mL) and run on 0.8% agarose gels (200-400 ng/lane). The 
positive control was cells treated with 8% DMSO for 24 hours. The absence o f a smear in the 
lapachol lanes is an indication of DNA integrity.
C. Influence of AC201 on DNA fragmentation. DNA was extracted from cells after 4 days in the 
presence of AC201 (32 pg/mL) and run on 0.8% agarose gels (200 ng/lane). The positive control 
was cells treated with 8% DMSO for 24 hours. The absence of a smear in the AC201 lane is an 
indication of DNA integrity.
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At day 7, the number of intracellular M. avium (CFUs) in the presence of lapachol at 
32 or 16 pg/mL was 10 or 5 times smaller than in its absence, respectively. This decrease 
was only significant for 16 pg/mL (14 MIC) (Fig. 14, A). The proliferation of intracellular 
M. avium was prevented by the naphthoquinone, but the number of intra-cellular bacteria 
at day 7, in the presence of lapachol, was similar to that at time zero (Fig. 14, A). This is an 
indication of bacteriostasis rather than of bacterial killing.
In the presence of AC201 at 32 pg/mL, growth of M. avium was decelerated (Fig. 14, 
B). However, at day 7 bacterial numbers were still 10-fold higher than at time 0, reflecting 
the limited efficiency of this compound in an intra-cellular environment.
As a reference, the intra-cellular proliferation of M. avium was determined under the 
effect of the first line anti-mycobacterial compounds clarithromycin, rifampicine and 
ethambutol at the concentrations that have been reported as average serum concentrations 
24 h after their administration, namely 0.56, 1.60 and 0.35 pg/mL, respectively (Tomioka, 
Sano et al. 2002). At those low concentrations, these classical antibiotics just retard the 
growth of M. avium, higher concentrations being necessary for them to exert full activity 
(Fig. 14, C).
4. Distinguishing between bactericidal or bacteriostatic activity of lapachol
As described in the preceding section, lapachol was able to arrest the intracellular 
growth of M. avium at 32 pg/mL (132 pM), and to a lesser extent at 16 pg/mL (66 pM). It 
is known that a compound can be either bacteriostatic or bactericidal depending on the 
concentration used, according to the microorganism susceptibility (Rahal and Simberkoff 
1979). Since the interaction between lapachol and the cell environment could interfere with 
its anti-mycobacterial activity, time courses of M. avium growth were performed in 
Middlebrook 7H9 broth, in the absence or presence of the drug at 32pg/mL. Aliquots taken 
during this time course were diluted and plated on agar for CFUs counting.
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FIGURE 14. Anti-A/. avium activity of lapachol (A) , AC201 (B), and three first line 
antibiotics (C) against intracellular M. avium, within THP-1 macrophage-like cells.
Growth curves of M. avium (strain 485, serovar 21) within THP-1 macrophages treated or not with 
16 or 32 pg/mL lapachol (A); 32 pg/mL AC201 (B); 0.56 pg/mL clarithromycin, 1.6 pg/mL 
rifampicine or 0.35 pg/mL ethambutol (C). Results are expressed as logi0CFU/mL (mean ± S.E., 
n=3, independent experiments), normalized according to the protein content of each sample, which 
is equivalent to cell number. * Statistically significant (ANOVA, p < 0.05) reduction of 
intracellular M. avium CFUs compared with those in macrophages not treated with lapachol.
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The results shown in Fig. 15 indicate a bacteriostatic effect of lapachol, with an 
invariant, low number of viable colonies until day 3 and no evidence of bacterial killing. 
The fact that growth of the organisms was observed from day 3 to 7 is probably due to 
lapachol inactivation or metabolism in the bacterial broth.
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FIGURE 15. Bacteriostatic effect of lapachol toward M. avium
M. avium was grown until exponential phase in Middlebook 7H9 broth at 37°C, with constant 
agitation and with or without 32 pg/mL (132 pM) lapachol added at time zero. Aliquots were taken 
at time 0, day 1, 3 and 7, diluted and plated on agar for CFU counting. Bacterial replication was 
very slow until day 3. From day 3 to 7 bacterial growth in the presence of lapachol was 
considerably slower than that of the control culture. The proliferation observed from day 3 to 7 in 
the presence of lapachol could be ascribed to a loss of drug activity in the broth. There is no 
evidence of a bactericidal effect of lapachol against M. avium at 132 pM.
The graph represents the result of three different independent experiments (n=3). Statistical 
analysis was performed by ANOVA (* p < 0.05 corresponds to the comparison of CFUs in the 
absence or presence of lapachol, at day 7).
The bacteriostatic or bactericidal character of the compound AC201 was not examined 
because this drug showed a scarce intracellular activity (see above: section 3; Fig. 14, B) 
and therefore it did not appear to be a promising drug candidate, as studies described 
further below demonstrate (Chapter 2, section 1).
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Low MICs mean a better probability of in vivo applications, since side effects would 
be minimized. However, safe doses are related to the toxicity of the drug. For drugs to 
reach the site of action, they have to go through several biological barriers. They must be 
absorbed, distributed via the circulation system and finally arrive at tissues. Regarding 
mycobacterial infection, an active compound must also be able to enter the host cells and 
cross the phagosome membrane or reach somehow the phagosome where the 
microorganism resides. During this process, the putative anti-mycobacterial agent will be 
subjected to the cellular mechanisms directed at the elimination of foreign substances (Van 
Bambeke, Balzi et al. 2000; Van Bambeke, Michot et al. 2003; Goossens 2009). For that 
reason, MIC values will usually translate into higher in vivo doses. High doses imply an 
increase in the probability of side effects and toxicity. Still, a compound with a low MIC 
can be a poor in vivo performer, or one with a high MIC may be very efficient in the 
cellular environment and the dose necessary in vivo can even be lower than its MIC.
The MIC of the compounds tested here regarding M. avium growth in liquid broth 
ranged from 8 to 64 fxg/mL (Table 2). These values are relatively low or comparable with 
MICs induced by a number of other natural compounds against mycobacterium sp. 
(Jimenez-Arellanes, Meckes et al. 2003; Borges-Argaez, Canche-Chay et al. 2007; 
Gordien, Gray et al. 2009; Kuete, Tangmouo et al. 2009; Molina-Salinas, Borquez et al. 
2010), and higher than the MICs reported for plumbagin, a naphthoquinone analog to 
lapachol, totarol, ferruginol, ferulenol, and ferulenol acetate in relationship with some 
mycobacterium sp. (Mossa, El-Feraly et al. 2004; Kuete, Tangmouo et al. 2009).
As to the mechanism of action, lapachol probably interferes with bacterial cytochrome 
be systems, a known property of naphthoquinones and in particular those with branched 
alkyl side-chains like lapachol (Kumagai 1997; Kessl, Moskalev et al. 2007). It could also 
induce bacterial oxidative stress, which is associated to the redox-cycling properties of
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naphthoquinones, as reported for plumbagin and menadione (Guerra-Lopez, Daniels et al. 
2007).
The cytotoxicity of lapachol toward different tumour cell lines has been studied (Rao, 
McBride et al. 1968; Oliveira, Lemos et al. 2002; Eyong, Kumar et al. 2008), since this 
compound was originally intended for the treatment of soft tissue tumours. Leukemic cells 
lines seem to be more sensitive to lapachol than solid tumors and low concentrations, 
ranging from 16 to 25 pM, have been reported to be cytotoxic (Salustiano, Netto et al.
2009). Our experiments showed no toxicity when THP-1 macrophage-like cells were 
treated with lapachol at 32 pg/mL (132 pM), in agreement with Teixeira et al (Teixeira, de 
Almeida et al. 2001). These authors investigated the anti-leishmanial activity of lapachol 
and determined that this naphthoquinone only induced cytotoxicity of mouse peritoneal 
macrophages when its concentration was above 0.1 mg/mL (413 pM).
The fact that neither lapachol nor AC201 were toxic toward THP-1 macrophages at 
their anti-M avium MIC meant that studies of their activity against intracellular organisms 
could be conducted, the results of which are described in Section 3 above.
The antimicrobial effect of lapachol against intracellular M. avium was here found to 
be more efficient than that toward bacteria growing in liquid broth. The intracellular 
proliferation of M. avium was arrested by lapachol at 16 pg/mL (66 pM), i.e. half of its 
MIC. It can be speculated that the better intracellular activity of lapachol could be due to 
its lipophilic nature (Lira, Sester et al. 2008); to its being somehow concentrated within 
macrophages if it is not easily cleared from cytoplasm by efflux pumps or metabolizing 
systems; to its intracellular conversion into a more active derivative; to a higher stability 
within the phagolysosomal environment that provides protection against cytoplasmic 
clearing processes; to its superoxide generation activity (Bachur, Gordon et al. 1979) that 
could in turn react with NO and result in the generation of mycobactericidal peroxynitrate 
(Bogdan, Rollinghoff et al. 2000); or to a hypothetical inhibition of bacterial NO
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reductase/s (NORs) that normally function as detoxifiers of macrophage-produced NO 
(Watmough, Field et al. 2009) The latter is supported by the fact that some bacterial NORs 
consist of cytochrome be complexes (Suharti, Heering et al. 2004), and lapachol is able to 
interact with such complexes (Kessl, Moskalev et al. 2007). Another explanation for the 
higher intracellular activity of lapachol is linked to the fact that, as will be described in 
Chapter 3, lapachol affects some macrophage responses in a way that improves the 
capacity of the host cell to control the intracellular proliferation of mycobacteria. 
Therefore, there would be a combination of the intrinsic anti-mycobacterial activity of 
lapachol with a modulating effect on host cell responses.
As opposed to lapachol, AC201 was not satisfactory at arresting the intracellular 
growth of M. avium, although both drugs arrested M. avium growth in liquid broth with the 
same MIC. This illustrates how drug performance can differ depending on environmental 
conditions, in the present case those provided by the host cell.
The lack of induction of cell death by lapachol and AC201 was the starting point for 
the investigation of their influence on macrophage functions in relationship with some 
aspects of cellular immunity.
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Chapter 2. Macrophage functions in response to activation
The considerable length of the treatments needed for mycobacterial infections (> 6 
months), primarily intended to eliminate or control the growth of microorganisms, could 
have consequences at host cell and immune system level. Macrophage functions could be 
up- or down-regulated by the anti-mycobacterial agents being used, and this could have 
detrimental or beneficial effects. Therefore, knowledge on if and which macrophage 
functions are modulated is important to predict and consequently assess possible side 
effects in successive in vivo investigations. Macrophages are fundamental within the innate 
immune system since they generate reactive oxygen and nitrogen species, secrete 
mediators and cytokines, are able to phagocytose and degrade, and can present antigens. 
Basically, these cells provide a link between innate and adaptive immunity. Impairments of 
some of its functions could compromise the elimination of pathogens other than 
mycobacteria that the body may encounter during the long course of treatment to fight 
mycobacteria. Moreover, therapeutical anti-mycobacterial compounds could disturb 
cellular homeostasis, for instance inducing endoplasmic reticulum (ER) or oxidative stress. 
ER controls protein folding and the repair or elimination of missfolded proteins, and severe 
ER stress can trigger apoptosis (Tao, Ruan et al. 2009). The generation of oxidative and 
nitrosative metabolites is used by the cells to kill pathogens. However, host cell molecules 
such as lipids, proteins and DNA can be also oxidized, and apoptosis could be triggered 
(Roberts, Laskin et al. 2009).
In order to determine whether the anti-mycobacterial compounds being evaluated here, 
namely AC201 and lapachol, have any influence on macrophage responses to stimuli, we 
used resting or IFN-y-activated cells, cells agonised with the TLR2 lipopeptide P3CSK4 
and in some cases M. avium-infected macrophages. IFN-y is the main macrophage- 
activating cytokine (Schroder, Hertzog et al. 2004) and TLR2 is a major innate immune
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response mediator recognizing the broadest range of bacterial molecules (Takeuchi, Sato et 
al. 2002; Zahringer, Lindner et al. 2008).
All the experiments described and commented in sections 1 to 7 of this chapter were 
performed with THP-1 cells that became macrophage-like after 4 days of differentiation 
under the effect of 20 nM phorbol-lyristate acetate (PMA). These macrophage-like cells 
were left untreated (controls) or were treated with 300 nM P3CSK4 or 100 U/mL IFN-y for 
4 days, i.e. until day 8. In some cases, the macrophages were infected with M. avium (4 hr 
internalization) and then kept in culture for 4 days. At day 8, lapachol (32 pg/mL), 
compound AC 201 (32 pg/mL) or first line TB antibiotics (clarithromycin, rifampicin or 
ethambutol) were added or not, and cells were cultured for 4 additional days, i.e. until day 
12. In brief, activating or infecting agents were present from day 4 till day 12 in all cases. 
Lapachol, AC201 or first line antibiotics were present from day 8 till day 12. A graphic 
scheme of this working protocol is shown in Figure 16.
Tesl compound)
THP-1 Cells Activated or infected cells
Differentiated
cells
Harvest and
P3CSK4 or IFN-y or 
M. avium infection
P3CSK4 or IFN-y or 
M  avium infection
Time 0 Day 4 Day S Day 12
FIGURE 16. Experimental scheme of THP-1 differentiation and subsequent treatm ents of 
THP-1 macrophages.
THP-1 macrophages were incubated in 6 -well plates with 20nM PMA for 4 days, at 37°C. At this 
point cells were activated by addition of P3 CSK4  or IFN-y, or infected by M. avium, and incubated 
for 4 additional days to allow the establishment of intra-cellular infection. At day 8  cells were 
treated or not with test compounds for 4 additional days, after which they were harvested for 
analysis.
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After pathogens invade tissues, they can bind to a wide range of pattern recognition 
receptors (PRRs) abundant on phagocytic cells. Some of the PRRs actually mediate 
phagocytosis, i.e. the means through which pathogens can gain access to the intracellular 
environment. Pathogen surface components (PAMPs, pathogen-associated molecular 
patterns) are recognized by a variety of phagocytic receptors on the effector cell such as 
complement receptor 3, CD 14, Fc, mannose and scavenger receptors, etc, promoting 
microorganism uptake. For some pathogens, mycobacteria among them, the route of entry 
determines their fate in the intracellular environment. For instance, oxidative stress could 
or not be triggered (Ernst 1998). Internalized pathogens are confined in cytosolic vesicles 
called phagosomes, which acquire degradative enzymes (hydrolases, proteases) after 
fusing with lysosomes, giving rise to phagolysosomes. Proton-ATPase pumps present in 
cytoplasmic vesicles also fuse with phagosomes and acidify their lumenal space, 
generating the right conditions for some enzymes to be active (Sun-Wada, Wada et al. 
2003).
TLRs are transmembrane receptors, and PAMP binding triggers signaling cascades
leading to the secretion of pro-inflammatory cytokines such as TNF-a, IL-ip, IL-6 and IL-
12 (Kaisho and Akira 2006; Kumar, Kawai et al. 2009). TLRs do not mediate phagocytosis
but the establishment of adaptive immunity, and can induce inflammation. The cytokines
secreted act on surrounding cells and induce the secretion of chemotactic cytokines or
chemokines such as monocyte chemoattractant protein-1 (MCP-1 or CCL2), that is known
to attract monocytes to the site of inflammation (Deshmane, Kremlev et al. 2009). In order
to migrate, inflammatory cells adhere to endothelial cells via molecules such CD54 or
CD87. Local proteolysis by matrix metalloproteinases facilitates diapedesis through vessel
walls (van de Stolpe and van der Saag 1996; Plesner, Behrendt et al. 1997). The monocytes
recruited to the inflamed tissue differentiate into macrophages that can become activated,
recognize pathogen via PRRs and deal with the organisms. Internalized pathogens can be
killed due to the generation of reactive oxygen species (ROS) and nitrogen reactive
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intermediates (NRI). An oxidative phase takes place initially, after the switching-on of 
NADPH oxidase, followed by a prolonged nitrosative phase during which iNOS activity 
results in the inhibition of bacterial growth (Raupach and Kaufmann 2001; Bhatt and 
Salgame 2007).
Activation of macrophages by IFN-y is essential to fight against intracellular 
pathogens. IFN-y is the main macrophage activating cytokine and boosts the cellular 
machinery to increase its capacity to generate ROS and NRI and to express MHC 
molecules, among other effects. This enhances bacterial killing and antigen presentation by 
macrophages (Korbel, Schneider et al. 2008; Billiau and Matthys 2009) in combination 
with stimulating agents, e.g. LPS (Fang 2004).
Pathogenic mycobacteria have developed strategies to subvert the cellular machinery 
that controls pathogen growth, and can therefore persist in the host cells. They efficiently 
prevent phagosome maturation (Via, Deretic et al. 1997; Philips 2008), which results in 
phagosomes that are less acidified and in an impaired antigen presentation (Noss, Pai et al. 
2001; Hestvik, Hmama et al. 2005). Mycobacterium-infected macrophages also secrete of 
anti-inflammatory cytokines (IL-10, TGF-(3), which suppress immune responses and 
facilitate the intracellular survival and replication of the microorganisms within 
phagosomes, with the result of promoting chronic infection (Bogdan, Vodovotz et al. 1991; 
Ferrara, Bleck et al. 2008).
Physiologically generated ROS and NRI also play an important role as second 
messengers in different tissues (Kamata and Hirata 1999; Rhee 1999; Wang-Rosenke, 
Neumayer et al. 2008). Although an increased generation of these radicals is directly 
associated with improved pathogen killing, ROS and NRI are highly reactive and can 
damage biomolecules if they overcome the cellular antioxidant system, and can eventually 
induce cell death. In order to protect themselves against the deleterious effects of oxidative 
stress, macrophages and bacteria respond employing antioxidant systems based on the
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activity of superoxide dismutases, peroxidases, catalases and degradative enzymes that 
scavenge the reactive species (Bogdan, Rollinghoff et al. 2000; Ferret, Soum et al. 2002).
Natural products have been described to be anti-oxidant or pro-oxidant agents, 
protecting or harming cells. For instance, polyphenols such as quercetin and resveratrol 
have been described to control excessive oxidative stress (de la Lastra and Villegas 2007; 
Kumar, Sehgal et al. 2008). Quinones, e.g. plumbagin and lapachol, are able to generate 
reactive oxygen species by reducing oxygen to superoxide (Hemandez-Munoz, Gomez et 
al. 2009). This is considered to be an important mechanism to eliminate cancer cells 
(Srinivas, Gopinath et al. 2004).
Here are reported the effects of lapachol on the surface expression of TLR2, CD 14 and 
phagocytic receptors; in the levels of oxidative, nitrosative and ER stress proteins and in 
the secretion of some cytokines in/by THP-1 macrophages either resting or after TLR2 
agonism by the lipopeptide P3CSK4, IFN-y treatment or M. avium infection. The effect of 
the compound AC201 was only examined regarding ER and oxidative stress, since a 
cytoskeleton-altering effect was found at an early stage of the studies that led to the 
interruption of investigations on AC201 (see last paragraph of this section).
The analysis of the expression of the surface receptors TLR2, CD 14, CD 18, ManR, Fc 
receptors (CD 16, CD32, and CD64) and scavenger receptors was performed by flow 
cytometry. The expression of proteins involved in oxidative, nitrosative and ER stress was 
quantified by immuno-blotting, and cytokine secretion was determined by ELISA. Protein 
concentrations were accurately measured, on the basis of which equal amounts of protein 
from the different samples being compared were loaded on gels to be immuno-blotted. 
Actin and/or GAPDH were quantified on the same blotting membrane as the proteins being 
quantified, to detect possible differences in loading and/or blotting.
Measurement of actin proved misleading since levels of cytosolic, but not membrane-
associated, actin were found to be highly variable, particularly under the influence of the
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compound AC201 (Fig. 17, C). This fact led to the realization that AC201 was altering 
actin dynamics, which was the reason to discontinue its study, together with its poor 
control of intracellular M. avium growth (see Chapter 1, section 3). GAPDH was 
successively used as a sample loading/blotting indicator (sections 2 to 4). The expression 
variability of this marker was found to be 7-15%.
1. Endoplasmic reticulum (ER) stress
ER is the cellular compartment responsible for protein folding. Glucose deprivation, 
viral infection and an aberrant Ca2+ regulation can induce the accumulation of unfolded 
proteins, triggering an ER unfolded protein response (UPR) aimed at restoring ER normal 
function. UPR are orchestrated by chaperones such as Grp78. This multifunctional protein 
is a central regulator of ER homeostasis (Xu, Bailly-Maitre et al. 2005; Li, Ni et al. 2008), 
and its up-regulation is considered an ER stress marker. P3CSK4 treatment (TLR2 
agonism) induced a significant decrease in Grp78 (Fig. 17, A), while neither AC201 nor 
lapachol induced ER stress (Figs. 17, A and C). AC201 actually produced a significant 
decrease in Grp78 levels in cells treated with both the TLR2 agonist and IFN-y. The effect 
of M. avium infection on ER stress is shown in Fig. 17, B. Infection did not induce any 
increase in Grp78 levels. When infected cells were incubated with lapachol, the levels of 
Grp78 were significantly decreased (p < 0.05).
2. Oxygen metabolism
Oxygen metabolites are produced by macrophages and other phagocytes to kill 
pathogens in general (Bogdan, Rollinghoff et al. 2000), although their role in 
mycobacterial killing is not clear
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FIGURE 17. Effect of activation, M. avium infection and treatm ent with lapachol or AC201 
on the endoplasmic reticulum (ER) stress of THP-1 macrophages.
Macrophages were treated with the stimuli indicated above for 4 days, then cultured for 4 
additional days in the absence or presence of lapachol or AC201. Cells were fractionated in 
membranes (M) and cytosol (C). Membrane and cytosolic fractions were were electrophoresed and 
western blotted onto nitrocellulose, and the blotting membranes probed with antibodies against the 
ER stress marker grp78 (membrane), GADPH (cytosol) or actin (cytosol and membrane). Band 
intensities were determined using ImageJ software.
A. Macrophages treated with P3 CSK4  or IFN-y, in association or not with lapachol (32 pg/mL)
C: Control; L: lapachol; P: P3CSK4; P+L: P3CSK4 + lapachol; I: IFN-y; I+L: IFN-y + lapachol
B. Macrophages infected with M. Avium, then treated or not with lapachol (32 pg/mL)
M+L : M. avium + lapachol
C. Macrophages treated with P3 CSK4  or IFN-y , then treated or not with AC201 (32 pg/mL)
C: Control; A: AC201; P: P3 CSK4 ; I: IFN-y; P+I: PaCSIQ+IFN-y; P+I+A: P3 CSK4 +IFN- 
y+AC201
Results are expressed as means ± S.E. (n=3, independent experiments). Significant differences 
(p<0.05) in the comparisons indicated by brackets are shown by the symbol *.
GADPFI and actin were intended as controls of electrophoresis loading and western blotting. Actin 
turned out to be too variable and its use as loading marker was therefore discontinued.
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due to the fact that these bacteria express superoxide dismutase (Raupach and Kaufmann 
2001). The generation of 0 2‘ is catalyzed by the NADPH oxidase complex after its 
activation by microbial products, e.g. LPS. When activation is primed by IFN-y, it can 
reach higher levels. 0 2' can subsequently be converted in H20 2 by superoxide dismutase or 
to hydroxyl radical (*OH) through the Fe+3-catalyzed Haber-Weiss reaction (Bogdan, 
Rollinghoff et al. 2000). In the presence of NO generated by iNOS, 0 2‘ can generate 
peroxynitrite (Bartosz 1996; Guzik, Korbut et al. 2003).
During the present work, the capacity of NADPH oxidase to generate 0 2‘ was 
evaluated by determining by immunoblotting the levels of two inducible proteins: catalytic, 
membrane-bound gp9 \phox and cytosolic, regulatory p47phox, which docks to gp9 \phox 
after TLR agonism (El-Benna, Dang et al. 2008; El-Benna, Dang et al. 2009). Superoxide 
generation was not determined directly in view of the strong possibility of interference due 
to the ability of quinones, among them lapachol, to generate oxygen metabolites 
(Docampo, De Souza et al. 1978; Bolton, Trash et al. 2000; Goulart, Falkowski et al. 
2003). The superoxide produced could in turn consume NO, as explained above.
As expected, a significant increase in the expression of gp9\phox and p47phox was 
observed when THP-1 macrophages were TLR2-agonised (Figs. 18, A & C). In the case of 
IFN-y treated cells, only an increase in the levels of p47phox was observed (Fig. 18, C).
AC201 significantly reduced the levels of p47phox in TLR2/IFN-y-activated cells, and 
those of gp9\phox in both resting and TLR2/IFN-Y-activated cells (Fig. 18, C), suggesting a 
possible negative influence of this compound on the superoxide generation capacity of 
macrophages.
Lapachol significantly enhanced the induction of p47phox by TLR2 agonism (Fig. 18,
A). In association with M. avium infection, lapachol significantly reduced the levels of 
gp9lphox and p47phox in the membrane fraction to resting cell values (Fig. 18, B), whereas 
the significant up-regulation of cytosolic p47phox elicited by M. avium was not affected by 
the naphthoquinone.
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FIGURE 18. Effect of activation, M. avium  infection and treatm ent with lapachol or AC201 
on the expression of key proteins of oxygen metabolism by THP-1 macrophages.
Macrophages were treated with the stimuli indicated for 4 days, then cultured for 4 additional days 
in the absence or presence of lapachol or AC201. In A, total cell extracts (T) were used. In B and 
C, cells were fractionated in membranes (M) and cytosol (C). Total cell extracts, cytosolic or 
membrane proteins were electrophoresed, western blotted onto nitrocellulose and the blotting 
membranes probed with antibodies against the inducible components of NADPH oxidase gp91p/'0A 
and p47p/,ot. Band intensities were determined using imageJ software.
A. Macrophages treated or not with P3 CSK4  and IFN-y, in association or not with lapachol (32 
pg/mL)
C: Control; L: lapachol; P: P3CSK4; P+L: P3CSK4+lapachol; I: IFN-y; I+L: IFN-y+lapachol
B. Macrophages infected with M. avium, then treated or not with lapachol (32 pg/mL)
M+L: M. avium + lapachol
C. Macrophages treated or not with P3CSK4 or IFN-y, then incubated or not with AC201 (32 
pg/mL).
C: Control; A: AC201; P: P3 CSK4 ; I: IFN-y; P+I: P3 CSK4 +IFN-Y; P+I+A: P3 CSK4 +IFN- 
Y+AC201
Results are expressed as means ± S.E. (n=3, independent experiments). Significant differences (p < 
0.05) in the comparisons indicated by brackets are shown by the symbol *.
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3. Oxidative stress
Damage to the cell host caused by reactive oxygen species is controlled by scavenging 
enzymes, namely the mitochondrial MnSOD and the cytosolic CuZnSOD (Zelko, Mariani 
et al. 2002).
The TLR2 agonist P3CSK4 significantly increased the levels of MnSOD and this effect 
was not affected by either lapachol or AC201 (Figs. 19, A & C). CuZnSOD is 
constitutively expressed and its expression was not affected by any of the treatments (Fig. 
19, A).
M. avium infection induced a significant up-regulation of MnSOD, which was not 
affected by the association of infection and lapachol (Fig. 19, B). Again, levels of the 
constitutively expressed CuZnSOD were not affected by infection or by lapachol 
treatment.
4. L-arginine metabolism
The level of expression of iNOS (NOS2), the enzyme generating NO from L-arginine, 
was significantly up-regulated by P3CSK4 (Fig. 20, A). Levels of iNOS in resting and 
TLR2 treated cells were not affected by lapachol.
The expression of arginase-1, a negative regulator of iNOS, was significantly down- 
regulated by TLR2 agonism, IFN-y activation (Fig. 20, A) and M. avium infection (Fig. 20,
B), and these changes were not influenced by lapachol. Downregulation of the expression 
of arginase-1 results in driving the use of arginine by iNOS, facilitating the production of 
NO by activated macrophages (Durante, Johnson et al. 2007).
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FIGURE 19. Effect of activation, M. avium infection and treatm ent with lapachol or AC201 
on MnSOD and CuZnSOD expression by THP-1 macrophages.
Macrophages were treated with the stimuli indicated for 4 days, then cultured for 4 additional days 
in presence of lapachol or AC201. Membrane (M) and cytosol (C) fractions were electrophoresed, 
transferred to nitrocellulose membrane and western blotted, and the blotting membranes probed 
with antibodies against mitochondrial superoxide dismutase (MnSOD) (M) or CuZnSOD (C). Band 
intensities were determined using imageJ software.
A. Macrophages treated with P3 CSK4  or IFN-y, in association or not with lapachol (32 pg/mL)
C: Control; L: lapachol; P: P3CSK4; P+L: P3CSK4 + lapachol; I: IFN-y; I+L: IFN-y + lapachol
B. Macrophages infected with M. avium, then treated or not with lapachol (32 pg/mL)
M+L : M avium + lapachol
C. Macrophages treated with P3 CSK4  or/and IFN-y, in association or not with AC201 (32 pg/mL)
C: Control; A: A C 2 0 1 ; P: P3CSK4; I: IFN-y; P+I: P3CSK4+ IFN -y; P +I+A : P3CSK 4+IFN -
y+AC201
Results are expressed as means ± S.E. (n=3, independent experiments). Significant differences 
(p<0.05) in the comparisons indicated by brackets are shown by the symbol *.
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FIGURE 20. Effect of activation, M. avium infection and treatm ent with lapachol on L- 
arginine metabolism by THP-1 macrophages.
Macrophages were treated with P3CSK4 or IFN-y, or infected with M. avium for 4 days, then 
cultured for 4 additional days in presence or not of lapachol. Cell lysates were electrophoresed, 
transferred to nitrocellulose membranes and western blotted, and the blotting membranes were 
probed with antibodies against the inducible enzymes nitric oxide synthase (iNOS) and arginase-1. 
Band intensities were determined using imageJ software.
A. Macrophages treated with P3 CSK4  or IFN-y, in association or not with lapachol (32 pg/mL)
C: Control; L: lapachol; P: P3CSK4; P+L: P3CSK4 + lapachol; I: IFN-y; I+L: IFN-y + lapachol
B. Macrophages infected with M. avium, then treated or not with lapachol (32 pg/mL)
M+L : M. avium + lapachol
Results are expressed as means ± S.E. (n=3, independent experiments). Significant differences 
(p<0.05) in the comparisons indicated by brackets are shown by the symbol *.
5. Expression of pattern recognition, phagocytic and adhesion receptors
5.1. Expression of TLR2
TLRs play a major role among pattern recognition receptors (PRRs). They recognize
pathogen-associated molecular patterns (PAMPS), which are molecules well represented in
all pathogens. Basically, TLRs are able to trigger innate immune responses by identifying
non-self-molecules. PAMPs include bacterial lipopolysaccharide (LPS), flagellin,
lipoteichoic acid from Gram positive bacteria, peptidoglycans, surface carbohydrate-
containing molecules, lipids and nucleic acid variants normally associated with viruses
such as double-stranded RNA (dsRNA) or unmethylated CpG motifs. TLR2 forms
heterodimers with TLR1 or TLR6, and this association allows the recognition of a broad
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range of ligands. Recognition needs the engagement of auxiliary molecules such as CD 14 
(Carpenter and O'Neill 2007; Bowdish, Sakamoto et al. 2009). During the present work, 
the synthetic lipopeptide P3CSK4 was used as TLR2 ligand.
The expression of TLR2 by THP-1 macrophages was found to be significantly reduced 
by lapachol by about 50%, and the same effect was induced by P3CSK4 and M. avium 
infection (Fig. 21). These reductions can be interpreted as a cellular control to avoid over 
stimulation via this receptor. In the particular case of M. avium, the effect may represent an 
advantage, since TLR ligands trigger antimicrobial activity (Thoma-Uszynski, Stenger et 
al. 2001). No changes in surface TLR2 were induced by first line antibiotics.
5.2. Expression of CD14
CD 14 is a 55 KDa glycoprotein found in the membrane of phagocytes. It works in 
association with TLRs in the recognition of bacterial LPS (Wright 1995). There is evidence 
that CD 14 not only participates in cell activation by LPS but also mediates the 
phagocytosis of mycobacteria by macrophages, in association with other phagocytic 
receptors (Sendide, Reiner et al. 2005). CD 14 also represents an important way of 
mycobacterium internalization by microglia (Peterson, Gekker et al. 1995). Thus, changes 
in the expression of CD 14 can affect not only TLR-induced activations but also the 
phagocytosis of mycobacteria. CD 14 expression is down-regulated upon macrophage 
differentiation (Daigneault, Preston et al. 2010).
The surface expression of CD 14 was studied in THP-1 macrophages cultured in the 
presence of lapachol, P3CSK4 and during M. avium infection, as well as under the 
influence of first line antibiotics. Basal levels (resting cells) were very low, in agreement 
with Daigneault et al. (Daigneault, Preston et al. 2010). None of the cell treatments or 
infection produced significant changes in these low expression levels (Fig. 22).
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FIGURE 21. Effect of activation, M. avium infection and treatm ent with lapachol or 
traditional antibiotics on the expression of surface TLR2 by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of P3 CSK4  or infected with M 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with PE-conjugated mAb against TLR2 or the appropriate isotype controls, and analyzed by 
flow cytometry (FACS). Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in B.
B. Representative histograms of isotype controls and of TLR2 expression in control, activated or 
infected or/and lapachol-treated cells, as indicated.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA. * p < 0.05; and ** p < 0.01.
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3 CSK4 ; P+Lap: P3 CSICrHapachol; P+Cla: PsCSIQ+Clarithromycin;
P+Rif: P3CSK4 +Rifampicin; P+Etha: P3CSK4+ Ethambutol;
M: M. avium; M + L: M avium + Lapachol; M + Cla: M  avium + Clarithromycin;
M + R if : M avium + Rifampicin; M + Etha: M. avium + Ethambutol
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FIGURE 22. Effect of activation, M. avium infection and treatm ent with lapachol or 
traditional antibiotics on the expression of surface CD14 by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of P3CSK4 or infected with M. 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with PE-conjugated mAb against CD 14 or the appropriate isotype controls, and analyzed by 
flow cytometry (FACS). Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in B.
B. Representative histograms of isotype controls and of CD 14 expression in control, activated or 
infected or/and lapachol-treated cells, as indicated. The CD 14 expression level was very low.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA.
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3CSK4; P+Lap: P3CSK4+lapachol; P+Cla: P3CSK4+Clarithromycin;
P+Rif: P3CSK4 +Rifampicin; P+Etha: P3CSK4 + Ethambutol;
M: M. avium', M + L: M avium + Lapachol; M + Cla: M. avium + Clarithromycin;
M + R if : M. avium + Rifampicin; M + Etha: M. avium + Ethambutol
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5.3. Expression of CD18
CD 18 is the (3 subunit of p-integrins that associates with three different a  subunits, 
namely CD lla ( o x l ) ,  CD lib  ( c x m )  and C D llc (ax), to form LFA-1 (CD 11 a/CD 18), Mac-1 
or CR3 (CD 1 lb/CD 18) and CR4 (CD 11 c/CD 18). Integrins can ligate iC3b, the adhesion 
molecule-1 (ICAM-1), bacterial products such as LPS, fibronectin, and coagulation factor 
X. These molecules are recognized by the integrin a-subunit (Petty, Worth et al. 2002). 
CR3 can also recognize mycobacterial antigens such as the antigen 85C (Hetland and 
Wiker 1994) and glycopeptidolipids (Irani and Maslow 2005), and is involved in the 
phagocytosis of opsonized and non-opsonized mycobacteria (Velasco-Velazquez, Barrera 
et al. 2003). Therefore, variations in the expression of CR3 can influence pathogen 
recognition and uptake.
The expression of CD 18 was studied after TLR2 agonism, M. avium infection or 
treatment with first line antibiotics. It was significantly down-regulated by lapachol and M. 
avium infection (Fig. 23). A reduction of CD 18 on the cell surface could result in a certain 
decrease in the rate of uptake of pathogens by macrophages and/or in cell adhesion.
5.4. Expression of Fc receptors
Fc receptors (FcyR) are a family of surface molecules that bind to IgG-opsonised 
pathogens by recognizing the Fc portion of IgG. They belong to three different groups: 
FcyRI or CD64, FcyRII or CD32 and FcyRIII or CD 16, all of them being expressed on 
macrophages. FcyRI binds monomeric IgG with high-affinity, while FcyRII and III 
recognize only multimeric immune complexes and have, therefore, been named low- 
affinity receptors (Dijstelbloem, van de Winkel et al. 2001). Fc receptors promote 
microorganism internalization, an efficient antigen presentation, and can trigger oxidative 
stress (Amigorena and Bonnerot 1999; Park 2003). Binding to these receptors can generate 
immune response stimulatory or inhibitory signals (Gerber and Mosser 2001).
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The expression of FcyRI (CD64) was not affected by any of the treatments (Fig. 24). 
FcyRII (CD32) expression was significantly down-regulated by lapachol, TLR2 agonism 
and M. avium infection (Fig. 25). FcyRIII (CD 16) was not significantly affected by any of 
the treatments (Fig. 26). In brief, lapachol only reduced the expression of FcyRII, an effect 
produced also by TLR2 agonism and M. avium infection. Reductions in FcyRII could cause 
a decreased up-take of pathogens but the fact that the high affinity FcyRI was not altered 
suggests that phagocytosis of IgG-opsonised organisms might even be unaffected.
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FIGURE 23. Effect of activation, M. avium infection and treatm ent with lapachol or 
traditional antibiotics on the expression of surface CD18 by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of P3 CSK4  or infected with M. 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with PE-conjugated mAb against CD18 or the appropriate isotype controls, and analyzed by 
flow cytometry (FACS). Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in B.
B. Representative histograms of isotype controls and of CD18 expression in control, activated or 
infected or/and lapachol-treated cells, as indicated.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA. * p < 0.05.
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3 CSK4; P+Lap: P3 CSK4 +lapachol; P+Cla: P3 CSK4 +Clarithromycin;
P+Rif: P3 CSK4  +Rifampicin; P+Etha: P3 CSK4  + Ethambutol;
M: M. avium; M + L: M avium + Lapachol; M + Cla: M. avium + Clarithromycin;
M + R if : M. avium + Rifampicin; M + Etha: M. avium + Ethambutol
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FIGURE 24. Effect of activation, M. avium infection and treatm ent with lapachol or 
traditional antibiotics on the expression of surface CD64 by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of P3 CSK4  or infected with M. 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with PE-conjugated mAb against CD64 or the appropriate isotype controls, and analyzed by 
flow cytometry (FACS). Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in B.
B. Representative histograms of isotype controls and of CD64 expression in control, activated or 
infected or/and lapachol-treated cells, as indicated.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA.
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3CSK4; P+Lap: P3CSK4+ lapachol; P+Cla: P3CSK4 + Clarithrom ycin;
P+Rif: P3CSK4+Rifampicin; P+Etha: P3CSK4+ Ethambutol;
M: M. avium', M + L: M. avium + Lapachol; M + Cla: M. avium + Clarithromycin;
M + R if : M. avium + Rifampicin; M + Etha: M avium + Ethambutol
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FIGURE 25. Effect of activation, M. avium infection and treatm ent with lapachol or 
traditional antibiotics on the expression of surface CD32 by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of P3 CSK4  or infected with M. 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with PE-conjugated mAb against CD32 or the appropriate isotype controls, and analyzed by 
flow cytometry (FACS). Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in B.
B. Representative histograms of isotype controls and of CD32 expression in control, activated or 
infected or/and lapachol-treated cells, as indicated.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA. * p < 0.05.
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3CSK4; P+Lap: P3CSK4+ lapachol; P+Cla: P3CSK4 + Clarithrom ycin;
P+Rif: P3CSK4 + Rifampicin; P+Etha: P3CSK4 + Ethambutol;
M: M. avium; M + L: M avium + Lapachol; M + Cla: M. avium + Clarithromycin;
M + R if : M. avium + Rifampicin; M + Etha: M. avium + Ethambutol
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FIGURE 26. Effect of activation, M. avium infection and treatm ent with lapachol or 
traditional antibiotics on the expression of surface CD16 by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of P3 CSK4  or infected with M 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with PE-conjugated mAb against CD 16 or the appropriate isotype controls, and analyzed by 
flow cytometry (FACS). Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in B.
B. Representative histograms of isotype controls and of CD 16 expression in control, activated or 
infected or/and lapachol-treated cells, as indicated.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA.
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3CSK4; P+Lap: P3CSK4+lapachol; P+Cla: P3CSK4+Clarithromycin;
P+Rif: P3CSK4 +Rifampicin; P+Etha: P3CSK4 + Ethambutol;
M: M. avium', M + L: M avium + Lapachol; M + Cla: M avium + Clarithromycin;
M + R if : M. avium + Rifampicin; M + Etha: M. avium + Ethambutol
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5.5. Expression of Mannose Receptor (ManR)
ManR is a C-type lectin receptor that recognizes mannose-containing carbohydrates in 
a Ca^-dependent manner. ManR can promote the phagocytosis of a wide variety of 
pathogens, such as yeasts, virus and bacteria (Linehan, Martinez-Pomares et al. 2000; 
Willment and Brown 2008). It specifically recognizes as a ligand the mycobacterial cell 
wall component lipoarabinomannan (Schlesinger, Hull et al. 1994), thus promoting the 
internalization of these pathogens as well as antigen presentation (Amigorena and 
Bonnerot 1999).
The expression of ManR by THP-1 cells was significantly down-regulated by 
lapachol, M. avium infection and the association of infection and lapachol, as shown in Fig. 
27. These changes could compromise to some extent the internalization of yeasts and 
bacteria through ManR.
5.6. Expression of Scavenger Receptor Al (SR-AI)
SR-A receptors bind to modified oxidised or acetylated low density lipoproteins and a 
vast list of ligands including polyribonucleotides, polysaccharides and lipids. Trehalose 
dimycolate is a cell wall component of M. tuberculosis that binds to macrophage SR-A and 
this results in phagocytosis. SR-A is involved in the initiation of innate and acquired 
immune responses, and also plays a protective role against excessive responses (Gough 
and Gordon 2000; Palecanda and Kobzik 2001; Peiser and Gordon 2001).
The expression of SR-AI in THP-1 macrophages was not significantly affected by any 
treatment nor by M. avium infection (Fig. 28), hence recognition and internalization via 
SR-AI is not compromised.
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FIGURE 27. Effect of activation, M. avium infection and treatm ent with lapachol or 
traditional antibiotics on the expression of surface mannose receptor (ManR) by THP-1 
macrophages.
Macrophages were cultured in the absence (control) or presence of P3 CSK4  or infected with M 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with PE-conjugated mAb against ManR or the appropriate isotype controls, and analyzed 
by flow cytometry (FACS). Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in B.
B. Representative histograms of isotype controls and of ManR expression in control, activated or 
infected or/and lapachol-treated cells, as indicated.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA. * p < 0.05; and ** p < 0.01.
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3CSK4; P+Lap: P3CSK4+lapachol; P+Cla: PsCSIQ+Clarithromycin;
P+Rif: P3CSK4 +Rifampicin; P+Etha: P3CSK4 + Ethambutol;
M: M. avium; M + L: M avium + Lapachol; M + Cla: M. avium + Clarithromycin;
M + R if : M avium + Rifampicin; M + Etha: M. avium + Ethambutol
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FIGURE 28. Effect of activation, M. avium infection and treatm ent with lapachol or 
traditional antibiotics on the expression of surface Scavenger Receptor-A (SR-A) by THP-1 
macrophages.
Macrophages were cultured in the absence (control) or presence of P3CSK4 or infected with M. 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with FITC-conjugated swine Ab against SR-A or the appropriate isotype controls, and 
analyzed by flow cytometry (FACS). Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in B.
B. Representative histograms of isotype controls and of SR-A expression in control, activated or 
infected or/and lapachol-treated cells, as indicated.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA.
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3CSK4; P+Lap: P3CSK4+lapachol; P+Cla: P3CSK4+Clarithromycin;
P+Rif: P3CSK4 +Rifampicin; P+Etha: P3CSK 4+ Ethambutol;
M: M. avium; M + L: M. avium + Lapachol; M + Cla: M. avium + Clarithromycin;
M + R if : M. avium + Rifampicin; M + Etha: M. avium + Ethambutol
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5.7. Expression of CD87 (uPAR)
Urokinase-type plasminogen receptor (uPAR or CD87), is widely expressed and plays 
an important role in cellular migration. This receptor binds urokinase-type plasminogen 
(uPA) on the cell surface, and uPA converts plasminogen in plasmin. Plasmin activates 
metalloproteinases, the proteolytic action of which allows cellular penetration within 
tissues (Murphy, Stanton et al. 1999). There is also evidence that proteolysis is not the sole 
way by which uPAR can control cell migration (Ge and Elghetany 2003).
The expression of CD87 was studied in resting, TLR2-agonised and M. avww-infected 
macrophages, treated or not with lapachol or first line antibiotics. Significant reductions in 
CD87 levels were only produced by P3CSK4 treatment associated with lapachol, 
mycobacterial infection and treatment with lapachol (Fig. 29). CD87 decreases could 
compromise the ability of macrophages to migrate to infection foci.
6. Phagocytosis
The fact that lapachol and TLR2 ligation down-regulated the surface expression of 
some phagocytic receptors prompted studies on the phagocytosis ability of macrophages. 
Macrophages were treated with P3CSK4 for 4 days and then treated or not with lapachol for 
4 additional days. At this point cells were mixed with Gram-positive or Gram-negative 
organisms, mycobacteria or inert particles and uptake was measured. Analysis was by 
microscopy, FACS or colony counting, as indicated. Binding at 4°C was determined as a 
control of attachment to the cell surface as opposed to the attachment followed by 
ingestion that takes place at 37°C.
138
Ai 1
200 400 600 800 1000
FSC-H
Isotype control
CD87
Lap Cla R.f Etha P P+Lap P+CIa P+Rif P+Etha
Com rot
M avuv 
M+Lap
Mill MComrol Isotype control
Lapachoi
Isotype control P.CSK,
I 1
l l l l l  l l l l l l  l l l l l l
M M+Lap M+CIa M+Rif M+Etha
FIGURE 29. Effect of activation, M. avium infection and treatm ent with lapachol or
traditional antibiotics on the expression of CD87 by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of P3 CSK4  or infected with M. 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with PE-conjugated mAb against CD87 or the appropriate isotype controls, and analyzed by 
flow cytometry (FACS). Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used
for the analysis shown in B.
B. Representative histograms of isotype controls and of CD87 expression in control, activated or 
infected or/and lapachol-treated cells, as indicated.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA. * p < 0.05.
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3CSK4; P+Lap: PsCSIQ+lapachol; P+Cla: P3CSK4+Clarithromycin;
P+Rif: P3CSK4+Rifampicin; P+Etha: P3CSK4 + Ethambutol;
M: M. avium; M + L: M avium + Lapachol; M + Cla: M. avium + Clarithromycin;
M + R if : M. avium + Rifampicin; M + Etha: M. avium + Ethambutol
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6.1. Latex beads
When analyzing mean fluorescence intensities (Fig.30, C: Phagocytic activity plot), 
both binding and internalization of fluoresecent latex beads was decreased ~40% by 
lapachol in resting macrophages, as well as in TLR2-agonised cells. Nevertheless, analysis 
of the percentage of cells that had ingested any number of latex particles (Fig. 30, C: % 
Phagocytosis plot) did not show significant variations among the different cell treatments. 
This can be explained by a decreased uptake rate but not complete inhibition of ingestion 
under the influence of lapachol, which results in cells containing fewer particles each and 
therefore exhibiting a lower fluorescence.
6.2. 5. aureus
The binding and internalization of these gram-positive bacteria by resting cells was not 
significantly affected by lapachol (Fig. 30, A). TLR2 agonism resulted in an increase of 
both bound and internalized bacteria, with the latter being inhibited by treatment of TLR2- 
agonised cells with lapachol. Inhibition of internalization but not binding suggests a 
slowing down of the rate of microorganism uptake.
6.3. S. typhimurium
Lapachol diminished the number of resting but not TLR2-agonised cells that 
internalize this pathogen (Fig. 30, C: % Phagocytosis plot). However, the number of 
bacteria bound or internalized was not significantly affected by lapachol or any other 
treatment (Fig. 30, C: Phagocytic activity plot), which suggests that the uptake rate was not 
altered or was even increased by lapachol in this case.
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6.4. M. avium
The binding of M. avium to macrophages was not affected in any condition (Fig. 30, 
C: Phagocytic activity plot). Instead, internalization by either resting or TLR2-agonised 
macrophages was sensibly decreased (50-80%), although not suppressed, by lapachol (Fig. 
30, C: Phagocytic activity plot). Since the amount of cells that were able to phagocytose 
fluorescent M. avium was not significantly affected by lapachol or any other treatment 
(Fig. 30, C: % Phagocytosis plot), a decrease in the rate of uptake is likely to be occurring. 
The FACS results shown in Fig. 30 regarding M. avium phagocytosis were in agreement 
with those obtained by determining directly the number of intra-cellular bacteria by 
fluorescence microscopy, shown in Fig. 31.
The reduction in the uptake rate of M. avium and S. aureus caused by lapachol, 
without bacterial binding to cells being affected, is likely to be due to some signaling or 
cytoskeleton-related interference and not to a receptor binding defect.
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FIGURE 30. Influence of TLR2 agonism and lapachol on the binding and phagocytosis of 
latex beads, M. avium , S. aureus and S. typhimurium
Macrophages were cultured with 300nM P3CSK4 for 4 days and then treated or not with lapachol 
(32pg/mL) for 4 additional days. They were then incubated at 4°C or 37°C with FITC-M avium, 
for 4 hours, or with S. aureus, GFP-51. typhimurium or FITC-latex beads, for 30 minutes. Cell- 
associated bacteria/particles were determined after washing excess bacteria/particles with PBS.
A. S. aureus phagocytosis: Cells were lysed and plated on Luria agar for colony counting. Results 
are expressed as relative CFU values, taking as 1 for each experiment the value o f cell-associated 
CFUs corresponding to untreated macrophages. Means ± S.E. (n=3, independent experiments). B. 
Representative FACS histograms of a M. avium phagocytosis experiment. C. Phagocytosis (%) and 
phagocytic activity of fluorescent latex beads, M avium, and S. typhimurium. Phagocytosis (%) is 
expressed as [number of cells containing any number of particles]/[total gated cell number] X 100. 
Phagocytic activities are expressed as the median fluorescence intensities (MFI) of the FACS 
histograms (means ± S.E., n=3, independent experiments). Statistical differences were analysed by 
ANOVA (* p < 0.05, ** p < 0.01).
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FIGURE 31. Phagocytosis of M. avium by resting, activated and/or lapachol-treated THP-1 
macrophages, evaluated by fluorescence microscopy.
Macrophages were incubated with 300nM P3CSK4 for 4 days and then treated or not with lapachol 
(32pg/mL) for 4 additional days. Cells were then incubated at 37°C with M. avium-FITC for 4 
hours to allow internalization. They were washed 3 times to remove extracellular mycobacteria, 
fixed on glass slides with paraformaldehyde and reacted with phalloidin for actin counterstaining. 
The number of internalized bacteria was counted in 100 cells.
A. Illustrative picture showing phagocytosed (yellow arrow) and surface (green arrow) M. avium.
B. Bar graph of the ratios between internalized bacteria and cells observed in control, lapachol- 
treated and/or TLR2-agonised macrophages.
P+L : P3CSK4 + lapachol.
7. Secretion of pro- and anti-inflammatory cytokines
Tissue invasion by pathogens generates inflammation and this is orchestrated by a 
number of factors including cytokines. Cytokines can have pro- or anti-inflammatory 
effects, and the balance between them controls the immune response and minimizes tissue 
damage (Opal and DePalo 2000). Cytokines can be divided in two main groups according 
to their involvement in acute inflammation or in chronic inflammation. Acute 
inflammation is associated to pro-inflammatory cytokines and/or chemoattractants, and
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chronic inflammation is characterized by the secretion of anti-inflammatory cytokines 
mediating tolerance (Feghali and Wright 1997).
The expression of acute cytokines and anti-microbial proteins is regulated by nuclear 
factor-KB (NF-kB). NF-kB becomes activated after PAMP recognition by PRRs or by pro- 
inflammatory cytokines and plays a crucial role in the regulation of innate and adaptive 
immune response (Li and Verma 2002).
Some natural compounds have been shown to exhibit immunomodulatory effects. For 
instance, kavain present in root extracts of Piper methysticum prevents the secretion of the 
pro-inflammatory cytokine TNF-a by LPS-stimulated THP-1 cells (Pollastri, Whitty et al. 
2009). Plumbagin, a naphthoquinone found in plants, induces an anti-inflammatory effect 
by inhibiting the secretion of IL-2, IL-4, IL- 6  and IFN-y by stimulated mouse lymphocytes 
through preventing the degradation of IkB and the subsequent NF-kB activation (Checker, 
Sharma et al. 2009).
Lapachol, the object of the present work, is a naphthoquinone of the same family as 
plumbagin, and its effects on cytokine secretion or NF-kB activation have not been studied 
yet. Here, the effect of lapachol on the secretion of pro- and anti-inflammatory cytokines 
by P3CSK4- or IFN-y-treated macrophages or M. avz'ww-infected macrophages is shown.
7.1. TNF-a
TNF-a secretion is shown in Fig. 32. Lapachol suppressed the basal secretion of TNF- 
a  by resting and IFN-y-treated macrophages, but did not affect the significant up- 
regulation produced by TLR2 agonism. The increase in TNF-a secretion triggered by M. 
avium infection was reduced but not suppressed by treatment with lapachol. This reduction 
could be a consequence of the direct effect of lapachol on the viability of intracellular 
mycobacteria.
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7.2. IL-ip
The secretion of IL-lp, another pro-inflammatory cytokine, was significantly reduced 
(40-50%) by lapachol in resting and IFN-y-treated cells (Fig. 32). No other significant 
change was observed.
7.3. IL-10
IL-10 is an anti-inflammatory cytokine known to be secreted by M  av/ww-infected 
cells (Bermudez and Champsi 1993; Reiling, Blumenthal et al. 2001). A significant, 
pronounced inhibitory effect of lapachol on IL-10 secretion was observed in resting, 
TLR2-agonised, IFN-y-treated and M  av/w/w-infected cells (Fig. 32). IL-10 opposes the 
effects of pro-inflammatory cytokines such as IFN-y and TNF-a, therefore a reduced 
secretion of IL-10 is expected to result in an enhanced bacterial killing capacity of 
macrophages. In the case of M. ov/w/w-infected cells, treatment with lapachol would favour 
the intra-cellular killing of those microorganisms due to the curbing of IL-10 secretion 
(Roach, Barton et al. 1995). Since the secretion of TNF-a and IL-1(3 elicited by TLR2 
agonism was not significantly affected by lapachol, the additional reduction in IL-10 levels 
would create a scenario favouring the control of M. avium intracellular growth in 
macrophages.
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FIGURE 32. Cytokine secretion by resting, lapachol treated, TLR2-agonised, IFN-y-treated 
and M. avium-infected THP-1 macrophages.
Resting (control) cells or cells activated with IFN-y or P3CSK4 or infected with M. avium for 4 days 
were treated with lapachol (32pg/mL) for 4 additional days. Cell culture supernatants were used to 
determine TNF-a, IL-10 and IL-ip concentrations by ELISA.
The data shown are means ± S.E. (n=3, independent experiments), taking as 1 the control value 
(untreated cells) for each of the experiments. The absolute values of the controls were (ranges, 
n=3): 20 to 80 pg/mL for TNF-a, 9 to 22 pg/mL for IL-10 and 56 to 128 pg/mL for IL-ip. 
Statistical analysis was performed by ANOVA. Significant differences are indicated by star 
symbols (* p < 0.05; ** p < 0.01).
C: Control; Lap: lapachol; P: P3CSK4; P + L: P3CSK4+ lapachol;
I + L: IFN-y + lapachol; M: M. avium; M+L: M. avium + lapachol
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ER is a compartment of the secretory pathway that is responsible for the synthesis, 
modification, and delivery of proteins. The flux of protein synthesis and folding is 
controlled in this cellular location, and is disturbed when the influx of nascent, unfolded 
proteins chains exceeds the folding capacity of the ER. This generates ER stress, followed 
by the unfolded protein response (UPR) during which chaperones are up-regulated, since 
they are the molecules responsible to fold and unfold proteins (Schroder and Kaufman 
2005). In the present study we found that neither lapachol nor AC201 increased the levels 
of grp78, therefore their presence did not perturb ER function and homeostasis. 
Surprisingly, TLR2 agonism reduced the expression of grp78. It is known that TLR 
agonism can induce autophagy via its adaptor protein MyD8 8  and TRIF (Delgado, 
Elmaoued et al. 2008; Shi and Kehrl 2008). A reduction in grp78 levels could affect 
autophagy, since grp78 is required for autophagosome formation (Li, Ni et al. 2008).
Pathogen sensing by innate cells is mediated by PRRs, which constitute immune 
surveillance detectors by recognizing PAMPs present in pathogens. Among PRRs, toll-like 
receptors (TLRs) are responsible for the detection of various classes of pathogens and 
molecules derived therefrom. The ligation of PAMPs to TLRs activates a signal 
transduction cascade leading to the activation of the transcription factor NF-kB, which 
regulates the expression of pro-inflammatory cytokines such TNF-a, IL-lp and IL-12 that 
activate the immune response and enhance the killing ability of phagocytes by inducing the 
generation of oxygen active species (Henneke, Takeuchi et al. 2002) and nitrogen 
metabolites (Thoma-Uszynski, Stenger et al. 2001). The protective role of TLRs is 
demonstrated by the failure of TLR2 knockout mice to increase the levels of TNF-a and 
IL-12 after infection with M. tuberculosis (Drennan, Nicolle et al. 2004), with the result of 
an increased susceptibility to this disease. TLR2 deficiency also enhances the susceptibility 
to pneumonic tularemia (Malik, Bakshi et al. 2006). Moreover, polymorphisms in human 
TLR2 are associated with an increased susceptibility to tuberculous meningitis (Thuong,
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Hawn et al. 2007), and allergy-induced TLR2 down-regulation contributes to decreased 
mycoplasma clearance in mice (Wu, Martin et al. 2008).
During the present work, THP-1 macrophages responded to TLR2 agonism and 
infection with M. avium by secreting significant amounts of TNF-a (Fig. 32). The 
compound here being studied, lapachol, did not interfere with the TNF-a response since it 
did not affect the TLR2- elicited secretion of this cytokine. In the case of M avium- 
infected macrophages, lapachol inhibited the secretion of TNF-a to levels similar to those 
of resting cells. This is likely to be a consequence of the fact that lapachol is curbing the 
intracellular growth of the pathogen, therefore reducing the extent of TNF-a secretion by 
disappearance (degradation) of stimulating molecules from the bacterial surface. Lapachol 
treatment did result in a partial inhibition of IL-ip secretion by resting and IFN-y-treated 
macrophages (Fig. 32). Infection of macrophages with M. avium induces the secretion of 
the immunosuppressive, anti-inflammatory cytokine IL-10, which favours pathogen 
survival (Grutz 2005). The role of IL-10 in the resistance of M  avium to innate immune 
responses was highlighted by Murray et al (Murray and Young 1999), who observed that 
IL-10 deficient mice respond more efficiently to M. avium infections. The THP-1 
macrophages here used responded to M. avium infection with a non-significant increase in 
IL-10 levels, which were significantly reduced to basal values when the infected cells were 
treated with lapachol (Fig. 32). The general effect of lapachol, which suppressed even 
basal levels of IL-10, is in favour of a pro-inflammatory response and against 
mycobacterial survival.
The levels of expression TLR2 on phagocytic cells could regulate the level of cell 
response to stimuli. Mae et al (Mae, Iyori et al. 2007) demonstrated that TLR2 ligands do 
not change the expression of this receptor on THP-1 monocytes. Instead, Wang et al 
(Wang, Lafuse et al. 2000) detected increased levels of TLR2 mRNA after M. avium 
infection of mouse macrophages. The results here reported, using THP-1 macrophages,
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show that TLR2 agonism, as well as M. avium infection and treatment with lapachol, 
influenced negatively the expression of TLR2 by these cells (Fig. 21). The relatively 
modest down-regulation of TLR2 expression observed could represent a mechanism to 
avoid the over-activation of the PMA-treated THP-1 macrophages. In spite of the reduction 
in surface TLR2, many TLR2 agonism-mediated events were not affected by lapachol, 
namely increases NOS2 (Fig. 20), MnSOD (Fig. 19), $41phox (Fig. 18) and TNF-a 
secretion (Fig. 32); decrease in arginase-1 levels (Fig. 20). This suggests that the lapachol- 
induced decrease in surface TLR2 probably does not result in impairments of TLR2- 
mediated functions.
The present study has shown that stimulation of THP-1 macrophage-like cells with 
P3CSK4 or M. avium infection, or treatment with lapachol, often induced a partial down- 
regulation of the expression of surface receptors involved in bacterial internalization, 
including mycobacteria (Figs. 23 and 25). Some of these receptors can be also involved in 
cell migration (CD87, Fig. 29). Mannose receptor (ManR) but not scavenger receptor Al 
(SR-AI) expression was down-regulated by the TLR2 agonist P3CSK4 (Fig. 27 & 28). 
These results do not agree with those of Mae et al., who found an up-regulation of the 
mRNA levels of SR-AI and some C-type lectins. The differences can be due to the fact that 
Mae et al. have used non-differentiated THP-1 cells instead of inducing differentiation to 
macrophage-like cells with 20 nM PMA as performed during the present work. Besides, 
results based on mRNA levels often do not coincide with those from direct measurements 
of protein expression.
Mycobacteria can be opsonically or non-opsonically internalized after binding to a 
wide range of receptors. TLRs can regulate phagocytosis by activation of phagocytic 
function genes (Doyle, O'Connell et al. 2004). Since the results here shown indicate that 
TLR agonism and lapachol down-regulate to some extent the expression of some receptors 
involved in phagocytosis, it was important to determine whether particle/bacterial
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internalization was affected. However, it must be pointed that phagocytosis can also be 
altered by cytoskeleton-related and energy metabolism events and not just by variations in 
phagocytosis receptor levels. Mae et al. (Mae, Iyori et al. 2007) reported that TLR2 
agonism by the diacylated lipopeptide FSL-1 enhanced S. aureus and E. coli phagocytosis, 
but did not influence the internalization of latex beads by non-differentiated THP-1 cells. 
In the present work, THP-1 macrophage-like cells were treated with the triacylated 
lipopeptide P3CSK4 and this significantly increased the internalization of S. aureus but not 
the ingestion of latex beads, M. avium or S. typhimurium (Fig. 30). Lapachol reduced 
significantly the amount of ingested M. avium and latex, but not that of S. aureus. It is 
worth noting that even when lapachol inhibited internalization measured as the total 
number of particles ingested, it did not have an effect on the % of phagocytosis except for 
a decrease observed in the case of S. typhimurium. The % of phagocytosis was defined as 
the proportion of cells that have ingested any number of particles, i.e. independently of the 
amount ingested. The situation after treatment with lapachol is one where the number of 
macrophages that are actively phagocytosing is the same as for untreated cells, but 
lapachol-treated cells contain on average fewer particles/bacteria per cell than those 
untreated. In the case of S. typhimurium, there seems to be fewer phagocytosing 
macrophages under the influence of lapachol. The diminished internalizations observed in 
the presence of lapachol are not likely to have been caused by down-regulations of 
phagocytic receptor expression, since no significant differences in surface binding at 4°C 
were detected (Fig. 30). Phagocytosis is a complex event involving a continuous 
rearrangement of actin filaments (Aderem and Underhill 1999; Ernst 2000; May and 
Machesky 2001). Therefore, impairments in the efficiency of cytoskeleton dynamics or in 
the signaling leading to it could be the cause of the partially diminished phagocytosis 
produced by lapachol. The consequences of a lower internalization rate in a physiological 
context are difficult to predict. They do not necessarily have to result in a higher incidence 
of infection, since the ratios macrophages/bacteria in vivo are much higher than those in in
vitro experiments. A reduced ability of each individual macrophage to ingest 
microorganisms could mean a greater number of pathogen ingesting cells, each containing 
a smaller number of microorganisms. Besides, particle internalization by other important 
cells of the first line of defense (e.g. neutrophils and DCs), if not affected or less affected 
by lapachol, could take care of the clearance of many bacteria. This would diminish the 
impact of a reduced phagocytosis by macrophages. To conclude, even with lapachol 
causing a diminished rate of M. avium internalization, the ability of the naphthoquinone to 
arrest and control intracellular M. avium growth was still satisfactory.
Chemotaxis and cell adhesion are important events involved in cell migration from the 
bloodstream to tissues. Therefore, the expression of receptors involved in these phenomena 
was examined. Cell surface CD87 (uPAR) was down-regulated by lapachol in resting cells, 
by TLR2-agonism in association with lapachol and by M. avium infection (Fig. 29). Aung 
et al (Aung, Wu et al. 2005) reported the up-regulation of the expression of uPAR in blood 
monocytes but not in alveolar macrophages after M. tuberculosis infection. The up- 
regulation is associated with TGF-(3 activity. Juffermans et al (Juffermans, Dekkers et al. 
2001) reported a higher expression of this receptor on monocytes from M. tuberculosis 
infected patients. The down-regulations in uPAR expression observed in the present work 
could be explained by the fact that THP-1 macrophages are different from blood 
monocytes and by the use of M. avium and not M. tuberculosis.
ICAM-1 (CD54), another receptor involved in cell adhesion, binds to integrins such as 
LFA-1 and Mac-1, playing an important function as co-stimulator molecule during the 
formation of immunological synapses. Its expression was not affected by IFN-y treatment 
(Fig. 35). The up-regulation of CD54 expression is associated with the effect of the pro- 
inflammatory cytokines IFN-y and TNF-a (Roebuck and Finnegan 1999), whereas the 
anti-inflammatory cytokine IL-10 and M. tuberculosis infection down-regulate its 
expression in macrophages (de la Barrera, Aleman et al. 2004).
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In phagocytes, the generation of reactive oxygen and nitrogen metabolites is crucial 
for microbial killing. These reactive molecules are originated in the products of the 
inducible enzyme systems NADPH oxidase and nitric oxide synthase, whose activity 
and/or expression are up-regulated after pathogen recognition by phagocytes and cytokine 
action. In the present studies, the capacity to generate superoxide was evaluated by 
determining the levels of the NADPH oxidase inducible and regulatory subunits gp9\phox 
and ^Alphox. The compound AC201, initially studied, reduced the levels of these subunits, 
which would affect superoxide generation (Fig. 18, C). Instead, the naphthoquinone 
lapachol did not change the basal levels of these NADPH oxidase components and actually 
potentiated the levels of p4'lphox already up-regulated by P3CSK4 treatment. Surprisingly, 
IFN-y did not alter the expression of gp9\phox (Fig. 18, A), whose mRNA levels have been 
reported to be up-regulated by this cytokine in THP-1 cells (Newburger, Ezekowitz et al. 
1988). However, the up-regulation may just be a short term effect, since the same report 
shows an important reduction in gp9 \phox mRNA levels after 48 hours. This could be the 
case in the experiments here described, since effects were routinely determined after 4 
days. In addition, a correlation between mRNA levels and protein expression is not 
necessarily true in many cases. Regarding NOS2 (iNOS), its levels were found increased 
after TLR2 agonism (Fig. 20, A). It was surprising that no increase in NOS2 expression by 
IFN-y treatment was observed. IFN-y is known to induce NO formation (Chan, Tanaka et 
al. 1995; Shtrichman and Samuel 2001), but this effect depends on the concentration and 
activity of the cytokine. Lapachol did not affect either baseline or TLR2 agonism-induced 
NOS2 levels (Fig. 20, A). IFN-y-, TLR2 agonism- and M. avium infection-induced down- 
regulations of arginase-1 were observed (Fig. 20, A & B) that can be favouring NO 
formation by increasing arginine availability (Wu and Morris 1998). These potentially 
useful reductions were not affected by treatment with lapachol. The down-regulation of 
arginase-1 could in fact result in increased NO formation even in the absence of an
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induction of NOS2. However, interpretation of some of the blottings is complicated by the 
absence of proper loading controls.
The fact that quinones can promote superoxide generation could result in cell damage 
and even toxicity. The extent of action of the naphthoquinone lapachol in this respect does 
not appear to be pronounced, since it did not increase the number of apoptotic cells. 
Besides, the absence of a lapachol-induced oxidative stress, indicated by unchanged 
MnSOD levels (Fig. 19), supports the idea of lapachol not being a particularly toxic 
quinone at the concentration used during the present studies.
153
Chapter 3 : IFN-y responsiveness and antigen presentation
The immune response to mycobacterial infections involves different subsets of T cells, 
a (3 and yb T cells are two groups of T cells expressing different types of T cell receptor 
(TCR). a|3 T cell group is composed by three subsets, CD4+, CD8 + and CD1 restricted 
cells. During the attempts to control mycobacterial infection, CD4+ T cells play a major 
role. After activation by mycobacterial antigens, T cells can be directly cytotoxic or can 
secrete the main macrophage activating cytokines IFN-y and TNF-a, which enhance the 
intracellular killing of mycobacteria (Boom, Chervenak et al. 1992; Boom, Canaday et al. 
2003; Felio, Nguyen et al. 2009). The first encounter with pathogens triggers a primary 
response where T cell proliferation is induced and T and B memory cells are generated. 
Memory cells are the basis of a quick response during a second contact with the same 
pathogen (Bonilla and Oettgen 2010).
T lymphocyte activation is dependent of two signals originated in the interaction of T 
cells with APCs during antigen presentation. The main signal is antigen specific, and is 
generated by TCR after binding to the antigen-MHC complex displayed on the surface of 
APCs. A secondary, but not less important, signal is antigen non-specific and is mediated 
by the interaction of the co-stimulatory molecules CD28, CTLA-4, and CD83-ligand on 
the T cell surface with CD80, CD83 and CD8 6  on the APC membrane. These events 
represent a link between innate and adaptive immunity, aimed at mounting an effective 
immune response against the invading organisms (Lenschow, Walunas et al. 1996; 
Greenwald, Latchman et al. 2002; Breloer and Fleischer 2008).
Protein antigens are presented by APCs in different ways depending of their origin. 
Bacteria are internalized by phagocytes and, as a consequence of a degradative process, 
their proteins are broken down to small peptides that associate with MHC II molecules. 
MHC II-peptide complexes translocate to the APC membrane where they are recognized
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by CD4+ T cells. Mycobacterial components can also gain access to the cytosol of host 
cells and the antigens originated are presented on the APC surface associated with MHC I 
molecules, like any other intracellular antigen. The cross presentation phenomenon exerted 
by dendritic cells, represent another mechanism of mycobacteria antigens presentation 
associated with MHC I. Antigen-MHC I complexes are targeted by CD8+ cells. 
Mycobacterial lipids, e.g. mycolic acids, cannot associate with MHC I or II molecules due 
to their chemical characteristics. These molecules are presented associated with the 
hydrophobic groove of CD1 receptors. y6 T cells recognise phospho-antigens which are 
presented by APCs in a still unknown manner (Moody, Besra et al. 1999; Boom, Canaday 
et al. 2003).
In brief, macrophages are efficient phagocytes, responsible for removing pathogens, 
erythrocytes and cell debris (Mosser and Edwards 2008). Moreover, they prime T cells for 
cell proliferation, synthesis of IFN-y and immortalization (Pozzi, Maciaszek et al. 2005). 
IFN-y secreted by activated lymphocytes enhances the antimicrobial and antigen 
presentation function of macrophages (Boehm, Klamp et al. 1997). Despite the 
macrophage ability to eliminate intracellular pathogens and present their antigens, 
pathogenic mycobacteria developed evading strategies that allow their proliferation within 
the host cell, as commented in the Introduction, section 9.2. (Chang, Linderman et al. 
2005; Huynh and Grinstein 2007; Baena and Porcelli 2009).
The immunomodulatoiy effect of some natural products on antigen presentation has 
been studied. Smoke tobacco extracts (Gong and Chen 2003), the plant compound albacol 
(Liu, Shu et al. 2008), and cyanobacterial grassystatins (Kwan, Eksioglu et al. 2009) inhibit 
remarkably antigen presentation by APCs. The influence of lapachol on the expression of 
receptors/molecules involved in IFN-y responses and antigen presentation by THP-1 
macrophages was here studied.
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1. Expression of IFN-yRl
Two populations were detected that expressed surface IFN-y receptor (IFN-yRl) to 
different extents (Fig. 33, A). Treatment with lapachol or P3CSK4 increased the percentage 
of cells expressing high levels of IFN-yRl as shown by a shift from low to high IFN-yRl - 
expressing cells (Fig. 33, B and C). Such up-regulation could be favouring responses to 
IFN-y, considering the relative paucity of these receptors on the cell surface (Finbloom, 
Hoover et al. 1985). To determine whether the increase in the IFN-yRl surface signal was 
due to the translocation of pre-existing molecules from cytoplasmic storage vesicles or to 
new protein synthesis, the fluorescence signal of permeabilised cells (i.e. cytoplasmic + 
surface expression) was determined. Figure 34 shows histograms and bar graphs 
corresponding to control, lapachol-treated, TLR2-agonised and TLR2-agonised/lapachol- 
treated cells. No significant differences were observed among permeabilised cells that had 
been differently treated, as opposed to what was observed in intact cells (Fig. 33). This 
means that the lapachol- and TLR2 agonism-induced increases in IFN-yRl detected on the 
cell surface are originated in a decrease of IFN-yRl molecules stored intracellularly. The 
most likely explanation is a translocation of IFN-yRl-containing cytoplasmic vesicles to 
the cell membrane, an event reported to occur in relationship with CD86 in macrophages 
(Smyth, Logan et al. 2005) and CR1 in neutrophils (Berger, Wetzler et al. 1991).
In view of the modulation of the surface expression of IFN-yRl by lapachol and TLR2 
agonism, the surface expression of the following receptors known to be up-regulated by 
IFN-y was examined: CD54 (ICAM-1), CD64 (FcyRI) and MHC II.
156
0 200 400 600 800 1000
FSC-H
B Control
A  I
Lapachol P3CSK, P+L
10* to' to2 to* to4 0® to' to2 to2
fU-*l Rl-tt
.02riwi to2rim to2
IFNyRI
co
■A 
■ B
FIGURE 33. Effect of TLR2-agonism and lapachol treatm ent on the expression of surface 
IFN-yRl by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence o f 300 nM P3CSK4 for 4 days and 
then for 4 additional days in the absence or presence o f 32 pg/mL lapachol. Cells were stained with 
FITC-conjugated mAb against IFN-yRl or the appropriate isotype controls, and analyzed by 
FACS. Number o f total (ungated) events = 10 000.
A. Dot plot o f forward vs side scatter o f THP-1 macrophages showing the cell gating region used 
for the analysis shown in C, and a representative histogram of a control (resting cells) sample and 
an isotype control.
B. Representative dot plots o f forward scatter vs FITC fluorescence o f two cell populations (A and 
B) expressing different levels o f IFNyRI.
C. Bar graphs showing the mean % o f events corresponding to both the low (A) and high (B) 
expressing areas (mean ± S.E., n=3, independent experiments). Statistical analysis was by ANOVA 
(* p < 0.05; ** p < 0.01).
C: Control; Lap: lapachol; P: P3CSK4; P + L: P 3 C S K 4 + lapachol
Control
Isotype control
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2. Expression of CD64 (FcyRI)
The expression of FcyRI (CD64), involved in the high affinity binding and 
phagocytosis of IgG-opsonized pathogens, was not significantly affected by lapachol nor 
by TLR2 agonism, IFN-y activation or M. avium infection (Fig. 24). The lack of response 
to IFN-y could be due to the cytokine dose used or to the fact that the present experiments 
examine late phase events.
3. Expression of CD54 (ICAM-1)
CD54 is involved in cell attachment and migration. Its expression was not 
significantly affected by lapachol or any of the cell treatments (TLR2 agonism, IFN-y) 
(Fig. 35, B). Similarly to CD64, the lack of response to IFN-y could be due to the dose 
used or to the fact that the present experiments examine late phase events.
4. Expression of receptors involved in antigen presentation
4.1. Major histocompatibility molecule II (MHCII)
MHCII is involved in the presentation of exogenous antigens. Presentation is achieved 
by being recognized by T cell receptors on CD4+ T lymphocyte membranes. This molecule 
is expressed at very low levels on resting cells (Fig. 35, A). Incubation with lapachol alone 
and in association with IFN-y or P3CSK4 induced a significantly higher expression of MHC 
II (Fig. 35, A) that could potentiate antigen presentation. The fact that IFN-y did not result 
in an increase in MHCII was in line with the results obtained regarding CD64 and CD54, 
supporting the idea that it could be due to the IFN-y dose used or to the fact that the present 
experiments examine late phase events.
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FIGURE 34. Effect of TLR2 agonism and lapachol treatm ent on the total (surface + 
cytoplasmic) expression of IFN-yRl by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of 300 nM P3 CSK4  for 4 days and 
then for 4 additional days in the absence or presence of 32 pg/mL lapachol. Cells were then fixed 
and permeabilized with Fix & Perm® in order to detect both cytoplasmic and surface IFN-yRl, and 
subsequently stained with FITC-conjugated mAb against IFN-yRl. Appropriate isotype controls 
were run, and samples were analysed by FACS.
A. Dot plot of forward vs side scatter of permeabilized THP-1 macrophages, showing the cell 
gating region used for the analysis shown in C.
B. Representative histograms of IFN-yRl expression by permeabilized cells and of an isotype 
control.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA. No significant (p > 0.05) differences 
were observed.
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FIGURE 35. Effect of activation, M. avium infection and treatm ent with lapachol on the 
surface expression of MHCII and ICAM-1 (CD54) by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of P3 CSK4 , IFN-y or infected with 
M. avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol Cells were stained with PE-conjugated mAb against MHCII (A) or ICAM-1 (B) or the 
appropriate isotype controls, and analyzed by flow cytometry (FACS). Number o f total (ungated) 
events = 1 0  0 0 0 .
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in C.
B. Representative histograms of isotype controls and of MHCII and ICAM-1 (CD54) expression in 
control, activated or infected or/and lapachol-treated cells, as indicated.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA. ** p < 0.01.
C: Control; Lap: lapachol; P: P3CSK4; P + L: P3CSK4+ lapachol; I + L: IFN-y + lapachol;
M : M. avium; M+L: M. avium + lapachol
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4.2. Expression of co-stimulatory receptors
Macrophages are antigen presenting cells and as such they are engaged in the 
processing and presentation of pathogen antigens to T cells. CD83, CD80 and CD86 are 
members of a family of receptors that, together with MHC molecules, participate in the 
interaction with and activation of CD4+ or CD8+ T cells through their CD28 and CTLA-4 
surface receptors. These so called co-stimulatory molecules trigger a signal on T cells that, 
together with MHC signaling, result in T cell activation and proliferation. Lapachol did not 
affect the expression of CD80 and CD83 but did inhibit the levels of the CD86 (Fig. 36, 
37, 38), as did TLR2 agonism and M. avium infection.
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FIGURE 36. Effect of activation, M. avium infection and treatm ent with lapachol or 
traditional antibiotics on the expression of surface CD80 by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of P3 CSK4  or infected with M. 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with PE-conjugated mAb against CD80 or the appropriate isotype controls, and analyzed by 
FACS. Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in C. B. Representative histograms of isotype controls and of CD80 
expression in control, activated or infected or/and lapachol-treated cells, as indicated. C. Bar graph 
results are expressed as means ± S.E. of the median fluorescence of 3 independent experiments. 
Statistical analysis was performed by ANOVA and showed no significant (p>0.05) differences.
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3CSK4; P+Lap: P3CSK4+lapachol; P+Cla: P3CSK4+Clarithromycin; P+Rif: P3CSK4
+Rifampicin; P+Etha: P3CSK4 + Ethambutol;
M: M. avium; M + L: M  avium + Lapachol; M + Cla: M. avium + Clarithromycin;
M + R if : M. avium + Rifampicin; M + Etha: M. avium + Ethambutol
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FIGURE 37. Effect of activation, M. avium infection and treatm ent with lapachol or 
traditional antibiotics on the expression of surface CD83 by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of P3 CSK4  or infected with M 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with PE-conjugated mAb against CD83 or the appropriate isotype controls, and analyzed by 
FACS. Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in C.
B.  Representative histograms of isotype controls and of CD83 expression in control, activated or 
infected or/and lapachol-treated cells, as indicated.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA and showed no significant (p>0.05) 
differences.
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3CSK4; P+Lap: P3CSK4+lapachol; P+Cla: PsCSIQ+Clarithromycin; P+Rif: P3CSK4
+Rifam picin; P+Etha: P3CSK4 + Ethambutol;
M: M. avium; M + L: M. avium + Lapachol; M + Cla: M. avium + Clarithromycin;
M + R if : M. avium + Rifampicin; M + Etha: M. avium + Ethambutol
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FIGURE 38. Effect of activation, M. avium infection and treatm ent with lapachol or 
traditional antibiotics on the expression of surface CD86 by THP-1 macrophages.
Macrophages were cultured in the absence (control) or presence of P3 CSK4  or infected with M 
avium for 4 days and then cultured for 4 additional days in the absence or presence of 32 pg/mL 
lapachol, 0.56 pg/mL clarithromycin, 1.6 pg/mL rifampicin or 0.35 pg/mL ethambutol. Cells were 
stained with PE-conjugated mAb against CD8 6  or the appropriate isotype controls, and analyzed by 
FACS. Number of total (ungated) events = 10 000.
A. Dot plot of forward vs side scatter of THP-1 macrophages showing the cell gating region used 
for the analysis shown in C.
B. Representative histograms of isotype controls and of CD8 6  expression in control, activated or 
infected or/and lapachol-treated cells, as indicated.
C. Bar graph results are expressed as means ± S.E. of the median fluorescence of 3 independent 
experiments. Statistical analysis was performed by ANOVA (* p < 0.05 and ** p < 0.01).
C: Control; Lap: Lapachol; Cla: Clarithromycin; Rif: Rifampicin; Etha: Ethambutol;
P: P3CSK4; P+Lap: P3CSK4+lapachol; P+Cla: P3CSK4+Clarithromycin; P+Rif: P3CSK4
+Rifampicin; P+Etha: P3CSK4 + Ethambutol;
M: M  avium; M + L: M  avium + Lapachol; M + Cla: M. avium + Clarithromycin;
M + R if : M. avium + Rifampicin; M + Etha: M. avium + Ethambutol
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IFN-y is a pro-inflammatory cytokine involved in innate and acquired immune 
responses. Infections stimulate antigen-presenting cells to secrete IL-12, which attracts NK 
cells to the site of inflammation and induces them to secrete IFN-y. IL-12 secretion by 
macrophages is enhanced by IFN-y, and this increase in IL-12 further stimulates NK and T 
cells to secrete IFN-y, in an amplifying mechanism. Macrophages are strongly activated by 
IFN-y, which enhances pathogen recognition, antigen processing and presentation and 
microbicidal mechanisms (Schroder, Hertzog et al. 2004). The results obtained during this 
work regarding expression levels of key components of the NADPH oxidase and NO 
generation systems are shown in Chapter 2, sections 2 and 4. No up-regulation of gp9\phox 
and NOS2 expression by IFN-y treated THP-1 macrophages was observed (Figs. 18 and 
20). This could be a consequence of the fact that the experiments performed corresponded 
to responses at the 8th day of treatment with IFN-y. In fact, Newburger et al (Newburger, 
Ezekowitz et al. 1988) found a reduction in mRNA levels for gp9\phox after 48 hours of 
treatment. The only effect of IFN-y was an increase in the cytosolic levels of pAlphox (Fig. 
18).
Concerning antigen presentation, a double signal induced by MHC molecules on the 
APC side and co-receptors on both APC and T cell sides are required. Lapachol did not 
affect the expression in macrophages of CD80 (Fig. 36) or CD83 (Fig. 37) and induced a 
decrease in CD86 (Fig. 38), as TLR2 agonism and M. avium infection did. M. avium 
infection has been previously reported to reduce CD86 levels (Mohagheghpour, Gammon 
et al. 1997; Rajavelu and Das 2008). Lapachol treatment, instead, led to a substantial 
increase in the cell surface expression of MHC II in resting, TLR2 agonised and M. avium 
infected macrophages (Fig. 35 A). Altogether, the results point to a possible improvement 
of antigen presentation by lapachol. Albacol, a plant-derived compound, and 
davallialactone, a compound isolated from mushrooms, produce a decrease in co­
stimulatory molecules in DCs and RAW264.7 cells, respectively (Lee, Lee et al. 2008; Liu,
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Shu et al. 2008) what inhibited T cell activation. The expression of CD54 (ICAM-1), 
shown by Zuckerman et al (Zuckerman, Pullen et al. 1998) to be able to induce 
proliferation of naive T cells after binding to LFA-1 on the T cell surface, is not affected 
by lapachol in THP-1 macrophages (Fig. 35 B). This molecule could also participate in 
macrophage-T cell co-stimulation events.
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Chapter 4. Proteomics approach to the effect of lapachol on
macrophage activation.
IFN-y or TLR activation of macrophages result in the stimulation of the production of 
inflammatory cytokines, enhance cell migration and tissue infiltration, phagocytosis and 
degranulation, endowing appropriately this cell to kill invading pathogens. All this is a 
consequence of transcription regulation events affecting gene expression (Ehrt, 
Schnappinger et al. 2001; Akira and Takeda 2004). Gene expression regulation results in 
changes in protein expression or modification. The primary goal of comparative 
proteomics is to detect and associate changes in protein expression to cellular changes, 
helping to elucidate the cause of the changes. Proteomic techniques are powerful tools to 
study protein expression and, according to the complexity of the analysis performed, can 
provide information about amounts, chemical modifications, cellular location and protein- 
protein interactions (Arthur 2003).
Proteomic approaches have been used for the study of changes in the protein profile of 
monocytes when they differentiate into macrophages, a crucial event in the innate 
response, or to describe the influence of stress or different inflammatory stimuli (Wang, 
Zhao et al. 2004). Differentiation of monocytes into macrophages is marked by changes in 
the profile of secreted and cellular proteins, as reported for U937 cells treated with PMA to 
become macrophages (Sintiprungrat, Singhto et al. 2010). Proteomic studies of IFN-y- 
activated macrophage phagosomes shows delays in the acquisition of lysosomal hydrolases 
and peptidases for the gain of antigen presentation. This gain in antigen presentation 
depends on phagosomal cytoskeletal networks and on vesicle-trafficking proteins, Src 
kinases and calpain proteases (Trost, English et al. 2009).
Using proteomic techniques, alterations in protein expression in response to cell stress 
(Miura, Kano et al. 2005), TLR agonism (Xue, Yun et al. 2008) and challenges with
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mycobacterial lipids (Shui, Gilmore et al. 2009) or with lipopolysaccharide (Gadgil, Pabst 
et al. 2003) have been reported. These techniques have also shown promising for the 
identification of possible anticancer drug targets (Hemers, Duval et al. 2005), as well as to 
elucidate the mechanism of cytotoxicity induced by anticancer drugs (Wang, He et al. 
2005; Wang, He et al. 2006).
Among the different techniques used to separate, quantify and identify proteins, two-
dimensional separation (isoelectrofocusing and polyacrylamide gel electrophoresis, 20-
PAGE) was described as early as 1969 and has considerably improved since then. It is a
powerful technique for the resolution of complex protein mixtures, allowing quantification
as well as identifications, including post-translational modifications. In association with
mass spectrometry (single and/or tandem), protein masses and precise identifications are
possible. The proteins present in the mixture are separated in the first dimension according
to their isoelectric points, on a strip coated with a gel prepared as a fixed pH gradient (pi 3
to pi 11 or fractional ranges). The second dimension, dodecyl sulfate (SDS) gel
electrophoresis, separates according to their molecular weight the proteins that had been
first resolved on the pH gradient strips (Ong and Pandey 2001; Issaq and Veenstra 2008).
This is done by placing each strip horizontally over the electrophoresis gel. The final result
is a two-dimensional array of proteins spots (a protein 2D map) that can be visualized by
staining the gel. Sensitive staining techniques (e.g. colloidal Coomassie, fluorescent dyes)
allow the detection of protein spots containing down to lng (Candiano, Bruschi et al.
2004). The number of protein spots that can be detected is limited by the maximum of
protein that can be loaded on the pH gradient strip. This limitation can be partially
bypassed by performing cell fractionation before the bi-dimensional separations. In this
way, the maximum protein load corresponds to a cell fraction. Since cell fractions contain
fewer proteins than the whole cell, the cell fractionation procedure increases the total
number of protein spots that can be detected, i.e. the number of spots in the different cell
fractions added together. Understandably, the total number of protein spots detected is
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smaller than the total number of proteins in a cell. The human genome sequence shows 
20000 to 25000 protein-coding genes (Consortium 2004), from which at least 10000 
proteins are estimated to be expressed in mammalian cells (Gorg, Weiss et al. 2004). This 
number of proteins will result in a higher number of spots due to protein modifications, 
isoforms and degradation fragments. Approximately 3000 protein spots can be detected by 
bi-dimensional (IEF/SDS-PAGE) separation if the cell is previously separated in cytosolic 
(soluble proteins) and membrane-associated (membrane-bound cell structures = plasma 
membrane + cytoplasmic organelles) fractions, as was the case in the present work. The 
number of protein spots detected, therefore, is < 15% of the total, which means that many 
proteins of low abundance are not being detected. Nevertheless, the number of protein 
molecules whose expression changes can be examined in relationship with cell stimulation 
or drug treatments is much greater than that provided by any other method. Techniques 
like e.g. FACS or western blotting combined with a high sensitivity method of 
visualization can detect proteins of low abundance but only with prior knowledge of their 
existence and subjected to the availability of antibodies in the market. Antibody arrays 
cover a limited number of proteins within specific fields. Transcriptomics does provide 
wide ranging information, with chips allowing the screening of the expression of about 
29000 genes (Perco, Muhlberger et al. 2010). Nevertheless, changes at the RNA level do 
not always correlate with protein expression. Besides, information about protein isoforms, 
post-translational modifications or proteolysis is not obtained.
Bi-dimensional separations can also be used for the detection of proteins of lower 
abundance with the addition of a protein mining step where abundant proteins are excluded 
from a cell extract, yielding an extract enriched in the less represented ones (Boschetti and 
Righetti 2008). A cell sample should therefore be divided for analysis: a smaller portion 
for the detection of abundant proteins and a larger portion for the selection of low abundant 
proteins. Both portions are separately processed using the bi-dimensional techniques.
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Macrophage functions and activation will in most cases be reflected by changes in 
protein patterns and expression. The proteomic section of the present work studied the 
influence of the naphthoquinone lapachol on the bi-dimensional patterns of protein 
expression corresponding to: 1) resting cells, 2) TLR2-agonised cells, and 3) IFN-y-treated 
cells. Resting cells or cells that had been treated with the lipopeptide P3CSK4 (TLR2 
agonist) or IFN-y were treated or not with lapachol, harvested and separated into cytosolic 
and membrane fractions by high speed centrifugation. Proteins in each of the fractions 
were separated by isoelectrofocusing (IEF) followed by SDS-PAGE, obtaining 2D-gels. 
Duplicate gels were stained and images were taken by scanning. The images were analysed 
by means of a commercial program (Ludesi AB, Lund, Sweden: www.ludesi.com) that 
aligns and normalizes all gels and quantifies all the protein spots. Each spot is given a 
number that is the same in all gels and corresponds to a unique position. The images 
corresponding to each cell situation (resting, TLR2-agonised or IFN-y-treated, in the 
absence or presence of lapachol, i.e. a total of 6  situations) and each cell fraction (cytosolic 
or membrane, i.e. making a total of 1 2  groups of 2  gel images each) can be compared 
following the researcher’s criteria regarding group comparisons to be made. The operator 
also establishes parameters such as statistical significance (p < 0.05 in the studies here 
reported) and the extent of the differences between spots in different groups (> 1.5-fold in 
the present studies). A list of spot locations and intensity differences is obtained (Ludesi 
Report), along with the corresponding bar or spread plot graphs showing the differences. 
On that basis it is decided which protein spots to excise from gels and identify by MS after 
tryptic proteolysis.
1. Changes induced by lapachol in resting cells
The number of protein spots whose expression level was altered by lapachol by > 1.5- 
fold in resting macrophages was determined. Changes were found in 25/1450 cytosolic 
spots (1.7%) and 60/1293 membrane spots (4.6%) (Figure 39). Protein identification was
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not performed because it was considered to be more relevant to examine the effect of 
lapachol in relationship with macrophage activated states.
Control Lapachol
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FIGURE 39. Representative cytosolic (A) and membrane (B) protein maps (2D-PAGE) of 
THP-1 macrophages untreated (Control) or treated with lapachol.
Cells were cultured in the absence of additions for 8  days (control); or without additions for 4 days 
and then with lapachol (32pg/mL) for 4 additional days (lapachol).
2D-PAGE: 1st dimension IEF, 2nd dimension SDS-PAGE (mol. masses of markers in kDa). 
Staining: colloidal Coomassie. The corresponding images were analysed, yielding 1293-1450 spots 
per gel.
The spots encircled blue or red correspond to lapachol-regulated proteins and were not identified. 
The red circles are the result of a technical feature of the gel image analysis program (Ludesi 
Redfin); they have the same meaning as the blue ones.
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2. Influence of lapachol on IFN^y-regulated protein expression levels
IFN-y modulated the intensity of 1 1 1  out of the 1352 cytosolic protein spots detected 
on gels by > 1.5-fold, comparing IFN-y-treated with untreated cells. Treatment of IFN-y- 
activated cells with lapachol resulted in > 1.5-fold changes, either increases or decreases, 
in the intensity of 8  out of the 111 cytosolic protein spots regulated by IFN-y (Figs. 40 and 
42). Regarding membrane protein spots, 65 out of 1248 were found to be regulated by 
IFN-y by > 1.5-fold, comparing IFN-y-treated with untreated cells. Only 6  out of the 65 
were further affected by lapachol by > 1.5-fold (Fig. 41 and 43).
Out of the total of 14 protein spots ( 8  in cytosolic and 6  in membrane fractions) of 
IFN-y-regulated proteins affected by treatment with lapachol, 10 proteins could be 
identified by MS: 7 from the cytosol and 3 from the membrane fraction (Table 3). The 
changes in intensity of the corresponding spots are illustrated in Fig. 42 (cytosolic spots) 
and Fig. 43 (membrane spots), which show both the section of the gels where each spot is 
present and their quantification bar graphs. The extent of the changes observed varied 
considerably among spots, with the meaning of infinity ratios being the total absence of a 
spot in one of the situations being compared with each other. The characteristics of the 
proteins identified are summarized in Table 3.
The 10 IFN-y-regulated proteins affected by lapachol identified were classified in 
terms of cellular function (Table 3), based on information from the protein knowledge 
database Swiss-Prot/TrEMBL {http://www.expasv.cli). As shown in Figure 44, the largest 
group of proteins was that of chaperones (40%), involved in protein folding. The other 
proteins were distributed among proteolysis, glycolysis and actin-binding.
171
C o n t r o l Lapacholpi 11 pi  3 pi  I I
‘ * w «•«• » S3&? 
• * .  -  f t
•  •
2 5 -
3 2 .5 -
2 5 -
«*
*
16  5 -
6 5 - 6 .5 -
pl 3
175 —  
S3 —
62  —
47.5—
3 2 .5 —
IFN-y
D
-  -  
«. - * W m
* * • — ^  
•  - V  ♦
pi n  pi 3
1 7 5 --------
S 3 --------
6 2 --------
47 5-------
IFN-y + lapachol pm
»  * j J p i2 6 « o c 3 U 4 a -  .  .V - V
32  5 -
2 5 -
16 5 - 16 5-
6  5 -
FIGURE 40. Representative cytosolic protein maps (2D-PAGE) of THP-1 macrophages 
untreated (A) or treated with lapachol (B), IFN-y (C) or IFN-y + lapachol (D).
Cells were cultured in the absence of additions for 8  days (A), without additions for 4 days and 
then with lapachol (32pg/mL) for 4 days (B), in the presence of IFN-y for eight days (C); with 
IFN-y for 8  days and with lapachol (32pg/mL) from day 4 to 8  (D).
2D-PAGE: 1st dimension IEF, 2nd dimension SDS-PAGE (mol. masses of markers in kDa). 
Staining: colloidal Coomassie. The corresponding images were analysed, yielding 1350-1450 
spots per gel.
The spots encircled blue or red correspond to IFN-y-regulated proteins that were affected by 
lapachol, and were identified (Table 3). The red circles are the result of a technical feature of the 
gel image analysis program (Ludesi Redfin); they have the same meaning as the blue ones.
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Control Lapachol
IFN-y + lapacholpi 11 pi 3
IKVS
pi 11
FIGURE 41. Representative membrane protein maps (2D-PAGE) of THP-1 macrophages 
untreated (A) or treated with lapachol (B), IFN-y (C) or IFN-y + lapachol (D).
Cells were cultured in the absence of additions for 8 days (A), without additions for 4 days and 
then with lapachol (32pg/mL) for 4 days (B), in the presence of IFN-y for eight days (C); in the 
presence of IFN-y for 8 days and of lapachol (32pg/mL) from day 4 to 8 (D).
2D-PAGE: 1st dimension IEF, 2nd dimension SDS-PAGE (mol. masses of markers in kDa). 
Staining: colloidal Coomassie. The corresponding images were analysed, yielding 1250-1350 spots 
per gel.
The spots encircled blue or red correspond to IFN-y-regulated proteins that were affected by 
lapachol, and were identified (Table 3). The red circles are the result of a technical feature of the 
image analysis program (Ludesi Redfm); they have the same meaning as the blue ones.
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spot 52 : Pyruvate kinase; 
spot 914: SUMO-1; 
spot 1275 HSP90
spot 166 : CAP-1; 
spot 1152 : Calreticulin;
C 1FN I-L
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spot 349: Alpha-enolase; 
spot 1266 : PDI;
FIGURE 42. Detail of the alterations induced by lapachol on IFN-y-regulated cytosolic 
protein expression.
Cells were cultured in the absence of additions for 8  days (Control), in the presence of IFN-y for 
eight days (IFN-y); with IFN-y for 8  days and additionally lapachol (32pg/mL) from day 4 to 8  
(IFN-y + lapachol). Cytosolic proteins were analysed by IEF/ SDS-PAGE, in duplicate. Gel 
images were subjected to quantitative analysis (www.ludesi.com). which includes a normalization 
step. The figure illustrates the areas of the gels showing proteins (red encircled spots) regulated by 
IFN-y activation, the expression of which was affected by lapachol. The bar graphs show the 
quantification of the spots, in each case.
C: Controls (untreated cells); IFN: IFN-y; I+L: IFN-y + lapachol.
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spot 256 : Cathepsin B; spot 586 : DnaJ homolog subfamily B;
spot 1328: (3-actin-like protein 2.
FIGURE 43. Detail of the alterations induced by lapachol on IFN-y-regulated membrane 
protein expression.
Cells were cultured in the absence of additions for 8  days (Control), in the presence of IFN-y for 
eight days (IFN-y); with IFN-y for 8  days and additionally lapachol (32pg/mL) from day 4 to 8  
(IFN-y + lapachol). Membrane proteins were analysed by IEF/ SDS-PAGE, in duplicate. Gel 
images were subjected to quantitative analysis (www.ludesi.com). which involves a normalization 
step. The figure illustrates the areas of the gels showing proteins (red encircled spots) regulated by 
IFN-y activation, the expression of which was affected by lapachol. The bar graphs show the 
quantification of the spots, in each case.
C: Controls (untreated cells); IFN: IFN-y; I+L: IFN-y + lapachol.
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FIGURE 44. Functional classification of the IFN-y-regulated proteins the expression of which 
was influenced b y  lapachol.
Pie charts representing the distribution of identified proteins according to their biological function. 
Assignments were made based on information from the Swiss-Prot/TrEMBL protein database 
(http://www.expasv.ch).
2.1. Protein folding
Four proteins classically involved in ER protein folding were identified (40%): protein 
disulfide-isomerase A3 (PDI), calreticulin, heat shock protein 90 (HSP90) and DnaJ 
homolog subfamily B #1. Three of these proteins, namely PDI (spot 1266), calreticulin 
(spot 1152) and HSP90 (spot 1275), were found in the cytosolic fraction of IFN-y-treated 
but not in non-treated (control) cells, and increased further in the presence of lapachol 
(Table 3, Fig. 42). The unusual cytosolic localization of these proteins is not likely to be 
the result of ER damage during cell disruption because a very abundant ER protein, grp78, 
was not found up-regulated. PDI A3, also known as ERp57, is thought to be involved in 
Stat3 complexing and in disulfide bond cleavages coupled to protein degradation in the 
cytosol of Hep3B cells (Turano, Coppari et al. 2002). It has also been reported to be 
present in the cytosol of breast cancer cells, where is cleaved by caspase-3 and -7 during 
induced apoptosis (Na, Park et al. 2007). The lapachol-induced up-regulation of cytosolic
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PDI A3, which was detected uncleaved and at the correct pi position in the 2D protein map 
(Table 3), is in agreement with the lack of an apoptotic effect of lapachol.
Calreticulin is known to express non-ER functions (Gold, Eggleton et al. 2010) such 
as to retrotranslocate from the ER to the cell cytosol (Afshar, Black et al. 2005), where it 
can be arginylated and associate to stress granules (Carpio, Lopez Sambrooks et al. 2010). 
The results here obtained indicate that the cytosolic calreticulin up-regulated by lapachol 
(Fig. 42) has a pl=5.2, against a theoretical value of 4.3 (Table 3), and this is compatible 
with a protein modification conferring positive charges such as arginylation (Karakozova, 
Kozak et al. 2006).
HSP90 is a heat-shock protein known to associate with MHCI and II molecules during 
cargo loading. HSP90 inhibition studies (Rajagopal, Bal et al. 2006; Callahan, Garg et al. 
2008) have shown that inhibited macrophages fail to load antigen on MHCI and II, which 
could compromise CD4+ or CD8 + activation. The enhancement of the expression of HSP90 
by IFN-y and the further increase induced by lapachol (Fig. 42) could therefore be 
beneficial.
An up-regulation of DnaJ homolog (spot 586) was detected in the membrane fraction, 
which is compatible with its ER localization. In this case, its IFN-y-induced up-regulation 
was suppressed by lapachol treatment (Fig. 43). The lumenal domain of this protein 
stimulates the basal ATPase activity of grp78/BiP, which may favour grp78 
monomerization (Chevalier, Rhee et al. 2000). Lapachol could therefore be interfering to 
some extent with grp78 function.
2.2. Glycolysis
IFN-y increased the expression of two cytosolic proteins involved in glycolysis: a- 
enolase (spot 349) and pyruvate kinase (PK, spot 52), and the increase reverted to control 
values by treatment with lapachol (Table 3). The change observed for enolase only
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concerned an acidic form of pi 5.7, compared to pi 7.0 for the unmodified form, and not 
the rest of enolase isoforms. It is therefore difficult to predict the possible consequences of 
the isoform down-regulation observed. The effect of lapachol could be related to an 
interference of a post-translational modification of enolase. The lapachol-induced 
reduction in PK levels corresponded to the molecular form of normal pi (Kang, Kim et al. 
2006). It could have some effect on glycolysis and the subsequent ATP generation, since 
PK is a regulatory enzyme (Munoz and Ponce 2003; Mazurek, Boschek et al. 2005). The 
present result is the first report about a positive regulation of PK expression by IFN-y. 
Since the generation of an excess of pyruvate has been reported to participate in an anti­
oxidant action (Miwa, Fujii et al. 2000), the IFN-y-induced increase in PK could have a 
protective effect against possible oxidative damages elicited by IFN-y. The lapachol- 
induced return of PK levels to those of untreated cells could therefore have some 
secondary effect on the protection against free radicals. The main protective mechanisms, 
due to MnSOD and CuZnSOD, are not affected by lapachol (Chapter 2, section 3; Fig. 19).
2.3. Post-translational modifications
A protein involved in post-translational modification, sentrin-specific protease 6  or 
SUMO-1 (spot 914), was identified. Its cytosolic expression was down-regulated to non- 
detectable levels by IFN-y, and restored to levels similar to control after lapachol treatment 
(Table 3). SUMO family proteins modify many proteins involved in cellular functions such 
as transcription, genome integrity, nuclear transport and signal transduction by forming 
conjugates (Seeler and Dejean 2001; Johnson 2004). Although most SUMO conjugates are 
nuclear proteins, some are cytoplasmic like SUMO-RanGAPl and SUMO-IkBcx. SUMO- 
RanGapl is the most abundant SUMO conjugate in vertebrate cells. It is a GTPase 
activating protein acting on Ran. Ran plays a central role in nucleocytoplasmic transport, 
being found on the cytoplasmic fibrils of nuclear pore complexes, and participates in 
mitosis events. However, it is not yet clear what role sumoylation of RanGAPl could play
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in nuclear transport. Therefore, it is difficult to speculate on the meaning of the IFN-y- 
induced down-regulation of SUMO-1 observed and the restoration of its levels by lapachol 
treatment.
NF-kB activity is dependent on the ubiquitin-dependent degradation of the NF-kB 
inhibitor IkB. SUMO prevents IkBcx degradation by conjugation (sumoylation), leading to 
a reduction in NF-KB-dependent transcriptional activity (Desterro, Rodriguez et al. 1998). 
It can be speculated that by reducing SUMO-1 availability, IFN-y would promote NF-kB 
transcriptional activity, which is associated to the signalling of many pathways including 
TLR. By restoring SUMO-1 levels to normal, lapachol could somehow hamper NF-kB 
transcriptional activity. However, lapachol did not affect the TLR2 agonism-induced 
secretion of TNF-a, a typical NF-KB-mediated process (Collart, Baeuerle et al. 1990).
2.4. Proteolysis
Cathepsin B (CatB, spot 256) is a lysosomal cysteine protease that degrades 
exogenous and cellular proteins and can also work as an endopeptidase (Mort and Buttle 
1997). CatB can also be found in the cell cytosol, plasma membrane and pericellular 
spaces where it plays a role in tumour migration and invasiveness (Wickramasinghe, 
Nagaraj et al. 2005). The proteolytic activity of CatB is not required for antigen 
presentation by MHCII molecules, since cathepsin B deficient mice were able to present 
foreign antigens (Deussing, Roth et al. 1998). The results presented here show an IFN-y- 
induced reduction in CatB and differ from those obtained in THP-1 cells but using a 5-fold 
higher IFN-y concentration and measuring mRNA expression (Li and Bever 1997). The 
association of IFN-y with lapachol resulted in an increase in CatB levels back to those in 
untreated cells. CatB has been recently reported to be involved in the cytoplasmic traffic of 
TNF-a-containing vesicles to the plasma membrane (Ha, Martins et al. 2008). Thus, 
lapachol could facilitate the secretion of this cytokine.
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2.5. Actin-binding
The expression of adenylyl cyclase-associated protein-1 (CAP-1, spot 166) was down- 
regulated by IFN-y (Table 3) and lapachol restored its levels to those of untreated cells. 
This protein participates in the mechanism of cell polarization, which requires a 
cytoskeletal rearrangement mediated by CAP1 thanks to its capacity to regulate the F-/G- 
actin ratio. Cells deficient in CAP are bigger, in keeping with abnormalities in cytoskeleton 
structure (Hubberstey and Mottillo 2002). The reduction in CAP1 expression by IFN-y and 
its reversion by lapachol could result in transient, opposite effects on cell migration, 
although the extent of the changes observed (Table 3 and Fig. 42) is modest and such 
effects might not show. Indeed, lapachol did not cause relevant changes in cell shape or 
size of the THP-1 macrophages here used, as illustrated in Fig. 12.
P-actin-like protein 2 (spot 1328) was strongly down-regulated (7-fold) by IFN-y in 
membrane fractions, and still further by lapachol treatment. This protein spot is located 
below the bulk of actin in 2D-gels, and is comparatively very scarce (Fig. 44). Because of 
its smaller molecular mass, it could be a product of partial degradation from actin. Since 
total actin levels were not affected by IFN-y activation (Fig. 17, C), and cell shape and size 
were not seen to be affected either, it seems unlikely that p-actin-like protein 2  be of any 
relevance regarding the cytoskeleton unless some yet non described regulatory function is 
discovered for it.
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3. Influence of lapachol on PsCSKt-regulated protein expression levels
TLR2 agonism with the lipopetide P3CSK4 induced > 1.5-fold changes in the intensity 
of 150 cytosolic protein spots out of a total of 1400. When TLR2-agonised cells were 
treated with lapachol, the intensity of 22 of those 150 spots changed further by > 1.5-fold, 
either increasing or decreasing (Fig. 45). The intensity of 115 protein spots from the 
membrane fraction, out of a total of 1265, was changed by P3CSK4 treatment by > 1.5-fold, 
either in a positive or negative way. Treatment with lapachol resulted in the modification 
of the levels of 18 out of those 115 membrane protein spots (Fig. 46).
The proteins corresponding to 11 out of the total of 40 spots that were affected by 
lapachol (22 cytosolic and 18 membrane-associated) could be identified by MS. The 
changes in intensity of the corresponding spots are illustrated in Fig. 47 (cytosolic spots) 
and Fig. 48 (membrane spots). Both the section of the gels where each spot is present and 
their quantification bar graphs are illustrated. The extent of the changes observed was very 
variable, infinity ratios corresponding to the total absence of a spot in one of the situations 
being compared with each other. The characteristics of the proteins identified are 
summarized in Table 4.
The proteins identified were classified in terms of cellular function based on 
information from Swiss-Prot/TrEMBL protein database (http://www.expasv.chl. As shown 
in Fig. 49, they are distributed in the following cellular functions: actin-binding (28%), 
metabolism (27%), proteolysis (27%), ER stress (9%) and oxido-reduction (9%).
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FIGURE 45. Representative cytosolic protein maps (2D-PAGE) of THP-1 macrophages 
untreated (A) or treated with lapachol (B), P3CSK4 (C) or P3CSK4 + lapachol (D).
Cells were cultured in the absence of additions for 8  days (A); without additions for 4 days and 
then with lapachol (32pg/mL) for 4 days (B); in the presence of P3CSK4 (300 nM) for eight days 
(C); with P3CSK4(300 nM) for 8  days and lapachol (32pg/mL) from day 4 to 8  (D).
2D-PAGE: 1st dimension IEF, 2nd dimension SDS-PAGE (mol. masses of markers in kDa). 
Staining: colloidal Coomassie. The corresponding images were analysed, yielding 1400-1450 spots 
per gel.
The spots encircled blue or red correspond to P^CSlQ-regulated proteins that were affected by 
lapachol, and were identified (Table 3). The red circles are the result of a technical feature of the 
gel image analysis program (Ludesi Redfin); they have the same meaning as the blue ones.
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FIGURE 46. Representative membrane protein maps (2D-PAGE) of THP-1 macrophages 
untreated (A) or treated with lapachol (B), P3CSK4 (C) or P3CSK4 + lapachol (D).
Cells were cultured in the absence of additions for 8 days (A); without additions for 4 days and 
then with lapachol (32pg/mL) for 4 days (B); in the presence of P3CSK4 (300 nM) for eight days 
(C); with P3CSK4 (300 nM) for 8 days and lapachol (32pg/mL) from day 4 to 8 (D).
2D-PAGE: 1st dimension IEF, 2nd dimension SDS-PAGE (mol. masses of markers in kDa). 
Staining: colloidal Coomassie. The corresponding images were analysed, yielding 1260-1350 spots 
per gel.
The spots encircled blue or red correspond to P3 CSK4 -regulated proteins that were affected by 
lapachol, and were identified (Table 3). The red circles are the result of a technical feature of the 
gel image analysis program (Ludesi Redfin); they have the same meaning as the blue ones.
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spot 1445 : Fascin;
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FIGURE 47. Detail of the alterations induced by lapachol on P3CSK4 -regulated cytosolic 
protein expression.
Cells were cultured in the absence of additions for 8  days (Control), in the presence of P3 CSK4  for 
eight days (P3CSK4); with IFN-y for 8  days and additionally lapachol (32pg/mL) from day 4 to 8  
(P3CSK4 + lapachol). Cytosolic proteins were analysed by IEF/ SDS-PAGE, in duplicate. Gel 
images were subjected to quantitative analysis (www.ludesi.com). which includes a normalization 
step. The figure illustrates the areas of the gels showing proteins (red encircled spots) regulated by 
P3 CSK4  activation, the expression of which was affected by lapachol. The bar graphs show the 
quantification of the spots, in each case.
C: Controls (untreated cells); P: P3CSK4; P+L: P3CSK4 + lapachol.
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spot 32 : Grp78 (BIP); spot 274 : Proteasome subunit beta type-4;
spot 327: Cathepsin D; spot 1391 : 2,4-dienoyl-CoA reductase; spot 1860 : MnSOD
FIGURE 48. Detail of the alterations induced by lapachol on P3CSK4 -regulated m em brane 
protein expression.
Cells were cultured in the absence of additions for 8  days (Control), in the presence of P3 CSK4  for
eight days (P3CSK4); with IFN-y for 8  days and additionally lapachol (32pg/mL) from day 4 to 8
(P3CSK4 + lapachol). Membrane proteins were analysed by IEF/ SDS-PAGE, in duplicate. Gel 
images were subjected to quantitative analysis (www.ludesi.com). which includes a normalization 
step. The figure illustrates the areas of the gels showing proteins (red encircled spots) regulated by 
P3 CSK4  activation, the expression of which was affected by lapachol. The bar graphs show the 
quantification of the spots, in each case.
C: Controls (untreated cells); P: P3CSK4; P+L: P3CSK4 + lapachol.
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FIGURE 49. Functional classification of the P3CSK4 -regulated proteins the expression of 
which was influenced by lapachol.
Pie charts representing the distribution of identified proteins according to their biological function. 
Assignments were made based on information from the Swiss-Prot/TrEMBL protein database 
(http://www.expasy.ch).
3.1. Actin-binding
Cofilin-1 (spot 23) was down-regulated by TLR2 agonism and the combination of 
TLR2 agonism and lapachol diminished even more the levels of this protein in cytosolic 
fractions (Table 4, Fig. 47). Fascin (spot 1445) and Plastin-1 (spot 1466) were up-regulated 
by P3CSK4 from undetectable values in resting cell cytosols, and down-regulated back to 
undetectable amounts by the addition of lapachol (Table 4, Fig. 47). Actin polymerization 
is fundamental for cellular functions like motility, cell adhesion and phagocytosis. Actin 
polymerization and depolymerization is regulated by actin-binding proteins (Wear, Schafer 
et al. 2000). Polymerization occurs at one end of each actin filament, and the control of 
filamentous actin assembly depends on the regulation of the availability of these ends. 
Cofilin is an actin-binding protein responsible for the generation of available ends by 
cleavage of existing F-actins, acting in this way to regulate cell migration (van Rheenen, 
Condeelis et al. 2009). This was demonstrated by a reduction in cofilin expression by
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introduction of cofilin siRNA in neutrophils, which abrogated IL-18-induced cell 
migration (Hirayama, Adachi et al. 2007). The decrease in cofilin expression caused by 
TLR2 agonism and accentuated by addition of lapachol could compromise to some degree 
the migration capacity of macrophages. Migration is essential for phagocytes to reach 
infection/inflammation sites from blood vessels under the effect of chemotactic stimuli. 
Once having reached those sites, phagocyte challenging by microbial PAMPs occurs and 
this leads to phagocyte activation and the mounting of the fight against the invading 
microorganisms. At this point phagocytes do not need to migrate any longer. In agreement 
with this scenario of reduced mobility and enhanced killing capacity, reduction in cofilin 
expression by antisense oligonucleotides has been reported to enhance superoxide 
production in mouse macrophages (Adachi, Takeuchi et al. 2002). In the present work, the 
observed increases in the expression of the NADPH-oxidase components gp9 \phox and/or 
p4 7 phox by XLR2 agonism and/or M. avium infection of macrophages (Fig. 18) coincide 
with the reduction in cofilin detected by proteomics. Lapachol on its own resulted in 
decreased cofilin levels similar to those after combined PsCSKVlapachol treatment (Fig. 
50). Therefore, lapachol could be inducing an impairment in migration.
Fascin and L-plastin are actin-binding proteins with the capacity to bundle F-actin 
filaments (Arpin, Friederich et al. 1994; Adams 2004). Their dramatic up-regulation after 
treatment with P3CSK4 (Table 4, Fig. 47) could be linked with the cofilin down-regulation 
mentioned above, which would increase the cytosolic F-actin content (Adachi, Takeuchi et 
al. 2002). Since lapachol abolished the PsCSIQ-induced increase, actin filament bundling 
would be impaired, with possible consequences regarding cell adhesion, phagocytosis 
and/or migration.
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FIGURE 50. Detail of two of the alterations induced by lapachol on the cytosolic protein 
expression of resting cells. Cells were cultured in the absence of additions for 8 days (Control), or 
in the presence of lapachol (32pg/mL) from day 4 to 8 (lapachol). Cytosolic proteins were 
analysed by IEF/ SDS-PAGE, in duplicate. Gel images were subjected to quantitative analysis 
(www.ludesi.com), which includes a normalization step. The figure illustrates the areas of the gels 
showing proteins (red encircled spots) regulated by lapachol. The bar graphs show the 
quantification of the spots, in each case.
C: Controls (untreated cells); L: lapachol.
3.2. Metabolism
Lapachol affected the levels of some PsCSfCrinduced enzymes involved in metabolic 
reactions. Cytosolic tryptophan-tRNA ligase (TrpRS, spot 2122) was strongly up-regulated 
by P3CSK4 treatment, with lapachol reverting completely this effect (Table 4, Fig. 47). 
TrpRS is an aminoacyl-tRNA synthetase that activates tryptophan by catalyzing the 
aminoacylation of 3'-terminal adenosine residues in its cognate tRNAs (Kisselev 1993). 
The effects of this protein are not restricted to the initial steps in protein biosynthesis. After 
proteolytic cleavage by extracellular proteases such as plasmin or by alternative splicing, 
small TrpRS are generated that exert an anti-angiogenesis effect on tumor endothelial cells 
(Kapoor, Zhou et al. 2008; Zhou, Kiosses et al. 2008). IFN-y increases the expression and 
activity of TrpRS in amnion cells (Fleckner, Rasmussen et al. 1991) and fibroblasts 
(Rubin, Anderson et al. 1991), while TGF-|3 is inhibitory. The up-regulation of TrpRS
190
levels observed after P3CSK4 treatment of THP-1 macrophages can be a cellular response 
to increase metabolism or could related to iNOS (NOS2) activity. An unusual TrpRS has 
been reported to interact with and potentiate the activity of iNOS in prokaryotes (Buddha, 
Keery et al. 2004), and this might also be the case in eukaryotes. TLR2 agonism resulted in 
an increase of NOS2 levels (Fig. 20, A), which might be enhanced by TrpRS. This effect 
would not be operating in TLR2-agonised cells treated with lapachol, since in that case 
TrpRS levels decrease to undetectable levels (Table 4, Fig. 47).
Glucose-6 -P-dehydrogenase (G6 PD, spot 339) was up-regulated by TLR2 agonism 
and the addition of lapachol further enhanced its levels (Table 4, Fig. 47). This is the first 
enzyme of the pentose phosphate pathway, catalyzes the formation of NADPH and is rate- 
limiting. It is involved in the redox equilibrium of the cell because NADPH, of which 
G6 PD is an important source, is needed for both the generation of reduced glutathione 
(GSH) by glutathione reductase and the formation of active catalase tetramers (Pandolfi, 
Sonati et al. 1995; Salvemini, Franze et al. 1999; Ho, Cheng et al. 2007) that result in the 
conversion of H2O2 into H2O by glutathione peroxidase and catalase. Treatment of 
macrophages with P3CSK4 resulted in a 2.3-fold increase in G6 PD which in association 
with lapachol became 6.4-fold (Table 4, Fig. 47). Lapachol on its own induced a 5-fold 
increase (Fig. 50). This effect could help protect macrophages from reactive oxygen 
species. The lapachol-induced enhancement of G6 PD levels could be related to an 
activation of NADPH-dependent cytochrome P450 reductase by the naphthoquinone, 
which would require additional NADPH (Kumagai 1997).
Dienoyl-CoA-reductase (spot 1391) was strongly up-regulated in the membrane 
fraction of PsCSICrtreated macrophages and the addition of lapachol halved its expression 
(Table 4, Fig. 48). Fatty acids are degraded by (3-oxidation, in mitochondria. The protein 
2,4-dienoyl-CoA-reductase participates as an auxiliary enzyme in fatty acid oxidation. It 
can process saturated and unsaturated molecules by catalyzing the reduction of 2,4-
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dienoyl-CoA to enoyl-CoA in a NADPH-dependent manner (Alphey, Yu et al. 2005; Yu, 
Chu et al. 2005). The increases in 2,4-dienoyl-CoA-reductase levels caused by TLR2 
agonism in THP-1 macrophages might be a consequence of a higher fatty acid 
turnover/energy requirement. The increase in this enzyme is reduced by lapachol, but 
levels are still higher than in untreated, control cells.
3.3. Proteolysis
Proteolytic enzymes catalyze the degradation of proteins. Aminopeptidase (spot 1293) 
and proteasome endopeptidase (spot 274) were both up-regulated by P3CSK4 and down- 
regulated on addition of lapachol. Instead, cathepsin D (CatD, spot 327) was down- 
regulated by P3CSK4 and its levels were reduced further by lapachol.
Aminopeptidase and proteasome endopeptidase are involved in the ATP-dependent 
proteolysis of cytosolic proteins (Kristensen, Johnsen et al. 1994; Herrera-Camacho, 
Rosas-Murrieta et al. 2007). Both proteins are involved in the generation of peptides for 
antigen presentation to CD8+ cells via via MHC I (Harris, Hunte et al. 1992; Kloetzel and 
Ossendorp 2004; Hammer, Gonzalez et al. 2007). Up-regulation in the expression of 
proteasome by TLR2 agonism could be the consequence of the capacity of the cell to 
improve antigen presentation following pathogen recognition, which lapachol opposed.
Cathepsin D (CatD) is an abundant lysosomal cysteyl protease which promotes an 
initial cleavage of proteins (Minarowska, Gacko et al. 2008). CatD was shown to be 
dispensable for MHCII-dependent antigen presentation, using splenocytes from Cat D-/- 
mice (Deussing, Roth et al. 1998). The reduction in CatD levels by P3CSK4 and lapachol 
would therefore inconsequential regarding MHCII presentation. No interpretation can be 
provided at this stage about the possible effects of the observed reduction in lysosomal 
proteolysis by CatD.
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3.4. ER stress
Grp78 is a chaperone that orchestrates the unfolded protein response (UPR) in ER, 
after the accumulation of unfolded or misfolded proteins in this organelle. Its expression is 
an ER stress indicator, since grp78 is a central regulator of ER homeostasis (Xu, Bailly- 
Maitre et al. 2005; Li, Ni et al. 2008). P3CSK4 treatment down-regulated the expression of 
grp78 (spot 32, Table 4 and Fig. 48), in agreement with the reduction in grp78 detected by 
Western blotting (Fig. 17, A). Lapachol restored grp78 levels to those in non-treated cells.
3.5. Redox state
The mitochondrial Mn-superoxide dismutase (MnSOD, spot 1860) is a main enzyme 
in the control of cell damage by the enhanced oxygen metabolism that results from 
infection-induced macrophage activation. It catalyses the conversion of O2' to H2O2 and O2 
(Zelko, Mariani et al. 2002). The expression of MnSOD can be increased by cytokines 
such as TNF-a (Wong 1995) and treatment with lipopolysaccharide (Gadgil, Pabst et al. 
2003), preventing excessive oxidative stress. TLR2 agonism by P3CSK4 has been reported 
to result in a 1.43-fold increase in MnSOD in macrophages (Xue, Yun et al. 2008). The 
present work showed that MnSOD was noticeably up-regulated by TLR2 agonism, and a 
modest reversion of this effect was induced by lapachol (Table 4, Fig. 48).
The first general observation from the proteomics section of the studies here reported 
is that treatment of THP-1 macrophages with the naphthoquinone lapachol resulted in 
some alterations in protein expression levels. In resting cells, the intensity of 1.7% and 
4.6% of cytosolic and membrane fraction spots, respectively, were affected by lapachol 
treatment. In IFN-y-treated cells the figures were 7.2% and 9.2% and in TLR2-agonised 
cells they were 14.7% and 15.7% for cytosolic and membrane spots, respectively.
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The total number of proteins that could be identified among those up- or down- 
regulated by lapachol was 10 from IFN-y-treated cells and 11 from TLR2-agonised cells. 
These proteins are involved in a broad spectrum of cellular functions (Figs. 46 and 49) and 
the possible consequences of the lapachol-induced changes here reported are discussed in 
the corresponding sections of this Chapter 4 (2.1 to 2.5 and 3.1 to 3.5). Considering more 
relevant those lapachol-induced changes in protein expression levels where the drug 
reverts a total abrogation or eliminates completely an up-regulation (returning to 
undetectable levels) generated by treatment with either IFN-y or P3CSK4, the following 7 
proteins are selected: SUMO-1 (#914, Fig.42), DnaJ homolog (#586, Fig. 43), fascin 
(#1445, Fig. 47), plastin-2 (#1466, Fig. 47), tryptophan-tRNA ligase (#2122, Fig. 47), 
aminopeptidase (#1293, Fig. 47), proteasome p type-4 protease (#274, Fig. 48). The down- 
regulation of cofilin (#23, Fig. 47) is also interesting because of its extent. The diversity of 
the protein functions does not allow drawing any clear conclusion about the possible 
mechanism of action of lapachol. Such analysis is difficult because: a. the number of 
proteins identified is relatively small, and 2 . the lapachol-induced changes observed could 
be secondary to upstream event/s, or the result of feed-back mechanisms of compensation. 
Nevertheless, the down-regulation of the actin-binding proteins cofilin, fascin and plastin-2 
suggests that lapachol could be influencing cell migration, phagocytosis and/or 
immunological synapses. Experimentation addressed to clarify this issue would provide 
more accurate information about possible impairments.
Apart from the proteins mentioned above, the clear enhancement of glucose-6 -P- 
dehydrogenase (#339, Fig. 47) by lapachol seems interesting. This enzyme generates 
NADPH, therefore measurement of cellular NADPH concentrations as well as the 
determination of the redox state of the cell (GSH/GSSG ratios) would be appropriate 
assessments. Another curious finding is the lapachol-induced enhancement of the cytosolic 
levels of three normally ER-resident proteins: calreticulin (#1152, Fig. 42), protein
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disulfide isomerase A3 (#1266, Fig. 42) and HSP90 (#1275, Fig. 42). This can be due to an 
activation of retrotranslocation-related processes. Retrotranslocation of calreticulin has 
been reported and shown to involve the removal of the signal peptide (Afshar, Black et al. 
2005). Protein disulfide isomerase has also been reported to be present in the cytosol of 
Hep3B and cancer cells (Turano, Coppari et al. 2002; Na, Park et al. 2007).
195
GENERAL DISCUSSION
This study reports a dual activity of the substituted hydroxy-naphthoquinone lapachol. 
Firstly, it showed anti-mycobacterial {Mycobacterium avium) activity at both extra-cellular 
and intra-macrophage level, a previously unknown effect. Secondly, it immunomodulated 
some resting and TLR2-agonised human macrophage functions in a manner consistent 
with an enhanced capacity to curb the intra-cellular growth of mycobacteria. Favourable 
effects on the cell host were an enhancement of IFNyRl and MHCII surface expression 
and a marked inhibition of IL-10 secretion. Besides, important aspects of host cell function 
such as ER or oxidative stress, capacity to produce oxygen and nitrogen metabolites, and 
TNF-a secretion were not affected by the naphthoquinone. The influence of lapachol on 
the expression of proteins modulated by IFN-y or TLR2 agonism was studied using a 
proteomic approach. This allowed the identification of proteins affected and led to 
hypotheses about the possible consequences of the changes observed.
Like other pathogenic mycobacteria, M. avium is an intracellular microorganism able 
to subvert the innate immune response. As a result, it can persist and replicate within 
macrophages as well as generate granulomas, a hallmark of mycobacterial infections 
(Hansch, Smith et al. 1996). In the present studies, M. avium replication within 
macrophages was observed to be biphasic (Fig. 14, A, upper curve), showing an initial 
inhibition followed by a faster replication. This phenomenon was described by Douvas et 
al (Douvas, May et al. 1992) and attributed to some serum factors able to inhibit transiently 
the replication of M. avium within macrophages.
During this work, the plant-derived compound lapachol was found to be active against 
M. avium growing in liquid culture, with a MIC of 32 pg/mL (132 pM). This concentration 
is smaller than that reported to inhibit the growth of other bacteria (Guiraud, Steiman et al. 
1994; Oliveira, Miranda et al. 2001; Riffel, Medina et al. 2002), of the same order as that 
needed by the naphthoquinone plumbagin to control M. smegmatis and M. tuberculosis
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liquid growth (Jimenez-Arellanes, Meckes et al. 2003), and higher than that of traditional 
antibiotics such as isoniazid regarding M. tuberculosis growth. Lapachol was not apoptotic 
nor necrotic toward the THP-1 macrophage-like cells used as host cells for intracellular 
growth. The cytotoxicity of lapachol toward different tumor cell lines has been studied, in 
relationship with the use of this compound for the treatment of tumours in soft tissues 
(Rao, McBride et al. 1968). Leukemic cell lines seem to be more sensitive to lapachol than 
solid tumors, with cytotoxicity being induced by lapachol at concentrations ranging from 
16 to 25 pM (Salustiano, Netto et al. 2009). Teixeira et al (Teixeira, de Almeida et al. 
2001), as part of their investigation on the anti-leishmanial activity of lapachol, exposed 
mouse peritoneal macrophages to different concentration of this naphthoquinone and found 
it to be cytotoxic from 0.1 mg/mL (413pM). The experiments reported here show that 
lapachol is not toxic to THP-1 macrophages at < 32pg/mL (132pM).
At its MIC, lapachol exerts a bacteriostatic effect, i.e. it prevents the growth of M. 
avium in liquid culture. This means that, physiologically, the immune system would have 
to take charge of eliminating the pathogen. Intra-macrophage M  avium proliferation was 
halted at 16 pg/mL (66pM), a concentration smaller than the MIC. The better efficacy of 
lapachol toward intracellular microorganisms could be due to a higher intracellular 
concentration, helped by its lipophilic nature (Lira, Sester et al. 2008); a higher stability 
within the phagosomal environment, protected from clearing processes; an intra­
macrophage conversion into a more active derivative; and/or a hypothetical inhibition of 
bacterial NO reductase/s, the scavengers of macrophage-produced NO (Watmough, Field 
et al. 2009). The anti-mycobacterial activity of lapachol is likely to be caused by 
interference with the bacterial cytochrome be system, a known property of 
naphthoquinones (Kumagai 1997), and/or by induction of bacterial oxidative stress due to 
the redox-cycling properties of naphthoquinones, as reported for plumbagin and 
menadione (Guerra-Lopez, Daniels et al. 2007). In any case, the action of naphthoquinones 
is related to their involvement in redox reactions.
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Another possible reason for lapachol to be more efficient toward intra-macrophage M 
avium could be the effects it has on some macrophage responses. Lapachol did not alter 
significantly the resting levels and/or the activation-induced (IFN-y, TLR2 agonism, M  
avium infection) increases in the expression of the L-arginine metabolism enzymes NOS2 
(NO synthesis) or arginase-1, a negative regulator of NO generation (Fig. 20). Thus, NO 
generation is likely to be unaffected. Moreover, lapachol did not influence the levels and/or 
activation-induced increases of the oxygen metabolism markers gp91p/,ox (NADPH oxidase 
catalytic component), p47p/,ox (NADPH oxidase regulatory component) (Fig. 18) and 
MnSOD (oxidative stress control) (Fig. 19); nor those of the ER stress marker grp78 (Fig. 
17). These data indicate that important microbicidal and detoxifying mechanisms of 
macrophages are not affected by the naphthoquinone. Hence, the role of these cells in the 
fight against microorganisms other than mycobacteria would not be compromised during 
periods of treatment with lapachol, and their action against mycobacteria could actually be 
improved. An important finding that could result in better responses to IFN-y and therefore 
better anti-microbial effects is the lapachol-induced increase in surface IFN-yRl (Fig. 33).
Reactions involving quinones can generate superoxide and promote oxidative stress. 
The fact that lapachol did not induce MnSOD increases (Fig. 19) suggests that this 
naphthoquinone in particular does not induce harmful oxidative stress at mitochondrial 
level.
The M  ov/w/w-induced increase in the secretion of TNF-a and IL-10 by macrophages 
observed during the present studies (Fig. 32) agrees with published work (Reiling, 
Blumenthal et al. 2001). The secretion of these cytokines is signaled by MAP kinases 
(Chanteux, Guisset et al. 2007), which are also related to mechanisms of mycobacterial 
survival. In fact, intracellular growth of highly replicative M. avium is associated to lower 
levels of MAP kinase phosphorylation and less secretion of TNF-a and IL-10 (Blumenthal, 
Ehlers et al. 2002). IL-10 is a key anti-inflammatory factor that mediates the inhibition of
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proinflammatory cytokine secretion and favours the intracellular growth of 
microorganisms (Fiorentino, Zlotnik et al. 1991; Bermudez and Champsi 1993; Vieth, Will 
et al. 1994; Via, Fratti et al. 1998; Meghari, Bechah et al. 2008). The absence of IL-10 in 
knockout mice has been reported to increase the acidification (maturation) of the 
mycobacterial phagosome (Via, Fratti et al. 1998), which is essential to prevent 
intracellular bacterial growth. This is due to the fact that IFN-y promotes phagosomal 
acidification, and IL-10 inhibits the expression of IFN-y by T cells (Schaible, Sturgill- 
Koszycki et al. 1998; Othieno, Hirsch et al. 1999). The M. avzw/w-induced secretion of IL- 
10 elicited by the host macrophages was inhibited by lapachol (Fig. 32), and this inhibition 
is likely to hamper the intracellular proliferation of mycobacteria by enhancing the growth 
control capacity of the host cells. The fact that the intra-macrophage growth of M. avium 
was halted by lapachol at 16 pg/mL (66 pM) (Fig. 14, A) as opposed to 32 pg/mL (132 
pM) for M. avium growing in liquid broth may be related to the lapachol-induced decrease 
in IL-10 secretion. A smaller concentration of lapachol would be sufficient to stop 
intracellular growth when the host cell is more efficient, i.e. in the presence of lower levels 
of IL-10.
The fact that lapachol did not affect the TLR2-induced increase in TNF-a secretion 
(Fig. 32) nor the corresponding increase in MnSOD (Visner, Dougall et al. 1990) (Fig. 19) 
is important because TNF-a is necessary to clear mycobacterial and other infections by 
enhancing oxidative and nitrosative reactions (Roach, Bean et al. 2002), and MnSOD is a 
necessary superoxide scavenger at times of cell activation/infection. The role of TNF-a is 
illustrated by the increased susceptibility of animals lacking the TNF gene or where TNF 
has been neutralized with anti-TNF antibody to granulomatous pathogens such as 
Mycobacterium tuberculosis, Listeria monocytogenes and Histoplasma capsulatum and to 
attenuated organisms such as M. bovis BCG (Kindler, Sappino et al. 1989; Allendoerfer 
and Deepe 1998; Kaneko, Yamada et al. 1999). The partial inhibition of M. avium-induced
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TNF-a secretion by lapachol (Fig. 32) is probably due to its causing M. avium growth 
arrest, which would result in decreased macrophage stimulation at phagosomal level 
compared with that of cells containing a higher number of bacteria because these are 
actively proliferating.
The results here presented are the first report about the immunomodulatory effects of 
the naphthoquinone lapachol on stimulated macrophages, and allow a first analysis of its 
action in infection/inflammation terms. Partially similar immunopharmacological studies 
have been published on the effect of the natural compounds ceftiofur and albaconol on 
LPS-stimulated macrophages and of the lapachol analog plumbagin on concanavalin 
(ConA)-stimulated lymphocytes. Ceftiotur is a cephalosporin antibiotic of veterinary use 
that down-regulates the LPS-induced secretion of TNF-a, IL-lp and IL-6 by blocking NF- 
kB and MAPKs signaling, but does not affect IL-10. Therefore, it shows anti-inflammatory 
effects combined with antimicrobial properties (Ci, Song et al. 2008). Albaconol is a 
prenylated resorcinol isolated from a mushroom that down-regulates LPS-induced TNF-a, 
IL-6, IL-ip and NO production; inhibits NF-kB activation and enhances suppressor of 
cytokine signalling-1 (SOCS-1) in RAW264.7 cells. This suggests that albaconol is a 
potential immunosuppressive and anti-inflammatory drug (Liu, Shu et al. 2008; Liu, Shu et 
al. 2008). Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is a compound of plant 
origin and a lapachol analog that possesses a potent anti-tumour activity. It has also been 
shown to augment the bactericidal activity of macrophages at low concentrations (Abdul 
and Ramchender 1995). It inhibits ConA-driven mouse T cell proliferation and the 
secretion of IL-2, IL-4, IL-6 and IFN-y, as well as NF-kB activation (Checker, Sharma et 
al. 2009). Lapachol has been described as an anti-inflammatory compound on the basis of 
an absence of paw edema in mice after treatment with the drug (de Almeida, da Silva Filho 
et al. 1990; Lira, Sester et al. 2008). In contrast with the effects of ceftiofur and albanocol 
on macrophages and those of plumbagin on lymphocytes, lapachol did not inhibit the
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TLR2 agonism-induced secretion of TNF-a and IL-ip by THP1 macrophages (Fig. 32). 
This is an indication of a different mechanism of action, which might not involve an 
inhibition of NK-kB activation.
Quantitative proteomics is a direct way of looking at cell perturbations due to diseases 
and drug treatments. Proteomic studies concerning the effect of drugs have been mostly 
performed with cells in culture and are concerned with anti-cancer agents in the majority of 
cases. No reports about the effect of anti-microbial compounds at cell proteomics level 
have been published to date. This type of approach can provide useful information such as 
the individualization of drug activity biomarkers and cellular pathways involved in the 
mechanism of action of the drug. The results here reported indicate a down-regulation of 
cofilin, fascin and plastin-2 by lapachol (Table 4, Fig. 46) that could compromise cell 
movement, which is involved in chemotactic migration and particle ingestion. Such effect 
would in fact be consistent with the lack of pad inflammation in mice treated with 
lapachol. The up-regulation of calreticulin (CalR), protein disulfide isomerase A3 (PDI) 
and the heat shock protein HSP90 in the cytosolic fraction of the cell (Table 3, Fig. 41) 
could indicate an increased, selective retro-translocation from the endoplasmic reticulum 
where these proteins are abundant. Retrotranslocation to the cytosol is the means by which 
misfolded or defectively glycosylated proteins are normally directed for proteosomal 
degradation. However, these three proteins (CalR, PDI, HSP90) were found intact as to 
molecular mass, therefore their retrotranslocation might have a yet unknown purpose. The 
important lapachol-induced enhancement of cytosolic glucose-6-P-dehydrogenase (G6PD) 
levels observed (Table 4, Fig. 46) could result in an augmented NADPH availability. In 
this respect, determining the influence of lapachol on the redox state of the host cells 
would be convenient. An increase in cytoplasmic NADPH could in turn favour the 
metabolization of the naphthoquinone by NADPH-dependent cytochrome P450 reductase
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(Bachur, Gordon et al. 1979; Komiyama, Oki et al. 1979), as well as increasing the 
potential of the host cell to produce oxygen and nitrogen metabolites.
The M. avium growth-arresting activity of lapachol combined with its beneficial 
immunomodulating effects makes this naphthoquinone a good candidate for future use in 
M. avium infections. Diseases caused by the non-tuberculous pathogen M. avium are 
increasing worldwide (Suharti, Heering et al. 2004). Studies using other mycobacterial 
species, M. tuberculosis in the first place, and strains of different virulence, will define the 
therapeutical potential of lapachol as an anti-mycobacterial agent in general. It would also 
be useful to perform in vitro studies about the effects of lapachol on macrophage migration 
and antigen presentation. Finally, in vivo studies will be necessary.
Research perspectives based on the results here reported include the study of the 
antimycobacterial activity of lapachol in hypoxic conditions. Bacilli become dormant 
under hypoxia, and their low rate metabolism makes them insensitive to the traditionally 
used antibiotics since these target metabolic pathways that have become inactive. Only 
metronidazole has been described as active against dormant mycobacteria (Wayne and 
Sramek 1994). A natural extension of the present studies will be to work with compounds 
structurally related to lapachol, i.e. 1,4-naphthoquinone derivatives, with the aim of 
selecting those with similar activities and requiring lower doses. In this respect, several 
substituted naphthoquinones have been synthesized and tested in several laboratories in 
relationship with antiplasmodial, antitumoral, antimicrobial, antiprotozoan and insecticide 
activities (Oliveira, Lemos et al. 2002; Riffel, Medina et al. 2002; Perez-Sacau, Estevez- 
Braun et al. 2005; Eyong, Kumar et al. 2008). The final objective is to find new, efficient 
and immuno-pharmacologically convenient anti-mycobacterial compounds to be used in 
the fight against tubercular diseases (Guerra-Lopez, Daniels et al. 2007).
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